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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting 
primarily motor neurons (MNs) but involving also non-neuronal cells. Nowadays, it is well 
recognised that astrocytes, microglia and oligodendrocytes play a central role in disease 
onset and progression. In particular, astrocytes acquire a toxic phenotype characterized by 
an abnormal proliferation and by the release of neurotoxic factors, including pro-
inflammatory cytokines (Lee et al., 2016). 
We have previously shown that the intravenous administration of mesenchymal stem cells 
(MSCs) in SOD1G93A mice prolonged survival, ameliorated motor skills and reduced 
gliosis and inflammation in spinal cord. These beneficial effects were not associated with 
MSC differentiation, being possibly mediated through paracrine mechanisms. We 
hypothesized that MSC-derived exosomes and exosome-shuttled miRNAs could mediate 
these positive effects. To verify our hypothesis we tested  here the effects of exosomes 
derived from INF-activated MSCs on cultured astrocytes prepared from the spinal cord of 
120 day-old late-symptomatic SOD1G93A mice.  
The phenotype of SOD1G93A astrocytes and the efficacy of the exosome treatment were 
characterized by Western blotting, confocal microscopy and ELISA immunoassay.  
Vimentin, GFAP and S100β, astrogliosis markers, were increased in astrocytes from 120 
days-old SOD1G93A  mice vs. age-matched WT astrocytes and their expression was reduced 
after exposure to exosomes. Nrf2, a booster of the response to oxidative stress, was 
decreased in SOD1G93A astrocytes vs. age-matched WT astrocytes. Exosome treatment 
normalized Nrf2 down-regulation both in the cytoplasm and nucleus.  
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The quantification of TNF-α, IL-1β, IL-6 and CCL2 expression and release showed that 
these four pro-inflammatory factors were more expressed in and more efficiently released 
from SOD1G93A astrocytes and that the exposure to exosomes resulted in a significant 
decrease of their over-expression and release.  
Conversely, the anti-inflammatory cytokine IL-10 was decreased in SOD1G93A astrocytes 
and its expression was normalized after exposure to exosomes. Also NLRP3 expression, a 
marker of the multiprotein oligomer inflammasome, was increased in SOD1G93A astrocytes 
and the increase was reversed by exosomes.  
The amelioration of SOD1G93A astrocyte phenotype had a positive impact on MN viability 
in astrocyte-MN co-cultures. We observed a constant decrease of MN survival during time, 
both in control and exosome-treated co-cultures; however, the viability of MNs seeded on 
exosome-treated SOD1G93A astrocytes was always significantly higher when compared to 
co-cultures with untreated astrocytes. 
Exosome cargo was analysed for miRNAs and potential mediators of exosome activity 
were identified. The selected miRNAs showed a significant efficacy to reduce GFAP, IL-
1β and TNF-α expression. Computational analysis highlighted their possible involvement 
in the modulation of NFκB and MAPK pathway activation, affecting numerous kinases 
and transcription factors involved in the regulation of these inflammatory signalling 
pathways. qPCR analysis confirmed the ability of these four miRNAs to reduce MAPK11 
expression and to regulate TNF-α synthesis.  
Finally, we translated this study to human astrocytes derived from healthy donors and ALS 
patients carrying the A4V-SOD1 mutation. Human ALS astrocytes were treated with 
exosomes derived from human MSCs, activated with INF. We observed only a slight 
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amelioration of ALS astrocyte phenotype after the exosome treatment. Remarkably, 
analysis of MN viability showed an increased MN number in co-cultures with exosome-
treated astrocytes compared to those co-cultured with untreated astrocytes. 
These results indicate that exosomes and exosome-shuttled miRNAs can reduce astrocyte 
reactivity and that this effect has a positive impact on MN viability. The in-vitro exosome 
activity, both in mouse and human models, paves the way to translational preclinical in-



















1.1  The ALS Disease 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. Main 
feature of the pathology is the death of motor neurons (MNs) in the motor cortex and 
spinal cord (Brown, 1995). The mean age of onset is 55-60 years of age and within 3-5 
years from clinical onset patients succumb to the disease (Williams and Windebank, 1991). 
The first clinical symptom is represented by muscle weakness, which evolves with the 
progression of the disease in severe muscle atrophy, paralysis and finally respiratory 
failure due to diaphragm denervation.  
The first ALS cases were reported in 1824 by Charles Bell, but the first to discover the 
relationship between the clinical signs and the findings at autopsy was Jean-Martin 
Charcot. He deduced the correlation that links the deformity of limbs due to muscle 
spasticity with the corticospinal tract pathology. From this evidence he coined the name of 
the disease (Rowland, 2001), the etymology of which describes some characteristics of the 
disease: “amyotrophic” describes the peculiar muscle atrophy, weakness and fasciculation 
due to death of the lower MNs; “lateral sclerosis” indicates the hardness to palpation of the 
lateral columns of the spinal cord in autopsy specimens, which is determined by gliosis 
following the degeneration of the cortico-spinal tracts. 
Currently, the incidence of ALS is 2-3 new cases per 100,000 inhabitants/year and the 
prevalence is about 7-9 cases/100,000 inhabitants in occidental countries (Hardimanet al., 
2017). The disease affects men more commonly than women. There are some world areas 
where the incidence is 50-100 times higher compared to normal values (Steele e McGeere, 
2008), such as in Japan, Guam Island, Kii peninsula and in south-west of New Guinea 
(Kurtzke, 1982; Kuzuhara et al., 2001). It is believed that this incidence augmentation 
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could be determined by environmental factors, in particular from a cyanotoxin, the β-N-
Methylamino-L-Alanine (BMAA), contained in cycadales seeds that are used to produce 
flour. One of the hypothesis is that these populations are unable to prevent BMAA 
accumulation, causing an high concentration of BMAA in the organism, that can determine 
an abnormal activation of glutamate receptors and lead to excitotoxicity (Cox et al, 2018; 
Rao et al., 2006).  
There a two different forms of ALS depending on the origin of the degeneration: bulbar 
ALS and spinal ALS. The bulbar form of ALS derives from secondary MN death. It is 
characterized by speech disorders, tongue atrophy, dysphagia and abnormal salivation. If 
the symptoms are due to primary MN degeneration ALS is consider pseudobulbar, in 
which patients can have problems to control emotions and they are affected by 
uncontrollable laugh and cry. In both forms muscle weakness occurs 1-2 years after first 
symptoms but the progression to respiratory failure is within 2-3 years, faster than spinal 
form of ALS. In the spinal form of ALS the disease arises in limb weakness that can affect 
both superior and inferior limbs. Moreover, spinal ALS patients can even develop bulbar 
symptoms during disease progression and respiratory failure occurs within 3-5 years. This 
form is characterized by asymmetric muscle atrophy and spasticity of hands, forearms, 
shoulders and legs.  
Unfortunately, there is not a treatment able to efficaciously contrast the fast progression of 
ALS for both forms of the disease. The Food and Drug Administration (FDA), and then 
also the European Medicine Agency, approved two drugs for ALS treatment: Riluzole and 
Edaravone, which act on neuron excitability and oxidative stress, respectively. But, since 
these two drugs have only a modest impact on ALS symptoms and on life quality of 
patients, there is an urgent needed to investigate deeper the mechanisms underlying the 
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pathogenesis of ALS in order to identify potential new targets to modulate the disease. Of 
primary importance is the possibility of selecting early biomarkers of ALS, to stratify 
patients according to their specific disease signature and to intervene at an early stage of 
the disease.  
1.2 Genetic bases of ALS 
1.2.1 Familial and sporadic ALS 
ALS patients can be divided in two groups, namely familial (fALS) and sporadic (sALS). 
Approximately 10% of the total ALS cases are familial and based on genetic mutations 
which are usually inherited in a mendelian autosomal dominant manner (Oskarsson et al. 
2018).  
The first ALS-linked mutation to have been discovered was on the gene encoding copper-
zinc superoxide dismutase (SOD1) (Rosen, 1993). SOD1 mutations represent about 15% 
of fALS cases (Volk et al., 2018). The most common mutation identified is a hexancleotide 
GGGGCC (G4C2) repeat expansion in the chromosome 9 open reading frame 72 (C9orf72) 
gene. This mutation was described for the first time in 2006 in Scandinavian and Dutch 
patients presenting ALS and fronto-temporal dementia (Vance et al., 2006; Morita et al., 
2006) and involves 30-40% of fALS (Oskarsson et al. 2018). Many other mutations have 
been described, such as in Trans-activation response (TAR) DNA-binding protein 43 
(TDP-43 or TARDPB), Fused in sarcoma/translated in liposarcoma (FUS/TLS or FUS), 
vesicle-associated membrane protein associated B (VAPB), valosin-containing protein 
(VCP), alsin (ALS2), tumor necrosis factor (TNF) receptor-associated factor NF-κB 
activator (TANK)-binding kinase 1 (TBK1) (Mathis et al., 2019; Volk et al., 2018). During 
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the last years an increased number of mutations linked to ALS has been described; indeed, 
at least 30 fALS-related genes have been discovered.  
On the contrary, the aetiology of sporadic ALS is still largely unknown. The main 
hypothesis at the basis of sporadic ALS pathogenesis is a higher genetic susceptibility to 
environmental factors. Some works determined a correlation between ALS risk and 
exposure to pesticides in patients with polymorphism of PON1, PON2 or PON3 genes 
(Slowik et al. 2006, Ticozzi et al. 2010) or with a reduction of their expression (Gagliardi 
et al. 2013). These genes codify for A-esterase paraoxonase, which is able to detoxify 
organophosphate pesticides and their activity is dependent on different genetic variants, 
which could determine a decreased detoxifying activity. Many studies reported a 
relationship between ALS and professional soccer activity. The cause of this supposed 
correlation is still unclear, there are many hypotheses trying to explain this epidemiological 
finding, such as an excessive physical activity, repeated head injuries, exposure to 
pesticides and dietary supplements or illegal substances. However, these results derived 
from retrospective studies that did not show a significant correlation between ALS and 
diverse environmental factors, therefore the role of these risk factors in ALS remains only 
a hypothesis, requiring further studies, possibly, over a long period of time (Chio et al., 
2005; Chio et al., 2009; Bozzoni et al., 2016). 
Even if the cause is different, fALS and sALS present indistinguishable clinical symptoms 
and biological features. Today it is well known that ALS is a multifactorial and non-cell 
autonomous disease. Indeed, many factors have been proposed to be at the basis of MN 
degeneration and cell types of central nervous system (CNS) other than neurons are 
subjected to alterations which promote the development of a toxic environment in ALS.  
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1.2.2 Genetic mutation in ALS 
1.2.2.1 SOD1 mutations 
A mutation of SOD1 was first discovered in 1993. Today, over 180 mutations have been 
identified, including single point mutations, deletions, insertions and truncations. The 
SOD1 gene is located on chromosome 21q22.11 and is composed of five exons encoding 
for 153 amino acids which generate the SOD1 enzyme protein. This enzyme is 
ubiquitously expressed and highly conserved across species and localizes in the cytoplasm, 
nucleus, lysosomes and intermembrane space of mitochondria, where it binds copper and 
zinc ions and forms a homodimer displaying dismutase function; thus removing dangerous 
superoxide radicals by metabolizing them to molecular oxygen and hydrogen peroxide, 
thus providing a defence against oxygen toxicity (Saccon et al., 2013).  
The most common mutations of the SOD1 gene are the D90A (aspartic acid at codon 90 
changed to alanine), the A4V (alanine at codon 4 changed to valine) and G93A (glycine at 
codon 93 changed to alanine). The D90A mutation is the most abundant mutation in SOD1 
gene, the A4V mutation is linked to approximately 50% of fALS case in the U.S.A. 
population and the G93A mutation is more rare but it is one of the most studied in a 
transgenic model of the disease, because it is able to generate degeneration of MNs and 
ALS symptoms close to human disease (Pansarasa et al., 2018; Andersen 2006). 
The mutations in SOD1 gene lead to an unknown gain of function of the enzyme that may 
determine increased production of reactive oxygen species (ROS). Moreover, the mutation 
in SOD1 gene determines the formation of misfolded SOD1 protein and the formation of 
aggregates, triggering abnormal mitochondrial function, endoplasmic reticulum (ER) 
stress, axonal transport defects, excessive production of extracellular superoxide, and 
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oxidative damage from aberrantly secreted mutant SOD1 (Illieva et al., 2009). In 
particular, mutated SOD1 is able to activate a cascade of events in different cellular 
pathways involving MNs, astrocytes and oligodendrocytes. Selective expression of 
mutated SOD1 in MNs determined changes in RNA expression at early stage of the 
disease, causing ER stress, synapse and metabolic abnormalities. Selective expression of 
mutated SOD1 in astrocytes stimulates RNA changes later in the disease, affecting gene 
involved in inflammation and metabolism (Sun et al., 2015). 
Finally, early RNA changes, consisting mainly in the dysregulation of myelination and 
lipid signalling pathways, appeared when expressing selectively mutated SOD1 in 
oligodendrocytes. This analysis revealed that ER stress in motor neurons is an initiating 
event, after which a dysregulation of lipid signalling occurs in the three cell types, 
probably due to an abnormal association with membranes of misfolded SOD1. Since MNs 
produce high levels of SOD1 and have very low levels of ER chaperones, they represent 
the most vulnerable cells to misfolded SOD1 accumulation. The subsequent damage 
caused by mutated SOD1 in astrocytes and oligodendrocytes is essential to sustain and 
amplify the first toxic events within MNs (Sun et al., 2015). 
New evidence shows that WT-SOD1 may be involved also in sALS pathogenesis. 
Gruzman and collegues (2007) detected a modified 32-kDa SOD1 polypeptide, 
characterized by a covalent bond between the two monomers, which is present, together 
with the well know 16-kDa SOD1 polipeptide, in spinal cord extracts from fALS and 
sALS patients but not in the control group (Gruzman et al., 2007). This discovery 
stimulated further studies on the role of SOD1 in sALS patients, which revealed that WT-
SOD1 can acquire the toxic properties of mutant SOD1, thus determining the development 
of aggregates, in particular in the nuclei of astrocytes of spinal cords of ALS patients (Ezzi 
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et al., 2007; Forsberg et al., 2011). Finally, a loss of function of WT-SOD1 in sALS was 
observed. Indeed, the level of WT-SOD1 inside the nuclei of MNs and leukocytes is 
strongly reduced in sALS patients, leading to increase of DNA damage and, consequently, 
to a more severe disease progression (Cereda et al., 2013; Sau et al., 2007). 
1.2.2.2 C9orf72 mutations 
The C9orf72 mutation in ALS and FTD patients was identified for the first time in 2006, 
but only in 2011 it was revealed that this mutation is an expansion of G4C2 hexanucleotide 
repeat (HRE) in a non-coding region of the C9orf72 gene. The size of the repeats in ALS 
and FTD cases ranges between 700 and 1,600 as compared to 2-23 in control individuals. 
As for the majority of ALS-related mutations, also the C9orf72 mutation presents 
autosomal dominant inheritance (Hosler et al., 2000). ALS caused by C9orf72 mutation is 
characterized by early disease onset with bulbar involvement, cognitive and behavioural 
disorders, marked by psychosis and Parkinsonism in many cases (Kumar et al., 2017).  
The C9orf72 protein functions are still unknown. From bioinformatic data, it seems to 
belong to the family of DENN (Differentially Expressed in Normal and Neoplastic Cells) 
proteins, which regulate membrane trafficking by activating RabGTPase proteins and 
control protein degradation through autophagy modulation (Leko et al., 2019). At the 
moment three different mechanisms have been described in C9orf72 patients leading to 
MN degeneration.  
In the first hypothesis, C9orf72 mutation determines a loss of function. In humans, three 
transcript variants have been identified. Transcript variants 2 and 3 originate two identical 
protein isoforms of 481 amino acids, while variant 1 is truncated and generates an isoform 
of 222 amino acids. Many studies highlighted a reduced expression of long or short protein 
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isoforms in brain and spinal motor neurons, respectively (Frick et al., 2018; Xiao et al., 
2015; Waite et al., 2014). Indeed, C9orf72 HRE induces DNA hyper-methylation leading 
to decreased C9orf72 transcripts (Gijselinck, 2016). In drosophila and zebrafish models the 
knock-out or knock-down of C9orf72 gene determined MN degeneration (Therrien et al., 
2013; Ciura et al., 2013), but the human C9orf72 gene has only partial homology with its 
ortholog in these two models. In mouse, which has a C9orf72 gene more similar to human, 
the knockout or knockdown of C9orf72 gene did not determine the development of the 
ALS and FTD classic phenotype, suggesting that C9orf72 loss of function is not the true 
cause of the disease (Sudria-Lopez et al., 2016; Koppers et al., 2015).  
The second possible mechanism of C9orf72-related neurodegeneration is represented by a 
gain of function. The sequence G4C2 is characterized by a high uniformity, determining the 
formation of high-order DNA structures, called G-quadruplex. These structures could 
increase the length of the repeats creating a heterogeneous mixture of G-quadruplexes 
through the DNA sequence (Fratta et al., 2012). When the G-quadruplexes are localized in 
the HRE region of the C9orf72 gene, they generate truncated RNA transcripts that are 
aborted in the hexanucleotide repeat region. In turn, this event can cause the formation of 
G-quadruplexes, RNA hairpin structures and hybrid structures between HRE-containing 
RNA and HRE-containing DNA (R-loops) (Hauesler et al., 2014; Reddy et al., 2014). All 
these high-order structures could promote and regulate the replication, transcription and 
translation of the surrounding region (Kendrick and Hurley, 2010), leading the cells to 
nucleolar stress and impeding the correct RNA processing (Hauesler et al., 2014). Indeed, 
one of the main biological features of ALS patients carrying HRE-C9orf72 mutation is the 
presence in the brain of nuclear aggregates of HRE-containing RNA (RNA foci) (DeJesus-
Hernandez et al., 2011). Antisense RNA and several proteins, which specifically bind the 
17 
 
aggregates, such as nucleolin, Pur-α, Heterogeneous Nuclear RiboNucleoProtein 
(hnRNPs), double-stranded RNA-specific adenosine deaminase B2 (ADARB2), 
Serine/arginine Rich Splicing Factor 1 (SRSF1), SRSF2 and ALYREF have been found 
within RNA foci (Lee et al., 2013; Cooper-Knock et al., 2014). The sequestration of these 
proteins within the RNA foci leads to impairment of ribosome maturation and RNA 
transport and translation (Haeusler et al., 2014). To test this hypothesis, ALS mouse 
models carrying transgenic C9orf72, determining RNA and protein toxic gain of function, 
have been studied. However, signs of neurodegeneration were observed only in some 
cases, requiring deeper analysis on the cause of ALS in C9orf72 patients (Moens et al., 
2018; Liu et al., 2016). 
The last mechanism, the same related with a toxic gain of function of C9orf72, considers 
the accumulation of Dipeptide Repeat (DPRs) proteins translated by C9orf72 HRE- 
containing RNA (Ash et al., 2013). DPR proteins, in particular when enriched in Arginine, 
are able to disrupt the regular transport between nucleus and cytoplasm (Jovičić et al., 
2015), thus interfering with RNA processing (Kwon et al., 2014), and to affect the 
ubiquitin proteasome system, followed by ER stress and formation of toxic amyloid fibrils 
(Zhang et al., 2014; Chang et al., 2016). Unexpectedly, even if there is clear evidence of 
DPR protein toxicity in C9orf72 mouse models, in ALS and FTD patients only low levels 
of DPRs were found in brain regions which are most involved in the disease (Mackenzie et 
al., 2013). Why of this discrepancy is still unknown, but the most accredited hypothesis 
sustains that, at the time of autopsy, the only survived neurons are the ones with lower 
levels of DPRs, while neurons containing high level of DPR proteins are more susceptible 
to degeneration and, therefore, precociously die (Wen et al., 2017).  
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In conclusion, many studies proposed a synergic toxic mechanism where the loss of 
function of C9orf72 makes cells more sensitive to its toxic gain of function (Maharjan et 
al., 2017).  
1.2.2.3 TDP-43 mutations 
TDP-43 is a ubiquitously expressed DNA-/RNA-binding protein. It is encoded by 
TARDBP gene, located in the short arm of chromosome number 1 at position 36.22 
(1p36.22) (Buratti and Baralle, 2001). TDP-43 is predominantly a nuclear protein, but can 
move to the cytoplasm following physiological inputs or stress insults (Winton et al., 
2008). Therefore, the main functions of TDP-43 are exerted in the nucleus, such as 
regulation of RNA splicing and modulation of microRNA (miRNA) biogenesis. 
Interestingly, TDP-43 is capable of autoregulating its own mRNA stability and 
consequently also the protein level. In cell cytoplasm, TDP-43 is essential for dendritic and 
somatodendritic RNA transport granules in neurons and for neuronal plasticity (Alami et 
al., 2014; Ayla et al., 2011). In ALS and FTD, TDP-43 is one of the major components of 
ubiquitinated neuronal cytoplasmic inclusions (Arai et al., 2006; Vance et al., 2009). It 
forms aggregates, containing both full-length and fragmented protein, that result to be 
detergent resistant and hyperphosphorylated. Moreover, it has been reported an enrichment 
of TDP-43 in cytosplasm and a consequent reduced level in the nucleus. 
TARDBP gene presents numerous mutations related to ALS or FTD (Sreedharan et al., 
2008). Among the most studied mutations we can mention A315T, Q331K, M337V, which 
originated ALS-disease mouse models (Buratti, 2015). Mutated TDP-43 has an increased 
propensity to aggregate, a high tendency to cytoplasmic mislocalization and alterations of 
binding interaction with other proteins (Prasad et al., 2019). The augmented translocation 
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of TDP-43 from the nucleus to cytoplasm causes a loss of function (Arai et al., 2006), 
characterized by a dysregulation of RNA processing (Freibaum et al., 2010). Although the 
precise sequence of events in TDP-43-linked ALS is still undefined, several findings 
sustain that TDP-43 loss of function and mislocalization are the first critical neutotoxic 
mechanisms, followed by the formation of insoluble aggregates (Ederle and Dormann, 
2017). These latter represent the basis of TDP-43 gain of toxic functions. Indeed, the 
deposition of insoluble TDP-43 inclusions causes alteration of autophagy by adsorbing 
proteins related to autophagy pathways, such as microtubule-associated proteins 1A/1B 
light chain 3B (MAP1LC3B or LC3-II) and p62, and determines reduction of protein turn-
over (Budini et al., 2017), impairment of endocytosis (Liu et al., 2017) and abnormal 
mitochondria morphology, transport and distribution (Wang et al., 2013; Magrane et al., 
2014). Finally, the coexistence of all these elements leads to an impaired response of MNs 
to oxidative stress, excitotoxicity, Calcium (Ca2+) homeostasis and protein degradation. 
1.2.2.4 FUS/TLS mutations 
FUS/TLS is a ubiquitously expressed RNA/DNA binding protein. It is located in the short 
arm of chromosome 16 at the position 11.2 (Ederle and Dormann, 2017). FUS is one of the 
components of the hnRNP complex. It is involved in several cellular processes, such as 
gene transcription and regulation, DNA repair, RNA shearing, transport and translation, 
processing of miRNAs, and maintenance of genomic stability (Lagiertourenne et al., 
2010).  
The first mutation in FUS gene was discovered in 2009 (Kwiatkowski et al., 2009). Then, 
several ALS-linked mutations have been identified, such as P525L, P525R and, recently, 
Y526C (Mackanzie et al., 2010; Corcia et al., 2017). It is recognized that mutated FUS 
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determines a severe and fast progressive form of ALS. In many cases the onset of the 
disease occurs before 40 years of age and for P525L and Y526C mutations first symptoms 
appear even at 20-25 years (Corcia et al., 2017). FUS mutations determine a 
mislocalization of the FUS protein, which translocates from the nucleus to the cytoplasm. 
In the cytoplasm, FUS causes the formation of stress granules during oxidative stress 
insults, mitochondrial dysfunction or viral infection (Gao et al., 2017).  
FUS mutation can lead to cytotoxicity by two mechanisms. Gain of toxic function, due to 
translocation to the cytoplasm, an event that favours aggregate formation and sequestration 
of other proteins involved in several physiological pathways (Ramaswami et al., 2013), or 
loss of function, due to mRNA instability in particular in the spines of neurons (Neumann 
et al., 2009). Furthermore, astrocytes and microglia produce a strong inflammatory 
response, by secreting high level of IL-1β, TNF-α and IL-6 and by increasing transcription 
of inducible nitric oxide synthase (iNOS) and Prostaglandin E2 (PGE2) (Ajmone-Cat et al., 
2019).  
A recent study, conducted on FUS iPSC-derived neurons and post-mortem tissue from 
FUS-ALS patients, demonstrated that FUS mislocalization determines an imbalance in 
RNA-binding protein (RBP) homeostasis [hnRNPA1, TATA-Box Binding Protein 
Associated Factor-15 (TAF-15), Ewing sarcoma breakpoint region 1(EWSR1),...], 
exacerbating FUS pathogenesis and accelerating neurodegeneration (Marrone et al., 2019). 
Since the level of p62 was increased in neurons with FUS mutations compared to control 
neurons, they hypothesized an impairment of the protein quality control system linked to a 
decreased clearance of FUS aggregates. Indeed, when they tested two different 
compounds, torkinib and PQR309, able to trigger autophagy, a decrease of FUS aggregate 
levels was observed, both in vitro and in vivo in Drosophila model, also RBP homeostasis 
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was rescued, increasing neuron survival and ameliorating Drosophila motor skills 
(Marrone et al., 2019).  
1.2.2.5 Ubiquilin-2 and sequestosome 1 mutations 
Ubiquilin-2 (UBQLN2) is a ubiquitin-linked protein involved in the protein quality control 
system at neuronal level. UBQLN2 gene is located on X chromosome at the position 
11.21; mutations in this gene determine a rare form of X-linked ALS/FTD. UBQLN2 
missense mutations have been identified in X-linked ALS and FTD, with most of the 
mutations occurring in or near a proline-rich repeat domain (Deng et al., 2011). UBQLN2 
behaves as an adaptor protein, shuttling ubiquitinated proteins to the proteasome for 
degradation (Ko et al., 2004). Moreover, it also modulates autophagy and interacts with 
several molecular chaperones (Hjerpe et al., 2016). Mutations in UBQLN2 cause an 
increase propensity to self-assembly and promote the formation of insoluble inclusions, 
leading to an imbalance of the protein quality control system and cell homeostasis 
(Sharkey et al., 2018). 
Sequestome 1 (SQSTM1), also known as the ubiquitin-binding protein p62, is an 
autophagosome cargo protein receptor required for selective macroautophagy. It acts as a 
bridge between polyubiquitinated cargo and autophagosomas (Clausen et al., 2010). It is 
located on chromosome 5 at the position 35.3. In the same way of UBQLN2, SQSTM1 
forms toxic aggregates in cell cytoplasm and alters the normal protein turn-over. Silencing 
SQSTM1 affects mitochondrial membrane potential and consequently inhibits 
mitochondrial electron transport chain. Moreover, a recent paper described a link between 
SQSTM1 mutations and mitochondrial dysfunction. In fibroblasts of two ALS patients 
harboring two different point mutations (A381V and K238del), SQSTM1 was 
22 
 
significantly reduced. NADH and FAD redox index was measured to evaluate the 
energetic metabolism in mutant cells and an impairment in complex I function was 
detected, leading to a decrease production of ATP. On the other hand, also FAD level 
was reduced, suggesting a possible shift to complex II respiration to compensate the 
inhibition of complex I. These altered mitochondrial functions promote ROS 
production, determining oxidative stress damage (Bartolome et al., 2017). Impairment 
of ATP production, together with an increase ROS formation, is one of the main 
mechanism causing MN degeneration. This mechanism could be related also to sporadic 
ALS and other forms of familial ALS, indeed SQSTM1 positive inclusions are common 
in almost all patients (Hiji et al., 2008; Pikkarainen et al., 2008). 
1.2.2.6 Optineurin mutations 
Optineurin is a polyubiquitin-binding protein, which regulates several physiological 
cellular processes (Ryan and Tumbarello, 2018). Optineurin is highly conserved among 
species and is located on chromosome 10 at the position 13, encoding a 577 amino acid 
cytoplasmic protein, in humans. It is ubiquitously expressed, but higher expression was 
observed in brain, retinal ganglion cells, spleen, skeletal muscle, and heart (De Marco et 
al., 2006).  
As anticipated, Optineurin has many functions: it controls signalosome assembly for NFκB 
activation, works as an autophagy adaptor; selectively binds to the cargo deputed to 
degradation of damaged mitochondria, protein aggregates, or intracellular pathogens and 
delivers them to autophagosomes. During autophagy, optineurin facilitates autophagosome 
maturation and its fusion to lysosomes, interacts with TBK1 to trigger the production of 
antiviral type I interferon (IFN) in response to viral infection, preserves the Golgi 
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apparatus structures and regulates post-Golgi transport and exocytosis, protects from 
nectroptosis and/or apoptosis during TNF-mediated NFκB stimulation (Markovinovic et 
al., 2017; Ryan and Tumbarello, 2018).  
Mutations of optineurin have been identified in fALS and sALS patients and more than 20 
ALS-linked missense optineurin variants have been reported (Maruyama et al., 2010; van 
Blitterswijk et al., 2012). The most accredited hypothesis for the toxic effects of optineurin 
mutations consists in a loss of function, due to the deletion of the transcriptional starting 
sites in exon 4 and exon 5 and non-sense mutations encoding truncated proteins lacking 
different portions of its C-terminus (G23X,Q165X, S174X, Q398X) (Maruyama et al., 
2010, Beeldman et al., 2015), causing the loss of optineurin functional domain.  
Because of the numerous functions of optineurin, its loss of function has disastrous 
consequences, such as autophagy impairment, mitochondrial dysfunction leading to 
energetic deficit, altered inflammatory response to damage-associated molecular patterns 
(DAMPs), incapacity to mitigate NFκB and necroptosis pathway activation in chronic 
stress condition, and imbalance of pro- and anti-inflammatory factors (Markovinovic et al., 
2017; Markovinovic et al., 2018). Mouse models with mutations or knock-out for 
optineurin have been generate to validate the loss of function hypothesis. A detailed 
characterization of CNS features for optineurin-/- mice showed a massive axonal 
degeneration, sustaining the idea that the loss of function of optineurin can lead to ALS 





1.2.2.7 VCP mutations 
VCP is a ubiquitously expressed protein involved in protein homeostasis, mitochondria 
quality control and apoptosis (Meyer et al., 2012). VCP gene is located on chromosome 9 
at the position 13.3.  
The 2% of fALS cases are caused by autosomic-dominat VCP mutations and more than 20 
different mutations in VCP gene have been identified (Johnson et al., 2010). Recent in 
vitro and in vivo studies on transgenic models highlighted the pathologic mechanisms 
determined by VCP mutation. Hall and colleagues (2017) demonstrated that VCP-mutant 
neurons, derived from induced pluripotent stem cells (iPSCs), showed increased synapse 
loss, cell death, transcriptional perturbations of genes encoding for ion channels and 
synapse structural proteins, ER stress and uncoupled oxidative phosphorylation leading to 
ROS production (Hall et al., 2017).  
Mutant VCP affects also skeletal muscle; one in vivo model generated by deleting VCP in 
differentiated skeletal muscle presented ALS symptoms, such as weight loss, weakness and 
reduced motor skills. The main cause for myofiber necrosis seemed to be the dysregulation 
of lysosomal homeostasis due to lack of VCP. Indeed, damaged endo-lysosomes are not 
recognized for autophagic degradation without VCP labelling, thus leading to damaged 
lysosome accumulation and consequently to mitochondria dysfunction and energetic 
impairment (Arhzaouy et al., 2019).  
1.2.2.8 TBK1 mutations  
TBK1, located on chromosome 12 (12q14.2), codes for a protein kinase involved in many 
pathways including immune response and autophagy. TBK1 is composed of 4 domains: a 
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kinase domain, responsible for its kinetic activity, an ubiquitin-like domain, a scaffold 
dimerization domain, and a C-terminal domain, involved in TBK1 association to binding 
partners such as OPTN (de Majo et al., 2018). TBK1 plays a key role in autophagy, 
through the phosphorylation of several autophagy adaptors including p62, OPTN and 
nuclear dot protein 52 kDa, enhancing their ability to link LC3-II and ubiquitinated 
cargoes. It regulates microtubule dynamics in mitosis and the cytoplasmic levels of dynein. 
Further, it is involved in the induction of interferons synthesis and release, modulating 
neuroinflammatory stimuli (Oakes et al., 2017). 
Mutations in TBK1 have been recently linked with ALS and FTD by two independent 
whole exome sequencing/whole genome sequencing studies. Many ALS-linked TBK1 
mutations generate premature stop codons, leading to non sense-mediated mRNA decay 
and haploinsufficiency that is predicted to impair autophagy (Cirulli et al., 2015; 
Freischmidt et al., 2015). 
A recent work in a mouse model knock-out for TBK-1 further validated the hypothesis of a 
loss of function of TBK-1 related to ALS and FTD pathogenesis. These mice showed 
aggregates positive for TDP-43 and p62, motor impairment, astrogliosis and reduced 
number of synapses in the cortex, supporting the involvement of TBK-1 also in learning 
and memory activity (Duan et al., 2019). However, the role of TBK-1 in ALS and FTD 




















1.3. Biomolecular aspects of ALS 
Nowadays, it is well recognized that ALS is a multifactorial disease, in which several 
mechanisms take place and different cellular types are involved, contributing to MN 
degeneration. Thanks to transgenic mouse models, in-vitro systems able to mimic 
pathologic conditions, and post-mortem tissue analysis, several alterations in physiological 
cellular homeostasis have been partially revealed, even if the precise ALS causative 
mechanisms are still unclear. These toxic events are similar both in fALS and sALS. 
1.3.1 Oxidative stress 
Oxidative stress is one of the main events in ALS and also one of the best studied, because 
of the numerous disease models based on SOD1 mutation. Oxidative stress biomarkers 
have been found in urine, blood, cerebrospinal fluid (CSF), and individual tissue of ALS 
patients (Kikuchi et al., 2002; Mendez et al., 2015).  
Oxidative stress derives from the imbalance between oxidants and anti-oxidants within a 
biological structure. An abnormal production of ROS or deficit in antioxidant systems 
could be at the basis of tissue damage and cell death (Singh et al., 2019). 
Hydrogen peroxide (H2O2), superoxide anion (O2-) and hydroxyl radical (HO•), but also 
reactive nitrogens species (RNS), such as nitric oxide (NO), are physiologically produced 
during cell life cycle. Indeed, many cell functions, such as signal transduction, gene 
transcription, oxidative phosphorylation and ATP production in mitochondria, require 
oxygen as a substrate (Halliwell, 2006; Uday et al., 1990). If these reactive molecules are 
not detoxified by anti-oxidant enzymes, as glutathione peroxidase, SOD1, and catalase, 
they can damage cell structure by causing oxidation of different biomolecules, such as 
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lipids, protein, DNA/RNA, etc. (Yu et al., 2012). Lipids are highly susceptible to oxidation 
and a damage at this level leads to a perturbation of plasmatic membrane fluidity and 
permeability, that promotes the entrance of substances, in particular ions, inside the cell 
(Brown and Murphy, 2009). Lipid peroxidation promotes the propagation of oxidative 
damage that ultimately affects also proteins and RNA/DNA, determining structural and 
functional modifications with increased protein aggregation and proteolysis (Halliwell and 
Gutteridge, 1984). 
The cell compartment in which most part of ROS/RNS originated is the mitochondrion, 
probably because mitochondria are enriched in redox enzymes (Halliwell, 2007). 
Mitochondria dysfunctions (e.g. due to mitochondria DNA damage) could improve 
ROS/RNS production, together with a reduced protective action from these reactive 
species. Since mitochondria are the main producers of the cell-needed energy, their 
malfunction leads the cells to apoptosis or senescence with catastrophic events, especially 
in non-proliferative cells, as neurons (Wang et al., 2013; Redza-Dutordoir and Averill-
Bates, 2016). 
Even if SOD1 mutations represent the direct link with oxidative stress in ALS, redox 
alterations have been found also in C9orf72, TDP-43 and FUS familial forms, suggesting a 
correlation between RNA metabolism dysregulation and oxidative stress. Cohen and Coll. 
demonstrated that oxidative stress causes TDP-43 delocalization from the nucleus to the 
cytoplasm and increases its tendency to aggregate (Cohen et al., 2015). Moreover, both 
TDP-43 and FUS co-localizes with stress granules, that represent one of the responses of 
cells to oxidative stress insults modulating gene expression by prioritizing translation of 
stress response-linked genes (Li et al., 2013; Bentmann, 2012). If stress granules persist, 
they can play a pivotal role in aggregate formation (Parker et al., 2012).  
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On the other hand, TDP-43, FUS and C9orf72 can co-localize with mitochondria and cause 
oxidative stress. Three hypotheses have been proposed to explain this mechanism. First, a 
direct damage may occur due to sequestration of mitochondrial proteins by RNA-binding 
proteins (Magranè et al., 2014; Deng et al., 2015). Second, through interaction with non-
mitochondrial proteins that are involved in mitochondrial protein synthesis. Among these, 
FOXO3 acts by down-regulating many nuclear-encoded genes that control mitochondrial 
function. TDP-43 exerts a negative control on FOXO3 and in TDP-43-linked ALS, where 
it translocated from the nucleus to the cytoplasm, FOXO3 showed an increased inhibitory 
activity leading to a reduction of the mitochondrial functions (Ferber et al., 2012; Zhang et 
al., 2014). Finally, TDP-43 and FUS could be involved in the regulation of specific 
mRNAs coding for proteins preserving mitochondria physiology. This last hypothesis is 
sustained by a recent study which demonstrated the ability of mutant TDP-43 to alter the 
splicing pattern of nuclear-transcribed mRNA, coding for mitochondrial fission regulator-1 
(Mtfr-1) and complex I subunits ND3 and ND6, causing complex I disassembly (Finelli et 
al., 2015; Wang et al., 2013).  
A reduced efficiency of the anti-oxidant response has been reported in ALS patients, in 
association with the increased production of ROS and free radicals. In particular, the 
Nuclear factor erythroid 2-related factor 2 (Nrf2), a key player to stimulate the resistance 
of the cells to oxidative stress, was decreased in ALS patients (Sarlette et al., 2008). In 
normal condition Nrf2 is bound to the endogenous inhibitor Kelch-like ECH associated 
protein 1 (Keap1). Nrf2 is activated by endogenous or exogenous stressors, which cause 
increased levels of free radicals; then, it translocated from the cytoplasm to the nucleus, 
where forms heterodimers with other transcription factors and binds to the antioxidant 
response element (ARE), a regulatory enhancer region. The Nrf2-ARE interaction 
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promotes the transcription of several genes involved in the cellular antioxidant and anti-
inflammatory defence, such as phase 2 detoxification enzymes [NAD(P)H quinone 
oxyreductase (NQO1), glutathione)], that are necessary for glutathione biosynthesis, 
extracellular superoxide dismutase, glutamate-6-phosphate-dehydrogenase, heat shock 
proteins and ferritin. Furthermore, Nrf2 promotes the synthesis of pro- and anti-
inflammatory enzymes, such as cyclooxygenase-2 (COX-2), iNOS, and heme oxygenase-1 
(HO-1) (Petri et al., 2012).  
Because of the key role of Nrf2 in regulating antioxidant response, many studies focused 
on the administration of Nrf2 activator to slowdown the disease progression. Neymotin et 
al. (2011) tested two analogs of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) in 
the SOD1G93A mouse model of ALS. In treated mice, Nrf2 expression was increased and 
function was recovered. Accordingly, the authors observed an upregulation of classical 
Nrf2-regulated genes. These positive effects at biomolecular level translated in an 
amelioration of motor performance, a reduction of weight loss and, finally, in a prolonged 
survival (Neymotin et al., 2011).  
Other activators of Nrf2 have been tested, such as tert-butylhydroquinone, DL-
sulphoraphane, lipoic acid, fumaric acid and curcumin (Petri et al., 2012). The 
unsuccessful results registered using these positive modulators have been ascripted to the 
low penetration of the blood brain barrier (BBB), but they were also related to the unclear 
mechanisms of action since it was reported that the expression of a large variety of non-





1.3.2 Mitochondrial dysfunctions 
Mitochondria are cellular organelles that cover an essential role in different cellular 
processes, in particular in energy metabolism, Ca2+ homeostasis, lipid biosynthesis and 
apoptosis. They are fundamental for neuron survival and function. Indeed, neurons require 
the 20% of the body’s resting ATP production (Engl and Attwell, 2015). For this reason 
mitochondrial dysfunction is one of the stronger hypothesis at the basis of ALS 
pathogenesis (Smith et al., 2017).  
1.3.2.1 Mitochondrial structure 
fALS and sALS patients showed structurally altered and aggregated mitochondria, with 
swollen and vacuolated morphology (Sasaki et al., 2007). The mitochondria morphology 
disruption can directly derive from mutated proteins, in particular mutations have been 
identified in the mitochondrial protein CHCHD10, which allows the contact between the 
inner and the outer mitochondrial membrane. Also other ALS-mutated proteins seem to be 
involved in the structure and function impairment of mitochondria. Mutant SOD1 
aggregates within the intermembrane space, decreasing the electron transport chain 
complexes, affecting the activity of voltage-dependent anion channel-1 (VDAC1) and 
promoting pro-apoptotic signals through interaction with Bcl-2 (Ferri et al., 2006; Israelson 
et al., 2010; Pasinelli et al., 2004). TDP-43 co-localizes with mitochondria and binds the 
mRNAs coding for mitochondrial proteins, reducing energy metabolism (Wang et al., 
2013). FUS co-localization with mitochondria reduces ATP production, probably due to an 
interaction with the mitochondrial chaperone heat shock protein of 60 kDa (HSP60) (Deng 
et al., 2015). 
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Mitochondrial fission and fusion, two essential functions for the auto-regulation of the 
mitochondrial dynamic network, were altered in diverse ALS models. Fusion permits 
mitochondrial exchange of metabolites, DNA and proteins and allows for dissipation of 
small changes in mitochondrial membrane potential. On the other hand, fission facilitates 
mitochondrial motility and determines the isolation of damaged parts of the network, 
before their degradation by mitophagy. Dynamin-related protein 1 (Drp1) and Fission 1 
(Fis1) sustain the fission process; while mitofusin (Mfn) 1 and 2 and Optic atrophy 1 
(Opa1) promote fusion (Chan et al., 2012; Westrate et al., 2014).  
In ALS models, an increased expression of fission proteins respect to fusion proteins was 
reported (Liu et al., 2013; Xu et al., 2010). An abnormal mitochondrial fission in ALS 
could cause the formation of smaller mitochondria, which are less energetically stable and 
more susceptible to ROS accumulation, if they cannot fuse back to the network (Hoitzing 
et al., 2015). A proof of concept for this pathogenic mechanism has been provided by some 
studies on the beneficial effects of mitochondrial fission inhibition or mitochondrial fusion 
upregulation in ALS models, in which a reduced mitochondrial fragmentation and an 
increase of MN viability were observed (Song et al., 2013; Wang et al., 2013). 
1.3.2.2 Mitochondrial axonal transport 
Axonal transport is essential for MN survival. Indeed MNs are highly polarized cells and 
require membrane-bound vesicles, organelles, protein, lipids and RNA to transport 
mitochondria from the soma to the axon terminal and vice versa. In physiological 
condition, kinesin-1 and dynein allow the transport of mitochondria along the entire length 
of MN axons, the first from the soma to the axon terminal (anterograde transport) and the 
second from axon terminal to the cell body (retrograde transport) (Smith et al., 2017).  
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Diverse SOD1 mutations affect anterograde transport of mitochondria in cultured cortical 
neurons and in embryonic MNs (De Vos et al., 2007). Other mutations causing impaired 
mitochondrial axonal transport has been identified in VAPB, TDP-43 and TBK1 (Magranè 
et al., 2014; Wang et al., 2013; Oakes et al., 2017). Dysfunctions in mitochondrial axonal 
transport cause redistribution of mitochondrial in axons, in particular MNs showed a 
decreased number of axonal mitochondria, already at an early stage of the disease, which, 
in addition, assume a cluster pattern (Sasaki et al., 2007). 
1.3.2.3 Mitochondria and calcium homeostasis 
In addition to an energetic deficit, mitochondria changes determine an alteration of 
intracellular Ca2+ levels. Loss of Ca2+ homeostasis has been detected in several ALS 
animal models and also in ALS patients, already at an early symptomatic stage of the 
disease (Stoica et al., 2016; Damiano et al., 2006; Mòrotz et al., 2012).  
One of the causes of Ca2+ dysregulation could be the loss of communication between 
mitochondria and the ER. Indeed these two organelles interact through protein complexes, 
such as Mnf1, Mnf2, inositol 1,4,5-trisphosphate receptor (IP3R) and VDCA1 (Manfredi et 
al., 2016). This interaction, that allows the exchange of Ca2+ between mitochondria and 
ER, has been found impaired in mutant SOD1-, TDP-43- and FUS-related ALS (Stoica et 
al., 2016; Bernard-Marissal et al., 2015; Stoica et al., 2014). 
Notably, MNs are more sensible to Ca2+ homeostasis disruption compared with other 
neuronal cells. They express a higher number of permeable Ca2+ receptors at the 
postsynaptic level, determining a massive Ca2+ influx during excitatory neurotransmission, 
and, at the same time, they suffer of impaired cytosolic buffering capacity, as they express 
low level of parvalbumin and calbindin, two essential Ca2+ buffering proteins. This make 
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MNs highly dependent from mitochondria to control the intracellular Ca2+ level (Van den 
Bosh et al., 2000).  
Loss of Ca2+ homeostasis can trigger numerous toxic events: elevated concentration of 
cytosolic Ca2+ directly impacts axonal transport of mitochondria by interacting with the 
mitochondrial kinesin-1 receptor Miro1 (Wang et al., 2009), increases ROS production and 
oxidative stress due to Ca2+ overload in mitochondria (Carriedo et al., 2000), activates 
calpain-1 leading to a massive proteolitic activity of specific substrates, such as nNOS, αII-
spectrin, NR2B subunit of NMDA receptor (Stifanese et al., 2014; Stifanese et al., 2010), 
cleaves and activates pro-apoptotic proteins (Ashkenazi  and Salvesen, 2014). 
Sigma-1 receptor (Sig1R), highly expressed at the mitochondria-associated ER 
membranes, has been found mutated in rare forms of ALS (Al-Saif et al., 2011) and 
downregulated in SOD1G93A mice and in patients with fALS and sALS. Its downregulation 
seems to be strictly related with the severity of disease progression (Mavlyutov et al., 
2013; Prause et al., 2013). Thanks to Sig1R role in Ca2+ homeostasis maintenance, Tadić 
and colleagues tested diverse agonists for Sig1R to restore mitochondria-ER 
communication. The SA4503 and PRE-084 compounds have been tested in non-transgenic 
and in SOD1G93A MNs from mice embryos. Only the Sig1R agonist SA4503 exerted a 
positive effect on motor neuron survival, by accelerating Ca2+ cytosolic clearance after the 
activation of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type 
glutamate receptors or bradykinin stimulus and up-regulating Sig1R expression (Tadić et 





1.3.2.4 Mitochondria and skeletal muscles 
Mitochondrial abnormalities were observed also in skeletal muscles of fALS and sALS 
patients, already at an early stage of disease progression. The first studies reported changes 
in the number and in the morphology of mitochondria, that appeared elongated and large; 
moreover, they form aggregates able to undermine the integrity of the sarcolemma 
membrane in subsarcolemma regions (Chung et al., 2002; Napoli et al., 2011). The altered 
morphology denotes also a functional impairment. Indeed, a lot of evidence showed a 
reduced efficiency of mitochondrial respiration and ATP production, probably due to 
decreased activity of several enzymes, among these the NADPH dehydrogenase (complex 
I) and cytochrome c oxidase (complex IV) (Crugnola et al., 2010; Echaniz-Laguna et al., 
2006). Subsequent studies, by microarray and qPCR analysis, revealed that also the mRNA 
for several proteins involved in mitochondrial biogenesis and dynamics were down-
regulated in skeletal muscles of ALS patients (Russell et al., 2013). As for MNs, muscle 
mitochondrial malfunction leads to an imbalance of intracellular Ca2+ concentration. 
Indeed, sodium (Na+) permeant nicotine receptors produce depolarization at the 
neuromuscular junction that allows a massive Ca2+ influx and muscle contraction (Fucile, 
2004). If mitochondria are not able to efficiently uptake Ca2+ from the cytosol, a cascade of 
toxic events, such as incapacity to generate an electric potential, can be triggered (Yi et al., 
2011). Oppositely, mitochondrial Ca2+ overload will induce abnormal ROS production in 
mitochondria (Muller et al., 2007) and excessive Ca2+ will exacerbate mitochondrial 
damage (Saotome et al., 2008; Yi et al., 2004). The final consequence of these events is 
represented by an interruption of the cross-talk between motor neurons and skeletal 
muscles and, finally, to muscular atrophy (Rasola et al., 2010). 
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1.3.3 Excitotoxicity  
1.3.3.1 Increased glutamate availability 
Excitotoxicity, that is the toxicity mediated by an abnormal concentration of glutamate in 
the synapses, is a well-studied feature of ALS. In 1996, Excitatory Amino Acid 
Transporter 2 (EAAT2) modifications were linked with ALS pathogenesis. Indeed, a 
deficit in the uptake of glutamate from the synapses was reported in cortex and spinal cord 
of ALS patients (Bristol and Rothstein, 1996). A further study revealed that EAAT2 
functional alterations derived from aberrant truncated transcripts of EAAT2 gene (Lin et 
al., 1998). Other factors able to affect EAAT2 transcription, translation and activity have 
been reported, such as oxidative stress, fatty acids, growth factors and cytokines (Rao et 
al., 2003;  Gegelashvili et al., 1997; Trotti et al., 1995). The reduced clearance of glutamate 
leads to an increased activation of MNs, with an abnormal influx of Ca2+. As described 
above, Ca2+ homeostasis dysregulation determines fatal changes in cell physiology, 
inducing ER stress, mitochondria overload and, finally, cell death (Van Damme et al., 
2005). 
Not only glutamate clearance but also an abnormal release of glutamate was observed in in 
vitro models of ALS. Synaptosomes prepared from spinal cord of SOD1G93A mice showed 
increased release of glutamate both in basal conditions and after the application of 
depolarizing stimuli, already at a presymptomatic stage of the disease (Milanese et al., 
2011; Bonifacino et al., 2016). Moreover, Group I metabotropic glutamate autoreceptors 
(mGluR1 and mGluR5) in the SOD1G93A mouse model resulted more sensitive to the 
glutamate released in synaptic space, compared to control mice, causing an increased 
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activation of these receptors and allowing excessive Ca2+ influx and glutamate release 
(Giribaldi et al., 2013, Bonifacino et al., 2019).  
1.3.3.2 AMPA receptor hyperfunction 
AMPA receptors are a class of ionotropic glutamate receptors permeable for Ca2+ or Na+, 
depending on the expression and the post-transcriptional editing of the mRNA of the 
different subunits that form the receptor (Lorenzini et al., 2018). Numerous findings 
support the involvement of this receptor in ALS pathogenesis and progression. Even if 
autoradiography binding did not show differences between AMPA receptor in ALS 
patients and in healthy controls (Allaoua et al., 1992), MNs are differentially vulnerable to 
toxic levels of kainic acid, an agonist of both AMPA and kainate receptors, in vitro 
(Carriedo et al., 1996; Bar-Peled et al., 1999) and in vivo (Sun et al., 2006). Therefore, it 
has been hypothesized that alteration of AMPA receptors are due to modifications in its 
composition. Indeed, the expression of GluR2 AMPA subunit, which normally blocks Ca2+ 
entry through the receptor channel, was decreased in spinal cord of mutant SOD1 mice and 
ALS patients (Van Damme et al., 2005; Takuma et al., 1999). However, the most validated 
hypothesis bases on changes in GluR2 AMPA subunit mRNA editing. In healthy 
condition, GluR2 mRNA is subjected to a post-transcriptional Q/R substitution, in which a 
glutamine is replaced with an arginine, making the receptor impermeable to Ca2+ (Swanson 
et al., 1997). Instead, in ALS the GluR2 mRNA editing resulted incomplete and AMPA 
receptor becomes permeable to Ca2+ (Takuma et al., 1999; Kawahara et al., 2004). The 
discovery of ALS-linked mutations in proteins regulating RNA processing further supports 
a possible alteration in GluR2 mRNA editing. Interestingly, C9orf72, TDP-43 and FUS 
sequestrate RNA transcript variants of adenosine deaminase 2 (ADAR2), which catalyzes 
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GluR2 mRNA editing, determining a reduction of the receptor activity and an increase of 
Ca2+ permeability in ALS MNs (Donnelly et al., 2013; Aizawa et al., 2010).  
A recent study on AMPA receptor expression and function reported differences between 
iPSC-derived MNs carrying C9orf72, SOD1, TDP-43 or FUS mutation (Bursch et al., 
2019). Although AMPA receptor mRNA did not change in C9orf72 MNs, these showed 
higher Ca2+ peaks following receptor activation compared to healthy controls. In mutated 
SOD1 and FUS MNs the Ca2+ peak amplitudes decreased when compared to healthy 
controls. Also in TDP-43 MNs the AMPA expression level was unchanged compared with 
healthy control. However, also in this case MNs displayed higher intracellular basal level 
of Ca2+ and increased Ca2+ peaks after AMPA receptor activation, compared to control 
MNs. These mutation-specific differences could explain the diverse responses to the 
pharmacological treatment with riluzole between ALS patients characterized by distinct 
disease aetiology (Bursh et al., 2019). 
1.3.3.3 Hyperexcitability 
Neuronal hyperexcitability represents a leading mechanism to explain excitotoxicity in 
ALS. Several studies in patients showed an alteration of MN excitability already at an 
early stage of the disease. Indeed, the MN-evoked potential and the resting threshold, 
measured in abductor pollicis brevis, were increased and decreased, respectively. These 
results suggest that a lower stimulus should be sufficient to generate a response in MNs at 
the beginning of the disease (Vucic and Kiernan, 2006). In accordance, the analysis of 
GABAergic interneurons, which strictly regulate neuronal signalling, revealed a decrease 
of their inhibitory action in the motor cortex of ALS animal models (Moser et al., 
2013;McGown et al., 2013). Of note, a reduction of mRNA for GABAA receptor subunit α, 
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which could directly impair GABAergic transmission reducing GABA binding to its 
receptors, has been observed in post-mortem tissue from ALS patients (Petri et al., 2003). 
This phenomenon can determine the generation of a MN response even if they receive a 
sub-threshold stimulus (Wagle-Shukla et al., 2009).  
Another mechanism, to explain hyperexcitability, is emerged in SOD1G93A mouse model of 
ALS. Cortical neurons from SOD1G93A mice showed unchanged fast transient Na+ currents 
and increased persistent Na+ currents; in particular the amplitude resulted higher, compared 
to control cortical neurons (Pieri et al., 2009). Persistent Na+ currents are essential to 
sustain and generate prolonged depolarization; thus, an alteration of their amplitude may 
represent a possible mechanism leading to hyperexcitability. As proof of concept to 
validate the involvement of persistent Na+ currents in hyperexcitability, Pieri and 
Colleagues tested the effect of riluzole on SOD1G93A cortical neurons. A low dose of 
riluzole significantly reduced the persistent Na+ currents and the firing frequency, but did 
not modify the resting membrane potential.  
The unaltered resting membrane potential suggests that persistent Na+ currents exert only a 
modest role and that other mechanisms can sustain hyperexcitability, such as alteration of 
potassium (K+) currents. Shibuya and Colleagues reported a decrease expression of Kv1.1, 
Kv1.2 and Kv7.1 K+ channels in ALS patients, compared to controls. A decrease of K+ 
outward currents causes a higher level of extracellular K+, increasing the resting membrane 
potential and the firing frequency in MNs (Shibuya et al., 2011; Kanai et al., 2006). 
1.3.4 Axonal transport dysfunction 
Axonal transport allows the exchange of mitochondria and vesicular or non-vesicular 
cargoes (lysosomes, signalling endosomes, amyloid precursor protein-containing vesicles, 
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AMPA receptor-containing vesicles, mRNA/protein complexes) between the MN soma 
and the axon terminals. We can distinguish axonal transport in fast axonal transport or 
slow axonal transport. Both typologies are mediated by the same molecular motors that 
move cargoes along microtubules and the different speed is determined by prolonged 
pauses between movement in slow axonal transport.  
Microtubules are polymers constituted of heterodimers of α-tubulin and β-tubulin. They 
are polarised with a fast growing plus end and a slow growing minus end, because of 
tubulin heterodimer head to tail rearrangement. The microtubule polarity defines the 
direction of the movement of the molecular motors along them. Two families of 
microtubule-based molecular motors are involved in axonal transport: kinesin family and 
dynein family. The first family mediates the anterograde transport and the second the 
retrograde transport (De Vos et al., 2017). 
As already mentioned in a previous paragraph, there is a lot of evidence supporting a 
defect of axonal transport in ALS. Indeed, accumulations of phosphorylated 
neurofilaments, mitochondria and lysosomes in the proximal axon of large MNs in the 
form of axonal spheroids are well documented in ALS animal models and in post-mortem 
tissues from ALS patients (Hirano et al., 1984a; Hirano et al., 1984b; Corbo and Hays, 
1992). Moreover, pre-symptomatic SOD1G37R mice showed a significant decrease in the 
slow anterograde transport of cytoskeletal components (Williamson and Cleveland, 1999), 
pointing at a key role of axonal transport impairment in neurodegeneration.  
The causes of axonal transport impairment are only partially understood. A large number 
of genetic mutations in proteins of axonal transport machinery has been found. Among 
these mutant proteins, we can list ALS2, which alters Rab5-dependent endosome 
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trafficking, AMPA receptor trafficking and retrograde neurotrophin trafficking (Lai et al., 
2009); charged multivesicular body protein 2B (CHMP2B) which fails in the recruitment 
of Rab7 to endosomes, determining a defects in retrograde transport of neurotrophin 
(Urwin et al., 2010); mutated Dynactin 1 (DCTN1), a subunit of the dynactin complex, that 
shows a loss of function leading to an impairment of axonal transport and vesicle 
trafficking (Puls et al., 2003). 
Recently, a new mutation in kinesin family member 5A (KIF5A) has been associated with 
ALS. It is part of a multi-subunit complex that acts as a microtubule motor in intracellular 
protein and organelle transport, including mitochondria (Hirokawa et al. 2009). Both 
mutation in the C-terminal and N-terminal of KIF5A leads to its loss of function. Mutation 
affecting the N-terminal tail causes a reduced binding of cargoes to KIF5A, leading to a 
severe form of ALS; instead, mutation affecting the N-terminal tail results in the decrease 
of axonal transport velocity and flux. This latter mutation is associated with mild 
pathologies, such as Charcot-Marie-Tooth disease type 2 and hereditary spastic paraplegia, 
but currently there is no evidence of its involvement in ALS (Brenner et al., 2018). 
One of the proposed mechanisms to explain axonal transport impairment includes the 
alteration of mitochondrial Rho GTPase 1 (Miro1) expression level. Miro1 allows the 
binding of mitochondria with kinesin-1 or cytoplasmic dynein and their transport along 
MN axons. Miro1 activity depends from Ca2+ concentration. Indeed, Ca2+ binding to Miro1 
modifies its interaction with kinesin-1 and through this alteration prevents kinesin-1-
microtubules binding or determines the release of kinesin-1 from mitochondria (Wang and 
Scharz, 2009). However, also mitochondria damage determines changes in Miro1, which is 
subjected to phosphorylation by phosphatase and tensin homolog (PTEN)-induced putative 
kinase 1 (PINK1), which targets Miro1 for parkin-dependent proteasomal degradation. 
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Obviously, Miro1 degradation leads to an irreversible detachment of molecular motors 
from the mitochondrial surface (Shlevkov et al., 2016). A study on rat cortical neurons 
transfected with WT-SOD1 or SOD1G93A, revealed a correlation between mutant SOD1 
and expression of Miro1. Indeed, the transfection with SOD1G93A determined a decrease of 
Miro1 in neurons, compared to WT-SOD1-transfected neurons. Miro1 degradation was 
caused by PINK1/parkin pathway activation; indeed, knock-down of PINK1 rescued the 
toxic effects of SOD1G93A on mitochondrial axonal transport (Moller et al., 2017). 
Nowadays, it is well demonstrated that SOD1G93A exerts its toxic function through the 
activation of specific kinase cascades, such as p38 mitogen-activated protein kinase 
(MAPK). MAPK was found to be activated in the spinal cord of pre-symptomatic 
SOD1G93A mice compared to wild type and WT-SOD1 controls. Interestingly, p38 MAPK 
activity was highest in early symptomatic SOD1G93A mice (Bisland et al., 2010). Gibbs and 
Colleagues demonstrated that the abnormal activation of p38 MAPK in SOD1G93A MNs 
determines an impairment of axonal transport and that its inhibition completely restores 
axonal transport of signalling endosomes. In particular, they observed that p38 MAPKα 
inhibits axonal anterograde transport through direct phosphorylation of kinesin-1, thus 
reducing the ability of the molecular motors to move along axonal microtubule of primary 
SOD1G93A MNs (Gibbs et al., 2018).  
In a TDP-43 mouse model of ALS has been observed a decreased number of mitochondria 
and lysosomes at the axon terminal level, suggesting an impairment of vesicular trafficking 
along the axon (Shan et al., 2010). Therefore, many studies have been done to discover the 
mechanisms underlying axonal transport deficit in TDP-43-related ALS. Since TDP-43 
binds mRNAs regulating brain development and synaptic stability and facilitates their 
trafficking from the nucleus to the axon terminal, one of the most convincing hypothesis is 
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a loss of function of mutant TDP-43 due to modifications in the prion-like domain of TDP-
43, which normally mediates the assembly of RNA granules (Alami et al., 2014). A second 
toxic mechanism could be related to mislocalization and aggregation of TDP-43, which 
determines a lack of TDP-43 activity in mRNA translation and splicing. For instance, 
TDP-43 stabilises neurofilament light chain mRNA, one of the major components of MN 
cytoskeleton (Strong et al., 2017). Moreover, a reduction of axonal growth and disruption 
in cytoskeleton morphology have been observed in TDP-43 related ALS, suggesting a 
massive involvement of TDP-43 in the regulation of translation and stabilization of several 
cytoskeletal proteins, included tubulin, microtubules and neurofilaments (Triphati et al., 
2014; Baskaran et al., 2018; Kreiter et al., 2018).  
Also, mutant FUS protein showed a gain of toxic function mechanism, which leads to a 
reduction of mitochondria trafficking along the axons. Guo and Colleagues demonstrated a 
direct correlation between mutant FUS and mitochondrial axonal transport impairment in 
iPSC-MNs derived from ALS patients carrying FUS mutations. Moreover, this observation 
was validated in iPSC-MN after mutant FUS correction by CRISP-Cas9 technology and by 
the over-expression of mutant FUS in H9-hESC lines following the induction with 
doxycycline. In the first case, the correction of the mutation in FUS gene rescued axonal 
transport; on the contrary, when mutant FUS over-expression was induced in hESC-
derived MNs a strongly reduction of mitochondria motility was recorded (Guo et al., 
2017). 
The mitochondria transport defect seems to be related to mitochondria-associated with the 
ER membranes, rather than to mitochondria morphological alteration or cytoskeletal 
changes. Indeed, the physiological overlapping between mitochondria and ER, which is 
involved in several crucial functions included intracellular trafficking, was reduced in 
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iPSC-MNs carrying FUS mutation compared to controls, indicating a general problem in 
axonal transport. To rescue axonal transport, inhibitors of histone deacetylase 6 (HDAC6) 
were tested on FUS iPSC-MNs. HDAC6 is a cytoplasmic deacetylase which modulates the 
acetylation state of α-tubulin, regulating its ability to bind molecular motor proteins to 
microtubules (Guo et al., 2017). It has also been reported that FUS and TDP-43 regulate 
mRNA transcript of HDAC6 (Kim et al., 2010). However, the amelioration of axonal 
transport in FUS iPSC-MNs after the inhibition of HDAC6 by pharmacological treatment 
or ASO silencing was due to increased acetylation of α-tubulin in the microtubules and not 
directly related to an effect on mutant FUS (Guo et al., 2017). In accordance with this 
hypothesis, the genetic deletion of HDAC6 in SOD1G93A mice prolonged survival 
probability by protecting the integrity of MN axons (Taes et al., 2013). 
1.3.5. Neuroinflammation 
Neuroinflammation is recognized as one of the main factors which affect ALS progression. 
A lot of evidence supports a toxic role of neuroinflammation in the late stage of the 
disease. Indeed, studies on mutant SOD1 mice described a protective role of microglia and 
astrocytes at the disease onset, when these two cell types attempt to protect MNs from 
degeneration by secreting anti-inflammatory cytokines and trophic factors, such as 
interleukin-4 (IL-4), interleukin-10 (IL-10), insulin-like growth factor-1 (IGF-1), brain-
derived neurotrophic factor (BDNF). On the contrary, at the late stage of the disease 
microglia and astrocytes shift to a pro-inflammatory negative phenotype, that exacerbates 
MN degeneration (Beers et al., 2011).  
An activated inflammation state is present also at the systemic level, involving the innate 
immune system. For instance, peripheral blood monocytes exert a pro-inflammatory action 
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in ALS patients; in particular, they are more active in fast progressing ALS (Zhao et al., 
2017). In addition, a dysregulation of T lymphocytes has been reported in ALS patients. 
The number of regulatory T lymphocytes (Tregs) and the expression of their specific 
transcriptional factor FOXP3 were reduced in ALS patients, who showed a fast progressive 
form of ALS. Moreover, Tregs isolated from the blood of ALS patients were not able to 
suppress responder T lymphocytes in vitro, suggesting a dysfunction and not only a 
decreased number of Tregs in ALS patients (Beers et al., 2017). 
Major histocompatibility complex I (MHCI) is a key molecule of the immune system for 
the antigen presentation to CD8+ T lymphocytes. Recently, MHCI has been found also in 
the CNS, where it regulates long-term plasticity of excitatory synaptic transmission 
(Chiarotto et al., 2017), where it has a relevant role in axon regeneration. In a mouse model 
knocked-out for β2 microglobulin (β2m), a subunit of MHCI, axonal regrowth after 
axotomy of peripheral sciatic nerve was impaired compared to WT mice (Oliveira et al., 
2004). On the other hand, transgenic mice with enhanced neuronal MHCI expression 
recovered more efficiently the locomotor function after spinal cord injury when compared 
to WT mice (Joseph et al., 2011), validating the importance of functional MHCI in CNS 
homeostasis. In SOD1G93A mice, an altered distribution of MHCI has been reported already 
at the beginning of the disease. In control animals, MHCI was localized in lumbar spinal 
cord MN perikarya, while in SOD1G93A mice it moved in efferent axons and axon terminals 
(Nardo et al., 2016). In addition, a higher expression level of β2m and Lmp7 
immunoproteasome subunits, responsible for antigenic peptides production, was detected 
in SOD1G93A mice, suggesting the ability of MNs to produce and expose MHCI linked with 
antigenic peptides to be presented to cytotoxic T cells, that infiltrate peripheral nervous 
system (PNS). This mechanism seems to be protective for MNs at an early stage of the 
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disease. Indeed, SOD1G93A mice knock-out for β2m showed an anticipation of motor 
performance decline, associated with an earlier axonal impairment and denervation of hind 
limb muscles (Staats et al., 2013). In contrast, MHCI overexpression at the late stage of the 
disease exerted a detrimental effect, due to the strongly activation of pro-inflammatory 
microglia, accelerating denervation and atrophy of forelimbs in SOD1G93A mice. On the 
contrary, the β2m deletion promoted the maintenance of forelimb innervations and 
prolonged mouse survival (Nardo et al., 2018).  
A loss of MHCI exposure on MN cell membrane has been reported at a late stage of the 
disease, probably due to ER stress and its dysfunction. MHCI are assembled in ER, but at 
the late stage of the disease ER works to maintain unfolded protein homeostasis (unfolded 
protein response to cell stress) and MHCI heavy chains move from ER membrane to the 
cytosol where they are degraded by the proteasome (Lilley and Ploegh, 2005). 
In astrocytes, silencing of MHCI regulates their state of activation and the production of 
pro-inflammatory cytokines in vitro, but no MHCI activation was detected in spinal cord of 
SOD1G93A mice during the disease progression (Rojas et al., 2014). Instead, microglia cells 
expressed high level of MHCI in spinal cord of SOD1G93A mice and recruited cytotoxic 
CD8+ T lymphocytes, which exacerbated inflammation in spinal cord of SOD1G93A mice 
and promote MN death (Nardo et al., 2016). A further demonstration supporting the role of 
MHCI in microglia activation derives from SOD1G93A mice knock-out for β2M, a 
component of MHCI, in which the inflammatory response was reduce both in vitro and in 
vivo (Nardo et al., 2018).  
NFκB is considered the first player in the development of the inflammatory response. It 
regulates the expression of genes of cytokines, chemokines, enzymes, adhesion molecules, 
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pro- and anti-apoptotic proteins. NFκB is formed by two of five DNA-binding proteins 
(p50, p52, p65 RelA, c-Rel, RelB) and a different assembly determines specific 
transcriptional activity. When inflammatory mediators bind their respective receptor, a 
signalling cascade is initiated that leads to phosphorylation and activation of I-Kappa-B 
Kinase (IKKB), which, in turn, phosphorylates the NFκB inhibitory protein IκBα and 
determines its proteasomal degradation. Finally, NFκB (p65/p50) can translocate to the 
nucleus where it modulates gene transcription (Ghosh and Karin, 2002).  
In glial cells derived from fALS and sALS patients, NFκB has been found up-regulated, 
confirming the involvement of neuroinflammation in ALS and the relevant role of 
astrocytes and microglia in disease progression (Haidet-Phillips et al., 2011; Swarup et al., 
2011). Frakes and Colleagues demonstrated that the selective partial deletion of IKKB and, 
consequently, NF-κB inhibition in microglia cells of SOD1G93A mice significantly 
increased the survival of these mice. The knock-down of IKKB in SOD1G93A microglia 
reduced typical markers of pro-inflammatory microglia (M1), such as CD68, CD86 and 
iNOS. A general analysis for GFAP and Iba1 revealed a lower astrogliosis and 
microgliosis in SOD1G93A mice. Unexpectedly, the same deletion in astrocytes did not 
produce an improvement in disease symptoms, suggesting different mechanisms for 
astrocyte-mediated toxicity (Frakes et al., 2014). 
p50 and p65 RelA subunits can assembly to form NFκB, which can have neuroprotective 
or neurotoxic effects, depending on the acetylation state of RelA (Lanzillotta et al., 2010). 
RelA subunit is highly expressed in mutant SOD1 MNs in vitro models and in ALS 
patients (Lanzillotta et al., 2013; Jiang et al., 2005). A following study demonstrated that 
RelA presents an aberrant acetylation state, represented by global lysine deacetylation and 
enhanced acetylation of a specific residue of lysine in position 310 (K310). This latter 
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promotes the transcription of pro-apoptotic factors inducing neurodegeneration (Schiaffino 
et al., 2018; Lanzillotta et al., 2013). The administration of MS-275, an HDACs inhibitors, 
and resveratrol, mediating the selective deacetylation of K310, reverted the aberrant 
acetylation state of RelA and increased the expression of Bcl-xL, an anti-apoptotic protein, 
in lumbar spinal cord of SOD1G93A mice. These biochemical read-outs translated in a delay 
of disease onset, an amelioration of motor skills and an increase of survival (Schiaffino et 
al., 2018).  
Cytosolic nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin 
domain containing 3 (NLRP3; inflammasome) is recognized as one of the main mediators 
of neuroinflammation development in ALS and in other neurodegenerative diseases and 
during brain aging. NLRP3 is formed by three components: a cytosolic pattern recognition 
receptor (PRR), pro-caspase 1 and apoptosis-associated speck-like protein (ASC) 
containing a caspase recruitment domain. Its assembly can be triggered by toll-like 
receptors (TLRs) activation, following pathogen-associated molecular patterns (PAMPs) 
and DAMPs binding, or by endogenous cytokines. TLRs and cytokines, through the NFκB 
pathway, promote the transcription of NLRP3, pro-IL-1β and pro-IL-18. After this first 
step, NLRP3 binds ASC and this latter recruits and activates caspase 1. The activation of 
caspase 1 leads to the proteolitic cleavage of pro-IL-1β and pro-IL-18 in their respective 
active forms, mediating the innate immune response (Singhal et al., 2014; Davis et al., 
2011; He et al., 2016).  
In SOD1G93A rat brain, increased level of NLRP3 and active caspase 1 were reported. This 
augmentation was associated with a higher expression of TLR4 and NFκB (Gugliandolo et 
al., 2018). Other studies described NLRP3 activation as an early event in ALS 
pathogenesis. Johann and Colleagues detected higher concentrations of inflammasome and 
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IL-1β in spinal cord of 60 days-old SOD1G93A mice and in post-mortem tissue from ALS 
patients (Johann et al., 2015). A next paper hypothesized that one of the causes of 
increased NLRP3 expression is protein nitration. As already described, ROS and RNS are 
hallmarks of ALS and these reactive species determine damage to proteins, such as protein 
tyrosine nitration. The treatment of SOD1G93A microglia with iNOS and NOX2 inhibitors 
reduced nitrotyrosine levels and, consequently, caspase 1 and NLRP3 activation, 
supporting the involvement of protein nitration in neuroinflammation spread (Belleza et 
al., 2018).  
Recently, a new neurotoxic mechanism mediated by TDP-43 has been uncovered. 
Microglial cells derived from cerebral cortex showed an increased activation of NLRP3, 
caspase 1 and caspase 3 after the exposure to exogenous TDP-43, which was internalized 
by microglia. Therefore, TDP-43 could promote TNF-α, IL-1β and IL-18 production and 
secretion, determining the genesis of a chronic inflammatory state. The internalization of 
TDP-43 aggregates and their toxic effects seem to depend on the chaperon HSP-27, which 
has been found up-regulated in CSF and spinal cord of ALS mouse models and in brain 
samples from ALS patients. HSP-27 exacerbated the pro-inflammatory response in TDP-
43-exposed microglia and induced the activation of caspase 3, ultimately leading to active 
IL-18 levels increase through an alternative pathway respect the classical NFκB/NLRP3 







1.4  Non-cell autonomous aspects of ALS 
The first studies aimed to unveil pathogenic mechanisms at the basis of ALS onset were 
focused on MNs, since they are the damaged cells leading directly to ALS symptoms. 
However, in the last decades a pivotal role in disease onset and progression also of non-
neuronal cell, such as astrocytes, microglia and oligodendrocytes, has been recognised. 
This change of viewpoint derives from many observations made after histological 
assessments and transcriptomic profiling of disease tissue, which highlighted a strong non-
neuronal signature in ALS and other neurodegenerative diseases (Lee et al., 2016; Chen et 
al., 2018).   
1.4.1 The role of astrocytes in ALS 
Nowadays, astrocytes are recognised as the main cell type regulating homeostasis of the 
CNS. They preserve an ancillary defensive response, i.e. astrogliosis, which is essential for 
neuroprotection and tissue regeneration and repair. However, astrogliosis response can 
worsen and cause several forms of neuropathologies.  
Astrocytes are electrically non-excitable, even if they express a large number of excitable 
molecules and mechanisms, such as plasmalemmal ion channels and receptors for 
neurotransmitter, neuromodulators and neurohormones, cytoplasmic structure modulating 
second messenger stimuli. Intracellular fluctuation of ions mediates astrocytes excitability 
through the modulation of ion channel opening, in particular Ca2+ and Na+ channels. These 
ion changes will balance homeostatic cascade signalling, including the monitoring of ion 
and neurotransmitter concentration, pH homeostasis, neutralization of ROS by secreting 
ROS scavengers.  
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Astrocytes play a fundamental role in synapse regulation. Perisynaptic astrocytes are 
enriched in various transporters which maintain neurotransmitter homeostasis in the 
synaptic space. This class of astrocytes are characterized by a high plastic capacity; indeed, 
they participate to synaptogenesis, synaptic maturation and synaptic extinction.  
In response to a damaging insult, astrocytes shift from a rest phenotype to a high reactive 
and proliferative one, in order to repair the damage and supply trophic factors to neurons 
and reduce neuronal degeneration. In many neurodegenerative disease this mechanism 
results impaired and it leads to neurotoxic events (Verkhratsky and Zorec, 2019). 
A recent analysis described the behaviour of astrocytes following a transient ischemia, 
induced by occluding the middle cerebral artery (MCAO) or after a treatment with the 
bacterial endotoxin lipopolysaccharide (LPS) to generate an inflammatory response. Both 
MCAO and LPS stimulated astrogliosis in brain cortex. However, mRNA analysis 
revealed two diverse population of astrocytes, depending on the causative stimulus. After 
MCAO, most of upregulated genes were associated with the production of neurotrophic 
factors and cytokines, including Cardiotrophin-like cytokine factor 1 (CLCF1), Leukemia 
inhibitory factor (LIF), IL-6, IL-10 and thrombospondines that may facilitate the 
regeneration of lost synapses. On the other hand, LPS-treated astrocytes showed an 
increased transcription of genes related to classical complement cascade activation (C1r, 
C1s, C3 and C4), playing a critical role in synapses pruning during development and, 
likely, leading to synapses loss in neurodegenerative diseases. Therefore, on the basis of 
this different transcriptional pattern we can divide astrocytes in A2, supporting neuronal 
repair, and A1 astrocytes, which exacerbate the damage and trigger a strong inflammatory 
response (Zamanian et al., 2012).  
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A deeper study on the mechanisms leading to A1 astrocytes activation highlights the role 
of microglia. LPS stimulation polarized microglia to M1 phenotype, characterized by high 
secretion of IL-1α, IL-1β, TNF-α and C1q, mediators of inflammatory response. When 
astrocytes were grown with medium derived from LPS-stimulated microglia, they shifted 
to A1 phenotype. Notably, if they were grown with unstimulated-microglia medium any 
change was detected. Moreover, a cytokine cocktail, containing IL-1α, TNF-α and C1q, 
was able to induce A1 astrocytes, validating the starting hypothesis. A1 astrocyte toxicity 
derives from secretion of soluble toxins, able to rapidly kill neurons. In ALS and in most 
neurodegenerative diseases the presence of neuroinflammation and M1 activated microglia 
has been reported; thus, suggesting astrocyte activation in the A1 manner. Indeed, 
complement component 3 (C3), highly up-regulated in A1 astrocytes and absent in A2 
astrocytes, was massively represented in post-mortem tissues from ALS, Alzheimer’s 
disease, Huntington’s disease, Parkinson’s disease and multiple sclerosis. This evidence 
demonstrates that A1 astrocytes are present in most neurodegenerative diseases, where, 
probably, they cover a non-marginal role in neuron death (Liddelow et al., 2017). 
The role of astrocytes in the regulation of innate immunity in CNS is currently well 
recognised. Astrocytes express TLRs, type I membrane glycoproteins characterized by 
leucine-rich-repeat motifs in the extracellular domain. TLR1, TLR2 and TLR6 recognise 
bacterial lipoproteins; TLR3, TLR7, TLR8 and TLR9 specifically bind nucleic acids; 
TLR5 identifies flagellin; TLR4 presents a wide spectrum of ligands, including LPS and 
fungal zymosan. The main TLR expressed on astrocyte membrane is TLR3. In particular, it 
has been reported that TLR3 expression can be induced by stimulating astrocytes with pro-
inflammatory cytokines, such as IL-1β and IFN-β or IFN-γ. Also TLR2 and TLR4 are 
expressed in astrocytes, although at lower levels.  
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The major signalling pathway activated by TLRs starts with the binding of MyD88 with 
the toll-interleukin 1 receptor (TIR) cytoplasmic domain, leading to the recruitment of the 
IL-1 receptor-associated kinase (IRAK4). This latter dissociates from MyD88, binds to and 
activates the TNF receptor associated factor 6 (TRAF6), promoting to the formation of 
Complex-1. Then, this triple association dissociates from TLR and mediates the 
recruitment of several proteins, including TGFβ related kinase (TAK-1), and TAK-1 
binding protein (TAB) 1-3, forming core components of Complex-2. These processes 
determine the phosphorylation of TAK-1 and induce the activation of IKK complex which 
in turn phosphorylates IκB protein, causing its degradation and allowing the translocation 
of NFҡB to the nucleus. On the other hand, Complex-2 can activate MAPKs, ERK1/2, p38 
and JNK via phosphorylation, which in turn modulate the activation of several 
transcription factors.  
The activation of these two different pathways leads to an increased transcription of iNOS, 
inducible COX-2, and stimulates the release of major inflammatory cytokines, such as IL-
1β, IL-6, and TNF-α (Rahimifard et al., 2017). These mechanisms are essential for the 
development of an appropriate response to pathogens. Indeed, mice that were knock-out 
for TLR3 were unable to activate the inflammatory response after Theiler’s murine 
encephalomyelitis virus (TMEV) and, therefore, to block its replication (So et al., 2006; 
Farina et al., 2007).  
The activation of NFκB in astrocytes highlights their involvement in neuroinflammatory 
response regulation and recovery function modulation after injury. A mouse model knock-
out for NFҡB showed a reduced production and secretion of cytokines and chemokines, 
reducing the recruitment of leukocytes and macrophages to the lesioned area. This less-
activated environment promoted functional recovery and tissue regeneration (van Loo et 
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al., 2006). On the other hand, the absence of inflammatory responses can be detrimental in 
CNS. Mouse model knock-out for IL-6 or IL-1β showed a delayed astrocyte activation and 
increased BBB permeability, causing an incapacity of astrocytes to reduce the lesioned 
area. Moreover, a decreased synthesis of the neurotrophic factors CNTF (Ciliary 
neurotrophic factor) and IGF-1, both helpful in tissue regeneration (Herx et al., 2001; 
Swartz et al., 2001), was registered. A strictly regulation of the inflammatory responses is 
essential to preserve the physiological homeostasis of CNS and a dysregulation of the 
balance between pro- and anti-inflammatory responses can be harmful for the organism. 
The first evidence of astrocyte alteration in ALS derived from animal models in which 
mutant SOD1 was selectively expressed or deleted in astrocytes. First experiments were 
carried out on chimeric animals composed of mixtures of normal cells and cells that 
express a human mutant SOD1 polypeptide at levels sufficient to cause fatal motor neuron 
disease. Researchers reported that the presence of wild-type non-neuronal cells in the 
SOD1G37R and SOD1G85R chimeras delayed disease onset and prolonged their survival. In 
accordance, chimeric animal characterized by the expression of mutant SOD1 in non-
neuronal cells but not in MNs showed histological signs of neurodegeneration, caused by 
the accumulation of ubiquitinated epitopes, that were never seen in age-matched wild-type 
littermates (Clement et al., 2003). Some years later, similar experiments using Cre-Lox 
recombination to delete mutant SOD1 gene selectively in microglia or astrocytes were 
performed. The reduction of mutant SOD1 expression in astrocytes of SOD1G37R or 
SOD1G85R mice did not delay disease onset and early disease progression, but it slowed the 
late disease course extending significantly mouse survival (Boille et al., 2006; Yamanaka 
et al. 2008; Wang et al., 2011). These experiments highlighted the non-neuronal 
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component of ALS and, moreover, identified astrocytes and microglia as pivotal players of 
disease progression rather than of disease onset. 
Another approach to validate the astrocyte role in neurodegeneration consisted in cell 
transplantion. Transplantation of WT astrocyte precursors in cervical spinal cord of ALS 
mice slowed the disease progression and prolonged survival probability (Lepore et al., 
2008). In accordance, transplantation of astrocyte precursors carrying SOD1G93A gene 
mutation promoted local degeneration in spinal cord and caused motor dysfunction in WT 
mice (Papadeas et al., 2011). Finally, Nagai and Colleagues confirmed by in-vitro co-
culture studies the detrimental role of ALS astrocytes: mutated astrocytes were able to 
induce neurodegeneration both in ALS MNs and healthy MNs, supporting the hypothesis 
of a gain of toxic functions of astrocytes in ALS (Nagai et al., 2007).  
During the last decades many studies tried to understand which are the toxic factors 
released by astrocytes in ALS. The first papers were focused on the role of astrocytes in 
excitotoxicity, because of the down-regulation of EAAT-2 in astrocytes membranes, that 
leads to a reduced uptake of glutamate from the synapses (Brujin et al. 1997), and their loss 
of control of the GluR2 AMPA-subunit editing, causing an abnormal influx of Ca2+ in 
MNs (Van Damme et al., 2007).  
Astrocytes represent one of the major sources of energy for MNs, in particular through the 
shuttle of lactate (Pellerin and Magistretti, 1994). MNs are able to promote aerobic 
glycolisis in astrocytes by glutamate release. This latter induces the activation of the 
Na+/K+ -ATPase pump that consumes the ATP produced by phosphoglycerate kinase 
(Pgk), triggering glucose uptake and its glycolytic processing, leading to the release of 
lactate from astrocytes. Lactate can then contribute to the activity-dependent fuelling of the 
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neuronal energy demands associated with synaptic transmission (Pellerin et al., 2007). 
However, gene expression analysis in SOD1G93A astrocytes revealed an impairment of 
many proteins involved in lactate shuttle, such as Glutamate Aspartate transporter-1 
(GLAST-1), Na+/K+ -ATPase, Pgk and the lactate efflux transporter Solute carrier 16a4 
(Slc16a4).  
The quantification of lactate level in the spinal cord of SOD1G93A transgenic mice validated 
the gene analysis results. SOD1G93A mice showed a significant reduction of lactate shuttle 
between astrocytes and MNs already at an early stage of the disease, followed by a further 
decrease during disease progression. SOD1G93A derived astrocytes showed the same 
impairment of lactate shuttle when co-cultured with transgenic or WT mouse MNs. 
Moreover, the expression of the lactate transporter Slc16a4 was down-regulated in spinal 
cord astrocytes isolated from three patients with ALS carrying SOD1 mutations, in 
comparison to control individuals. The impairment of the lactate shuttle leads to MN 
energetic deficit, causing alteration of membrane potential and imbalance of ion 
concentration (Ferraiuolo et al., 2011).  
Astrocytes secrete many trophic factors, including nerve growth factor (NGF). Mature 
NGF modulates neuronal differentiation and survival by binding Tyrosine receptor Kinase 
A (TrKA). On the other hand, Pro-NGF preferentially binds the p75 receptor, which 
determines axonal growth and remodelling during development, although its expression is 
barely detectable in adult. Notably, p75 expression increases in pathological condition, 
where it promotes the activation of apoptosis pathways by boosting NFκB, p53 and Bax. 
Ferraiuolo and Colleagues demonstrated that astrocytes derived from SOD1G93A mice 
expressed higher amount of NGF compared to WT astrocytes and, at the same time, p75 
receptor and its pro-apoptotic associate protein (Ngfrap1) were up-regulated in SOD1G93A 
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astrocytes. This alteration, together with a reduction of mature NGF, leads to a decrease 
MN viability in ALS mice (Ferraiuolo et al., 2011). 
The metabolism of nucleosides was also altered in astrocytes from C9orf72 and sporadic 
ALS patients. ALS models showed an increased release of ATP from MNs, determining 
microglia activation and increased astrogliosis and neuroinflammation. Moreover, 
adenosine, the last step of ATP metabolism, was also higher in ALS. An increased 
concentration of adenosine causes activation of low affinity receptors on astrocytes, 
promoting astrocyte proliferation and activation, reducing glutamate uptake and 
stimulating Ca2+-dependent glutamate release (Rothstein et al., 1996). The up-regulated 
levels of adenosine were related to a lower expression in ALS astrocytes of adenosine 
deaminase (ADA), an ubiquitously expressed enzyme that converts adenosine in inosine. 
Further evidence sustaining the detrimental role of low levels of ADA in ALS was 
collected by inhibiting ADA in control astrocytes. The inhibition of ADA in control 
astrocytes caused an impairment of MN viability in the co-culture model. In addition, 
exposure of ALS astrocytes to inosine was able to partially rescue MN survival, validating 
the relevant function of adenosine and inosine in ALS (Allen et al., 2019). 
Astrocytes are key players in neuroinflammation development. They are able to produce 
and secrete cytokines, thus they can actively modulate the inflammatory response in CNS. 
Increased serum/plasma and CSF levels of TNF-α, IL-6, IL-8, and IFN-β, have been 
detected in ALS patients when compared to controls (Philips and Robberecht, 2011; Hu et 
al., 2017). These findings promoted the study of the cytokine function and of inflammation 
in ALS.  
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Transforming growth factor βs (TGF-βs) are pleiotropic cytokines that exert key functions 
in immune homeostasis, neurotrophic response and microglia development. In ALS 
patients, TGF-β1 levels are elevated in serum, plasma and CSF (Houi et al.,2002). Endo 
and Colleagues detected high levels of TGF-β1 in astrocytes from sporadic ALS patients 
and from SOD1G93A mice. The over-production of TGF-β1 caused a faster disease 
progression, while the deletion of SOD1 mutation from ALS mice determined a reduction 
of TGF-β1 production and decreased disease severity. This neurotoxic effect seems to 
derive from a TGF-β1-dependent alteration of the balance between INF-γ and IL-4 
production in T cells and microglia. The pharmacological treatment with a TGF-β 
signalling inhibitor after the disease onset prolonged survival of SOD1G93A mice, rescuing 
INF-γ/IL-4 dysregulation and decreasing the number of activated microglial cells. 
Moreover, the correlation between TGF-β1 level and disease progression suggested the use 
of TGF-β1 as a predictive biomarker for disease progression and severity (Endo et al., 
2015).  
TGF-β1 is also involved in protein aggregation. Indeed the increased secretion of TGF-β1 
by astrocytes activates the mammalian target of rapamycin (mTOR) signalling pathway, 
which causes an impairment of autophagic function in MNs. In particular, TGF-β1 
activated mTOR pathway in MNs, inducing aggregation of p62 and LC3-II, the main 
proteins involved in autophagy (Tripathi et al., 2017). 
TNF-α is one of the main cytokines that have been found overexpressed in blood and CSF 
of ALS patients (Tateishi et al., 2010; Poloni et al., 2000). High concentrations of TNF-α, 
together with the up-regulation of TNF-α receptors (TNFRs), have also been reported in 
spinal cord of SOD1G93A mice before symptom onset (Brambilla et al., 2016; Yoshihara et 
al., 2002).  
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TNF-α can be differentiated in two diverse forms: membrane-bound TNF-α (mTNF-α) and 
soluble TNF-α (sTNF-α). The two forms of TNF-α act through TNFR1 and TNFR2. Both 
are able to mediate the cytotoxic and apoptotic effects of TNF-α. TNRF1 contains a death 
domain, while TNRF2 acts through a cell-to-cell interaction. In particular, TNRF2, by 
binding mTNF-α, can induce tumor and neuronal cell death. This second mechanism 
seems strongly involved in ALS. Indeed, a study on spinal cord astrocytes-MN co-cultures 
from SOD1G93A mice reported an increase of mTNF-α in MNs and the reduction of 
TNRF2, but not of TNRF1, completely rescued MNs. The same positive effects on MN 
survival were observed in SOD1G93A mice knock-out for TNFR2 (Tortarolo et al., 2015).  
On the contrary, the ablation of TNRF1 exacerbated the detrimental effects of TNF-α. 
Indeed, when TNRF1 is expressed on the astrocyte membrane, it promotes the production 
and secretion of glial-derived neurotrophic factor (GDNF), which supports neuron growth 
and survival (Brambilla et al., 2016). Another study demonstrated that both receptors exert 
their functions through activation of the ASK1/p38MAPK pathway, which resulted 
detrimental for MNs. The inhibition of p38 MAPK prevented MN death in SOD1G93A co-
cultures, suggesting the essential role of the TNFRs/ASK1/p38MAPK pathway in 
neurodegeneration (Dewil et al., 2007). TNF-α exerts its toxic function also in other 
models of ALS. For instance, astrocytes expressing mutant FUS secreted TNF-α as main 
toxic factor mediating MN death through NFҡB pathway activation. Moreover, TNF-α 
modulated the expression of AMPA receptors and GluA2 AMPA-subunit in MNs, 
determining an increase permeability to Ca2+and leading to excitotoxity (Kia et al., 2018).  
Finally, modifications of miRNA expression level were reported. Cortical astrocytes from 
SOD1G93A mice showed a down-regulation of miR-146a, miR-125 and miR-21 compared 
to control astrocytes. miR-146a works as negative-feedback regulator of TLR 
60 
 
inflammatory pathway (Iyer et al., 2012), while miR-125 and miR-21 are modulators of 
neurite outgrowth (Le et al., 2009; Kang et al., 2019). SOD1G93A astrocytes presented 
higher level of HMGB1 and NFκB, leading to an increase of cytokines production. In 
accordance, the down-regulation of these three miRNAs caused a reduction of MN 
viability (Gomes et al., 2019).  
At the same time, also the pattern of miRNAs released from astrocytes through 
extracellular vesicles (EVs) has been found altered. 
miRNAs secreted by astrocytes regulate a number of transcripts, encoding proteins 
involved in axonal growth and maintenance. EV cargo was found modified in C9orf72 
astrocytes and was able to induce MN toxicity. In particular miR-494-3p was strongly 
down-regulated in EVs derived from C9orf72 human astrocytes, determining an 
impairment of axonal development and inducing neurite retraction and MN death, by 
increasing Semaphorin-3A (SEMA3A) levels (Varcianna et al., 2019). 
As described above, astrocytes represent an essential support for MN survival and, in ALS 
and other neurodegenerative disease, they are subject to a shift from a supportive to a 
neurotoxic phenotype, causing metabolic alteration, loss of trophic function, secretion of 
toxic factors and development of a chronic inflammatory response. The totality of these 
alterations makes astrocytes good targets to modulate disease progression and rescue MNs 
in ALS. In particular, astrocytes are largely used for a first drug screening to select 
promising molecules (Gorshkov et al., 2018). Moreover, some drugs targeting astrocytes 
have been tested in patients. For example, ceftriaxone, which exhibits effectiveness in 
boosting EAAT2 expression, was tested in rodent models and then in ALS patients. 
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Unfortunately, the clinical trial failed in Phase III because of its lack of efficacy 
(Cudkowicz et al., 2014).  
1.4.2 The role of microglia in ALS 
Microglial cells are the sentinels of the CNS, playing a main role both in physiological and 
pathological conditions. Microglial cells fulfil crucial functions in embryonic and postnatal 
formation of CNS, promoting neuronal survival by releasing several neurotrophic factors, 
such as IGF-1 and CX3CL1. Moreover, microglia regulates CNS homeostasis through 
cellular pruning via NGF-induced cell death, removal of cellular debris and apoptotic cells 
by phagocytosis and lysosome degradation (Nayak et al., 2014).  
In many acute and chronic diseases characterized by a neuroinflammatory component, 
microglia cells show altered morphology and transcription pattern, classified in the 
following specific phenotypic profile M0, M1 and M2. M0 corresponds to a resting state, 
in which microglia receives inhibitory signals from the CNS environment. When these 
inhibitory signals are replaced by activating stimuli, microglia can undergo three different 
fates: classical M1 activation stimulated by IFN-γ, alternative M2a and M2b 
phagocytic/neuroprotective activation stimulated by IL-4 and IL-13, and, finally, acquired 
deactivation M2c stimulated by TGF-β and IL-10. The balance between these different 
activation states is essential for the maintaining of CNS integrity. In CNS pathology the 
strictly regulation of microglia phenotype can fail and cause deleterious immune response 
exacerbating neuronal death (Hammond et al., 2018). 
In post-mortem ALS patient tissue, a prominent microgliosis has been observed in the 
regions surrounding degenerated MNs, including motor cortex, in portions along the 
corticospinal tract and in ventral horn of the spinal cord. In adding, in vivo positron 
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emission tomography (PET) imaging showed microglia activation also at different stages 
of the disease and correlated the stronger microglia activation with the worse ALS clinical 
outcome (Chen et al., 2018).  However, the role of microglia is not univocal in ALS. For 
instance, microglia isolated from SOD1G93A mice displayed a peculiar phenotype that 
differs from the commonly characterized M1/M2 phenotypes and from those obtained after 
activation with LPS or with other stressors. Indeed, SOD1G93A microglia cells at pre-onset 
stages reduce immune response and exhibit an anti-inflammatory behavior, marked by high 
expression levels of BDNF and CD163; while, at later stages of the disease, the phenotype 
shifts to a highly proliferative pro-inflammatory one, accompanied by increased levels of 
ROS production and glutamate release, which are detrimental for MNs (Volontè et al., 
2019).   
Evidence for microglia involvement in ALS progression derives from different mutated-
SOD1 animal models, which demonstrated that the deletion of mutant SOD1 in microglial 
cells significantly increased the survival of SOD1G37R mice (Boillée et al., 2006) and that 
the administration of WT microglia in SOD1G93A mice slowed MN loss and extended 
lifespan compared to WT mice receiving SOD1G93A expressing cells or to SOD1G93A mice 
(Beers et al., 2006).  
More recent studies investigated the influence of microglia phenotype modulation on 
disease progression. For instance, NFκB or IL-1β inhibition in microglia suppressed 
inflammatory toxicity to MNs (Frakes et al., 2014; Meissner et al., 2010); inhibition of 
colony stimulation factor 1 receptor (CSF1R), supporting microglia differentiation and 
proliferation, reduced microglia growth and slowed disease progression in SOD1G93A mice 
(Martìnez-Muriana et al., 2016); CNS-delivery of IL-4 via a gene therapy strategy in 
SOD1G93A mice determined an amelioration of clinical symptoms at an early stage of the 
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disease, by inducing a slowly proliferating microglia expressing genes typical of 
embryonic microglia (Rossi et al., 2018). 
These results support the involvement of microglia in ALS onset and progression. 
However, the dual role of microglia in ALS makes it difficult to have a clear scenario of its 
beneficial function or detrimental effects.  
1.4.3 The role of oligodendrocytes in ALS 
Oligodendrocytes are the myelinating cells of the CNS, which origin from 
oligodendrocytes precursor cells (OPCs), deriving from the caudal region of the neural 
tube in the ventral midline, and secondly during development, from dorsal spinal cord. The 
main studied function of oligodendrocytes is the generation of myelin sheaths around 
target axons that results in enhanced rates of axonal conduction through the establishment 
of saltatory conduction (Tognatta et al., 2016).  
Another main function of oligodendrocytes consists in providing metabolic support to 
neurons. Indeed, the lactate produced by oligodendrocytes is transferred, through the 
monocarboxylate transporter-1 (MCT-1), to myelinated axons, in order to maintain their 
structure and function. Interestingly, the expression of MCT-1 is particularly high in 
oligodendrocytes compared to other glial cells, suggesting a crucial role of 
oligodendrocytes in furnishing energy to neuron. Notably, the expression of MCT-1 is 
reduced in oligodendrocytes from patients with ALS and from the SOD1G93A mice, 
indicating that MCT-1 may play a role in ALS pathogenesis (Lee et al., 2012). 
The contribution of oligodendrocytes to the disease has been demonstrated by deleting 
SOD1 from oligodendrocytes in the SOD1G37R mouse model. These mice showed a 
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significant delay of disease onset and an increase of survival, and did not exhibit motor 
neuron degeneration at the time of death. This evidence has suggested a more complex 
scenario in which each cell type plays a specific role in onset or progression of the disease 
(Yamanaka et al., 2008).  
In ALS patients, a reduction of gray matter myelin and reactive changes in NG2+ cells have 
been reported in the motor cortex and spinal cord. In accordance, an extensive 
degeneration of gray matter oligodendrocytes was observed also in SOD1G93A mice, 
already before the onset of the symptoms of the disease. These early alterations suggest 
that a loss of functions of oligodendrocytes, in particular in providing lactate to MNs, can 
lead to neurodegeneration. However, the mechanisms are still to be elucidated and the 
degeneration of oligodendrocytes before MN death remains an hypothesis. Among the 
proposed mechanisms affecting oligodendrocyte functions, we can list the formation of  
protein aggregates inducing ER stress and the strong pro-inflammatory environment 
characterized by a high level of IFN-γ; indeed, both conditions were capable to induce cell 
apoptosis (Kang et al., 2013).  
In-vitro studies with oligodendrocyte-MN co-cultures validated the crucial role of mutated 
SOD1 in oligodendrocyte functions. Ferraiuolo and colleagues analysed the viability of 
mouse MNs co-cultured with mature oligodendrocytes prepared from SOD1G93A mice, 
from iPSCs of three sporadic and one familial patients carrying a mutation in FIG4 or from 
iNPCs of four sporadic, three C9orf72, one SOD1 and one TARDBP patients. In all the 
experimental conditions, they observed a significant reduction of MN survival compared to 
co-cultures with control oligodendrocytes. The impaired MN survival was due to a 
decreased production and transport of lactate in oligodendrocytes, leading to energetic 
deficit in MNs, except for C9orf72-derived oligodendrocytes in which there was no 
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variation in lactate level. In accordance, MN viability was rescued by adding lactate to the 
medium. To elucidate the mechanisms determining the malfunction of oligodendrocytes, 
SOD1 was silenced in the different cell lines and MN viability was evaluated. The 
reduction of misfolded SOD1 in mouse and human oligodendrocytes determined a 
restoration of MN survival, supporting the hypothesis of a SOD1-dependent toxic 
mechanism. This amelioration, upon SOD1 silencing, was not detected in C9orf72 
oligodendrocytes, suggesting the involvement of different toxic pathways (Ferraiuolo et 
al., 2016).  
Another study on a zebrafish ALS model, in which mutated SOD1 was selectively 
overexpressed only in mature oligodendrocytes, confirmed the ability of misfolded SOD1 
to induce disruption of myelin sheaths and downregulation of MCT1, causing MN death. 
In adding, this model presented behavioural abnormalities, such as thigmotaxis, freezing 
behaviours, erratic movement and learning impairments, possibly due to myelin defect-
induced diminution of axonal conduction. The administration of 4-aminoprydine and 4-
aminopyridine-3-methanol, two potassium channel inhibitors already used in spinal cord 
injury and multiple sclerosis to restore axonal conduction, rescued motor deficits and 
behavioural changes, but MCT-1 expression remained unvaried, indicating the 







1.5 ALS treatment 
As widely described above, ALS presents a pathophysiology extremely complex and the 
disease phenotype is highly variable between patients. These aspects of ALS can explain 
the absence of efficacious drugs and the poor success of clinical trials. In addition, the 
triggering events that determine MN degeneration are still unknown. It is still hard to 
differentiate the triggers of the disease from the secondary consequences shaping the 
evolution of both the sporadic or genetic ALS types.  
The complexity of ALS determined the lack of a completely reliable animal model. The 
most studied is the SOD1 mouse model, which describes only a restricted part of ALS 
patients and showed limitations for translational research. During the last decade, more 
efforts have been dedicated to better clarify the clinical phenotypes related to ALS course 
and prognosis. ALS is now viewed as a syndrome rather than a pure disease. In the broad 
field of MN diseases (MNDs) is essential to stratify wisely patients for the clinical trials 
and, many studies aimed at identifying biomarkers, to allow a precocious diagnosis of 
ALS, or to indicate the prognosis of the disease. For instance, the AMBRoSIA project, 
funded by the Motor Neuron Disease Association (MNDA), was devoted to the discovery 
of specific biomarkers that characterize the genetic forms of MNDs by genetic blood, urine 
and skin cell analyses, looking for genetic mutations known to be linked to these 
pathologies. 
Finally, the newly identified genetic mutations, such as the C9orf72 mutation, opened a 
new area of research on the mechanisms of selective degeneration that will further help to 
increase the knowledge of ALS pathophysiology. On the other hand, nevertheless the 
67 
 
increased knowledge of this disease obtained during the last 20 years, only weak 
progresses have been done in finding an effective therapy (Mathis et al., 2016). 
1.5.1 Approved drugs for the treatment of ALS 
Currently, there are only two drugs approved from FDA for the treatment of ALS: riluzole 
and edaravone. 
Riluzole was approved in 1995 by FDA and it was the first drug for ALS treatment. The 
first studies of ALS pathogenesis highlighted a strong excitotoxic component, therefore 
riluzole was selected and tested in virtues of its anti-excitotoxic ability (Miller et al., 2012). 
Riluzole is a sodium channel blocker, and its neuroprotective effects in the spinal cord are 
exerted on neurons and axons to reduce the increase of intracellular Na+ ion concentration 
and to reverse operation of the axonal sodium Ca2+ exchangers (Schwartz et al. 2002). In 
addition, riluzole acts as an anti-glutamatergic agent via the prevention of glutamate 
receptor function, the increase of glutamate uptake, by activating glutamate transporters, 
and by reducing the release of glutamate (Wang et al., 2004). Unfortunately, the beneficial 
effects are only modest: it was observed a prolonged survival from three to six months, in 
particular in patients affected from bulbar-onset ALS. However, symptom amelioration 
was not significant since there was no improvement of muscle strength and only a small 
positive effect on quality of life of patients (Miller et al., 2012). One possible reason to 
explain, at least in part, the modest effects of riluzole, is that the blockade of Na+ channels 
affects the excitability of all neurons, thus reducing the release of both excitatory and 
inhibitory neurotransmitters. 
Edaravone was approved in 2017 by FDA in U.S.A. and in 2018 in Canada. Edaravone 
acts as a ROS scavenger and inhibits peroxyl radical (LOO•)‐induced peroxidation. One of 
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the most interesting findings suggests that edaravone scavenges H2O2 and protects cells 
against oxidative stress via upregulation of Peroxiredoxin‐2, downregulation of protein 
disulfide isomerase A3, and inhibition of apoptosis. Edaravone traps •OH and inhibits 
OH−‐dependent lipid peroxidation or tyrosine nitration induced by ONOO− (Jaiswal, 
2019). Unfortunalely, the beneficial effects are weak also with edaravone and there are 
limitations to the use, being the drug efficacious when administered timely in diagnosed 
patients. The need to act at an early phase of the disease, the repeated intravenous 
administration and the lack of data about edaravone side effects in a long-term therapy 
make the prescription of edaravone difficult for clinicians (Hardiman and van den Berg, 
2017). 
New therapeutic approaches are continuously studied. Between the new drugs we can list: 
anti-apoptotic substances, such as ursodeoxycholic acid and tauroursodeoxycholic acid, 
which acts on mitochondrial dysfunction and abnormal Ca2+ concentration, and Masitinib, 
that targets the inflammatory component of ALS, slowing ALS progress by 27% in 
preliminary results in a recent phase III study in combination with riluzole treatment 
(Nowicka et al., 2019).  
1.5.2 Cell therapy in ALS 
To date, most of the drugs tested for ALS did not show a significant efficacy in slowing 
disease progression, the attention has been moved also to innovative therapies, such as 
transplantation of human neural stem cells (hNSCs) and mesenchymal stem cells (hMSCs).  
hNSCs therapy is currently studied by two different clinical trials in Phase I and II. In one 
of the study hNSCs are produced by Neuralstem Inc.; they were isolated from fetal spinal 
cord and grown as an adherent monolayer in the presence of the fibroblast growth factor-2 
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(FGF-2). The other clinical trial uses hNSCs produced by Azienda Ospedaliera Santa 
Maria (Terni). Cells were derived from foetal brain and expanded as floating neurospheres 
with the support of endothelial growth factor (EGF) and FGF-2 (Mazzini et al., 2019). 
Preclinical results with neural progenitor lines showed a good tolerability and survival of 
several months after the transplantation. They may exert their beneficial action on MN 
degeneration, motor symptoms and survival through the integration into the tissue, the 
differentiation into astrocytes, oligodendrocytes and neurons and the formation of  
synapses with host neurons (Xu et al., 2006).  
A recent study showed that hNPCs expressing GDNF, that differentiate in vivo into 
astrocytes, ameliorated the health of upper MNs, supported lower MN survival, delayed 
paralysis and extended lifespan when transplanted in the cortex of SOD1G93A rats. This 
cells have been approved from FDA to proceed with clinical trials to explore their safety 
and efficacy in ALS patients (ClinicalTrials.gov Identifier: NCT02943850) (Thomsen et 
al., 2018). 
The study of the stem cell efficacy in the treatment of ALS and other neurodegenerative 
diseases started 20 years ago thanks to their potential advantages, such as the wide range of 
actions, the possibility to differentiate into neuron-like cells and the ability to release 
neuroprotective factors (Ciervo et al., 2017). There are different types of stem cells, 
depending on their source. The most studied at present are mesenchymal stem cells 
(MSCs) that can derive from umbilical cord, bone marrow, adipose tissue and peripheral 
blood and can differentiate in components of mesodermal origin, as cartilage, bone, fat, 
muscle and stroma. Bone marrow-derived (BM)-MSCs have been administrated by 
intravenous, intrathecal or intraparenchymal injection in the SOD1G93A rodent model by 
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several research groups. The results support the beneficial impact of MSC injection in ALS 
rodent models on disease onset, survival, MN viability and neuroinflammatory markers 
(Ciervo et al., 2017).  
The first clinical trial was conducted in 2001, even if there were not preclinical data. This 
study demonstrated the safety of BM-MSC transplantation, but it did not give clear results 
about the efficacy (Mazzini et al., 2003). Other studies validated the safety of BM-MSCs 
in patients, reporting the absence of tumorogenesis also in long-term analysis (Blanquer et 
al, 2012; Karussis et al., 2010). In 2015, Oh and Colleagues evaluated the clinical 
feasibility and safety of two repeated injection of autologous MSCs into CSF of ALS 
patients. CSF samples of two patients were collected before the first and the second 
injection in order to analyse cytokine content. Unexpectedly, IL-10, TGF-β and IL-6 were 
increased after MSC treatment, while the level of CCL2 was reduced. A phase II clinical 
trial is on-going to evaluate also the efficacy of the treatment (ClinicalTrial.gov Identifier: 
NCT01363401) (Oh et al., 2015).  
In 2016 a promising clinical trial was conducted to evaluate the efficacy of BM-MSCs 
secreting enhanced levels of multiple neurotrophic factors (NTFs), including GDNF, 
BDNF, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). 
MSC-NTF cell (NurOwn®) injection in patients with ALS was safe and well tolerated. 
Moreover, preliminary data showed a slower disease progression, characterized by a 
decreased decline of muscle volume and of the compound muscle action 
potentials (CMAPs), that were most prominent in the right (injected) arm and in the IM-
treated cohort (Petrou et al., 2016). A Phase III clinical trial is currently on-going to test 
the safety and efficacy of repeated administration of NurOwn® therapy. The autologous 
NurOwn® are back-transplanted into the patient intrathecally by standard lumbar puncture 
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where neurons and glial cells are expected to take up the neurotrophic factors secreted by 
the transplanted cells (ClinicalTrial.gov identifier: NCT03280056). 
The isolation of stem cells from adipose tissue (ADSCs) is easier and less invasive for the 
patients. Nevertheless, there are only few studies about ADSC treatment in ALS. In 
accordance with the results collected with BM-MSCs, ADSCs were able to delay disease 
onset and to extend the lifespan of SOD1G93A mice. Moreover, they presented a strong 
immunomodulatory function and determined an up-regulation of neurotrophic factors, such 
as VEGF and IGF-1 (Han et al., 2014). A recent work demonstrated that the administration 
of ADSC conditioned medium to SOD1G93A mice is sufficient to reduce neuromuscular 
junction denervation, highlighting the essential role of paracrine mechanisms in mediating 
beneficial effects of ADSC (Walker et al., 2018). 
The treatment with ADSC has been recently translated to patients: a first clinical trial 
evaluated the safety of a single or repeated intrathecal injections of ADSC in ALS patients. 
They reported classical adverse effects that appeared after the injection and became milder 
or absent within 1-3 weeks post-treatment, such as headache, low back and leg pain. The 
treatment with ADSCs resulted safe, but the efficacy is still debated. Indeed, treated 
patients presented a slight and temporary improvement of bulbar function, increased limb 
strength, decreased fasciculations, decreased stiffness, and improved energy (Staff et al., 
2016). At present, a new Phase II clinical trial is on-going to elucidate deeper the efficacy 
of ADSCs in the treatment of ALS (ClinicalTrial.gov identifier: NCT03268603).  
Another active clinical trial is sponsored by The Andalusian Initiative for Advanced 
Therapies. It is a multicentre phase I/II Clinical trial, randomized, controlled with placebo, 
triple blinded to evaluate the safety of the intravenous administration of 3 doses of 
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autologous MSCs from adipose tissue in ALS patients (ClinicalTrial.gov identifier: 
NCT02290886). 
1.5.3 Gene therapy in ALS 
Gene therapy is a new attractive approach to modulate ALS progression by modifying the 
expression of genes, that have been reported altered in ALS. In order to modulate gene 
expression, antisense oligonucleotides (ASOs) and viral-direct gene delivery strategies 
have been developed.  
ASOs are synthetic single-stranded DNA sequence that complemented selected sequences 
of target mRNA, determining mRNA degradation through RNase H enzyme recruitment. 
ASOs can also be modified to promote alternative splicing instead of mRNA degradation 
(Ly et al., 2018).  
The first ASO targets SOD1 mRNA and preclinical studies demonstrated a good 
distribution of ASO in CNS and an efficacious knock-down of SOD1 which lead to an 
extension of survival (Smith et al., 2006). A first clinical trial reported the safety of 
intrathecal injection of ASO 333611 (ISIS-SOD1RX) in SOD1-related ALS patients (Miller 
et al.,2013). Following these initial promising results, a clinical trial with a second 
generation SOD1-targeting ASO, BIIB067 (IONIS-SOD1RX), started in January 2016 and 
is still on-going (ClinicalTrial.gov identifier: NCT02623699). 
After the discovery of C9orf72 mutation in ALS, ASOs were designed to bind C9orf72 
mRNA in the downstream region of the expansion. In fact, an ASO produced by Ionis 
Pharmaceutical that recognised the region within or immediately upstream of the intronic 
expansion did not show efficacy in reducing C9orf72 expression (Donnelly et al., 2013). In 
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vivo preclinical studies of C9orf72 ASO effectiveness demonstrated that a single 
intraventricular administration of ASO could attenuate RNA foci and dipeptide aggregates 
and improve the behavioural and cognitive deficits associated with the C9orf72 repeat 
expansion (Jiang et al., 2016).  
Finally, another ASO tested in ALS was directed against ataxin-2, a protein that regulates 
stress granule formation of TDP-43 aggregates. Administration of anti-ataxin-2 ASO in 
mice expressing human TDP-43 reduced formation of TDP-43 aggregates, slowed disease 
progression, and extended lifespan (Becker et al., 2017).  
The most common viral vector is the adeno-associated virus (AAV). This type of 
technology can provide greater ease in drug administration because it is able to readily 
cross the BBB when given systemically and can be manipulated to promote tropism to 
specific cell types and structures (Ly et al., 2018).  
Nowadays, there are only preclinical results about the use of gene modulation through 
AAV injection. Thomsen and Colleagues suppressed mutant SOD1 in motor cortex and 
reported a significant delay in disease onset and extension in survival in transgenic 
SOD1G93A rats. In addition, they observed an increase survival of spinal MNs and an 
amelioration of neuromuscular junction (NMJ) healthy (Thomsen et al., 2014).  
The same research group tried the systemic injection of AAV9-GDNF in SOD1G93A rats. 
However, in these experiments they registered only a modest functional improvement of 
motor performance and any effects on survival in SOD1G93A rats. Moreover, AAV9-GDNF 
administration caused side effects, including slowed weight gain, reduced overall activity 
levels and impaired working memory (Thomsen et al., 2017).  
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Finally, AAV5-mediated delivering of a miRNA (AAV5-miC) that targets C9orf72 mRNA 
was tested in vitro in astrocytes, frontal brain-like neurons derived from FTD patients and 
in human-derived iPSCs neurons. A reduction of sense intronic transcripts of C9orf72 was 
observed in all the in-vitro models, where a lower dipeptide aggregation and RNA foci 
formation were determined. AAV5-miC was administrated by intra-striatal injection in 
C9orf72 mice. Also in these in-vivo experiments, a significant decrease of C9orf72 mRNA 
and of the sense intronic transcripts was achieved in injected area and surrounding regions, 
suggesting a potential ability in reducing the toxic aggregation of dipeptides and disease 





















In a previous study my research group reported that a single intravenous administration of 
MSCs, derived from bone marrow of 6 to 8 week-old female C57Bl/6J mice, in SOD1G93A 
mice extended lifespan, ameliorated motor performance and reduced astrogliosis and 
inflammation in spinal cord (Uccelli et al., 2012). 
They analysed survival of MSC-injected SODG93A mice compared to saline-injected 
SOD1G93A. These latter had a survival probability of 116.1 ± 3.4 days, while MSC 
administration prolonged the lifespan to 133.4 ± 3.8 days. Moreover, the performance of 
MSC-treated SOD1G93A mice in extension reflex of hind limbs, gait test and Rotarod task 
was significantly ameliorated compared to saline-treated SOD1G93A mice.  
The beneficial effects on survival probability and motor skills were related to a decreased 
number of cells which were positive for ubiquitin, reduced astrocytes and microglia 
activation, lower levels of IL-1β and TNF-α mRNA, normalization of oxidative stress 
response and, finally, to an increase in GLT-1 mRNA expression and a rescue of abnormal 
glutamate release.  
The distribution of MSCs after intravenous injection was tracked by transfecting MSCs 
with a Luciferase gene reporter vector. Luciferase positive cells were detected 24h and 48h 
after injection throughout the entire spinal cord. However the number of labelled MSCs 
appeared small; moreover, it significantly decreased 20 days after injection and was barely 
detectable 35 days after injection.  
These results highlighted that only a small number of MSCs can migrate into the CNS of 
SOD1G93A mice after intravenous administration and suggested that the positive read-out 
could be driven by paracrine mechanisms rather than long-term MSC engraftment. Indeed, 
it has been reported that MSCs release different cytokines and chemokines, including IL-
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10, CCL2, TGF-β, IL-6 and IL-7, growth factors (LIF, HGF), which can activate the 
regenerative potential of resident stem cells, promote angiogenesis and remodel stroma, 
anti-inflammatory factors, such as PGE2 and TSG6 and, finally, extracellular vesicles 
(exosomes, microvesicles) (Shi et al., 2018). 
Exosomes are nanovesicles with a diameter of 40-100 nm and constitute one of the main 
subclasses of EVs. The biogenesis of exosomes occurs via the endocytosis-exocytosis 
pathway when cells adsorb small amounts of intracellular fluid in a specific membrane 
region and form early endosomes. The early endosomes mature and expand into late 
endosomes, then intraluminal vesicles or multivesicular bodies (MVBs) are formed by 
internal budding of endosomal membrane and are released into the extracellular 
environment. Exosome exocytosis is regulated by p53 and under the control of the 
cytoskeleton activation pathway but not affected by calcium.  
Exosomes contain a cargo of genetic material (mRNA, miRNA, pre-miRNA, and other 
non-coding RNA) and of proteins, that are transferred to and released into target cells. 
Exosomes can interact with cells via three pathways: they may enter cell via the endocytic 
uptake, by direct fusion of the vesicles to the cell membrane or by transferring their 
contents through adhesion to the cell surface mediated by the interaction with a lipid ligand 
receptor (Keshtkar et al., 2018). 
It has been suggested that exosomes may be a way for the elimination of toxic substances 
from the affected cells and this may represent a mode for disease spreading, also in ALS. 
Mutant and misfolded WT-SOD1 can propagate  from different cells to recipient cells, in 
association with vesicles which are released into the extracellular environment (Silverman 
et al., 2016) and it has been shown that exosomes derived from primary astrocytes, isolated 
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from SOD1G93A mice, contain abnormal amount of mutant SOD1 and spread it, provoking 
MN death (Basso et al., 2013). Similarly, exposure of Neuro2a cells to exosomes from the 
brain of TDP-43A315T mice, but not from control brain, caused cytoplasmic redistribution of 
TDP-43, suggesting that secreted exosomes contribute to propagation of TDP-43 
proteinopathy. However, blocking exosome production in-vivo exacerbated the disease 
progression of mice expressing human TDP-43A315T. The in-vivo data suggest that exosome 
secretion plays an overall beneficial role in neuronal clearance of pathological TDP-43 
(Iguchi et al., 2016). In addition to TDP-43 and SOD1, other ALS-related proteins have 
been characterized in exosomes, such as FUS and C9Orf72, as well as non-coding 
miRNAs characteristic for the pathology (Roy et al., 2019). 
Therefore, although it was thought initially that exosomes contained unwanted ‘junk’ 
RNA, instead, nowadays, it is recognised that cells selectively sort specific non-coding 
RNAs into exosomes for active transport to neighbouring cells. In particular, miRNAs, 
which regulate the expression of approximately 30–70% of human genes through base-
pairing of their “seed” sequences with complementary mRNA, make up an important 
fraction of exosomal content, contributing to the overall biological functions of exosomes 
(Ferguson & Nguyen, 2016). Exosomes derived from MSCs substantially contain miRNAs 
that affect genes involved in specific processes related to cardiovascular development, 
angiogenesis and tube formation, pathways related to cell death and growth, and pathways 
related to fibrosis, such as platelet derived growth factor (PDGF) and TGF-β (Ferguson et 
al, 2018). Moreover, MSCs release exosomes containing miRNAs that are able to mitigate 
the inflammatory response, as miR-15a, miR-15b and miR-16, which act inhibiting the 
expression of CX3C-chemokine ligand 1 (CX3CL1), a potent macrophage 
chemoattractant, and miRNAs that suppress TLR signalling, causing the translocation of 
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NFҡB to the nucleus, and hampering macrophage activation by engulfed mitochondria 
(Maffioli et al., 2017; Phinney et al., 2015). 
The potential role of exosomes for therapeutic intervention in neurological and 
neurodegenerative disease, is well known (Croese and Furlan, 2018). Exosomes can 
transfer biological information over long distance and they are able to cross the BBB, they 
were then investigated as a potential therapeutic tool in ALS (Bonafede and Mariotti, 
2017). Exosomes derived from adipose stromal cells may increase NSC-34 cell line 
viability, protecting from oxidative damage and inducing anti-apoptotic pathway activation 
(Bonafede et al., 2016; Bonafede et al., 2019). Moreover, exosomes derived from adipose 
stromal cells ameliorated the aggregation of SOD1 in the SOD1G93A mouse model of ALS 
(Lee et al., 2016). In a recent study, exosomes from the NSC-34 neuronal cell line, 
previously transfected with the mutant SOD1G93A protein, which were enriched of miR-
124, caused a switch in the recipient N9 microglial cell line from a preferential M1 to a 
mixed M1 and M2 polarization (Pinto et al., 2017).  
Starting from these findings describing the pivotal role of exosomes in cell-to-cell 
communication and of the selective effects on cellular function due to their unique miRNA 
cargo, we hypothesized that exosomes could be one of the major mediators of MSC 
immunoregulatory function. Moreover, we wanted to elucidate the role of miRNAs 
shuttled by exosomes as the effectors of their functions. To validate our hypothesis I 
studied the effectiveness of exosomes derived from MSCs primed with IFN-γ, in order to 
increase their anti-inflammatory and immunomodulatory properties (Vigo et al., 2016), in 
modulating the altered phenotype of ALS astrocytes, isolated from spinal cord of 
SOD1G93A mice at 120 days of life, representing a late stage of the disease and, in turn MN 
survival. Characterization of INF-γ-primed MSCs through microarray analyses revealed 
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that nine miRNAs were up-regulated compared to unstimulated MSCs and these miRNAs 
were present in exosomes. In my study I analysed the contribution of these selected 
miRNAs, which are contained in exosomes, to the modulation of the astrocyte phenotype 
by transfecting the cells with single synthetic miRNA (mimic) and I elucidated some of the 
pathways affected from the nine up-regulated miRNAs to pave the way to a possible 



























B6SJL-TgN SOD1/G93A1Gur mice expressing high copy number of mutant human SOD1 
with a Gly93Ala substitution (SOD1/G93A) and (WT) (Gurney et al., 1994) were 
originally obtained from Jackson Laboratories (Bar Harbor, ME, USA) and bred at the 
animal facility of the  Pharmacology  and Toxicology Unit, Department of Pharmacy in 
Genoa, where they were kept until experiments were carried out. Transgenic animals were 
crossed with background-matched B6SJL wild-type females, and selective breeding 
maintained each transgene in the hemizygous state.  
All transgenic mice were identified by analysing tissue extracts from tail tips as previously 
described (Bonifacino et al. 2017). Tissue was homogenized in phosphate-buffered saline 
(PBS), freeze/thawed twice and centrifuged at 23,000 x g for 15 min at 4°C, and human 
SOD1 was evaluated by staining for its enzymatic activity after 10% non-denaturing 
polyacrylamide gel electrophoresis.  
Animals were housed (6/7 per cage) at constant temperature (22 ± 1°C) and relative 
humidity (50%) with a regular 12 h -12 h light cycle (light 7 AM -7 PM). Food (type 
4RF21 standard diet obtained from Mucedola, Settimo Milanese, Milan, Italy) and water 
were freely available. The number of animals of each sex was balanced in each 
experimental group to avoid bias due to intrinsic sex-related differences. For experimental 
use, animals were sacrificed at 120 days old, a late stage of the disease.  
Experiments were carried out in accordance with the guidelines established by the 
European Communities Council (EU Directive 114 2010/63/EU for animal experiments 
published on September 22nd, 2010) and the Italian D.L. n. 26/2014 and were approved by 
the local Ethical Committee and by the Italian Ministry of Health (Project Authorization 
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No.97/2017-PR). All efforts were made to minimize animal suffering and to use only the 
number of animals necessary to produce reliable results. In particular, the use of primary 
cell cultures leads to a reduction in the number of utilized animals; indeed, our optimised 
protocol permitted the isolation of astrocytes from adult mouse spinal cord with a yield that 
allowed to study diverse parameters through multiple techniques starting from cells 
prepared from a single mouse. Moreover, we obtained, at least, two dishes of SOD1G93A 
astrocytes from a single mouse spinal cord, thus gave us the possibility to treat primary 
astrocytes from the same mouse with vehicle or MSC-derived exosomes, decreasing the 
number of animals necessary to perform the experiments, but improving also the 
experimental design. 
3.2 Preparation of primary cultures of astrocytes  
WT and SOD1G93A mice (120 days old) were euthanized by cervical dislocation, without 
prior anaesthesia by personnel well-trained with this technique, and spinal cords were 
rapidly removed. Primary astrocytes were prepared from spinal cord of adult mice with a 
protocol optimised in our laboratory. The tissue was chopped with a scalpel to act a first 
mechanical breaking up and to facilitate the next step of homogenization of the spinal cord.  
The chopped spinal cord was transferred in a sterile 15ml falcon with 1 ml of Dulbecco’s 
Modified Eagle Medium (DMEM; Euroclone, Cat# ECM0728L) containing 10% Fetal 
Bovine Serum (Euroclone, Cat# ECS0180L), 1% glutamine (Euroclone, Cat# ECB3004D) 
and 1% Penicillin/Streptomycin (Euroclone, Cat# ECB3001D), then, with a P1000 pipette 
the tissue was further disintegrated until reaching a homogeneous preparation, which was 
seeded at the optimal density of two 35mm Petri dishes, pre-coated with poly-L-ornithine 
hydrocloride (1.5µg/ml; Sigma-Aldrich, Cat# P2533) and laminin (3µg/ml; Sigma-Aldrich, 
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Cat# L2020), for SOD1G93A spinal cord, and of one pre-coated 35mm Petri dish for WT 
spinal cord.  
The preparation was placed at 37°C in humidified 5% CO2 incubator for 5 days, then the 
medium containing tissue fragments was replaced with fresh complete DMEM. After 
10DIV astrocytes were detached by incubation at 37°C for 15 minutes with Trypsin-EDTA 
1X (Euroclone, Cat# ECB3052B). The trypsin solution was then neutralized with a volume 
of DMEM equal to four times the volume of trypsin and centrifuged for 5 minutes at 500 x 
g at room temperature. The cell pellet was re-suspended and re-plated on pre-coated 35 
mm Petri dishes, at the optimal density of 105 cells, for qPCR, Western blot and astrocyte-
MN co-culture analysis; while the astrocytes were re-plated on pre-coated glass coverslips 
placed in 24-wellplate, at a density of 3x104 cells per well for confocal microscopy studies.  
After 20DIV,when astrocytes reached the confluence and a proper degree of maturation, 
exosome treatment was started and, after 24 hours, samples were collected for the analyses. 
 
3.3 Human-fibroblast derived astrocytes 
Fibroblasts derived from healthy donor and ALS patients, carrying the SOD1 mutation, 
were converted in induced Neural Progenitor Cells (iNPCs) by exposure to retroviral 
vectors (Oct3/4, Sox2, Klf4, and c-Myc) for 24 hours and then, after recovery in regular 
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fibroblast medium, a NPC conversion medium was added to cells and it was changed every 
day.  
When cells changed shape and formed sphere-like structures, they were collected and 
expanded in individual wells of a six-well plate. As soon as the NPC culture was 
established, the medium was switched to NPC medium consisting of DMEM/F12 (Gibco, 
Waltham, MA, USA), Glutamax (Gibco, Waltham, MA, USA) 1% N2 (Gibco, Waltham, 
MA, USA), 1% B27 (Gibco, Waltham, MA, USA), 20 ng/ml FGF2 (Peprotech, Rocky 
Hill, NJ, USA), 20 ng/ml EGF (Peprotech, Rocky Hill, NJ, USA) and 5 ng/ml heparin 
(Sigma, St. Louis, MO, USA). The protocol for the conversion of fibroblasts in iNPCs lasts 
4 weeks.  
For astrocyte differentiation, iNPCs were seeded in NPC medium at low density in a 
fibronectin-coated 100mm Petri dish. The day after, the medium was switched to DMEM 
(Fisher Scientific, Hampton, NH, USA), 10% FBS (Life science production, Bedford, UK), 
0.2% N2 (Gibco, Waltham, MA, USA). Astrocytes were allowed to mature for at least 7 
days. 
3.4 Isolation and expansion of mouse and human mesenchymal stem cells 
Mouse bone marrow from 6- to 8-week-old C57BL/6J mice was flushed out of tibias and 
femurs. After 2 washes by centrifugation at 352 x g for 5 minutes in PBS, cells were plated 
in 75-cm2 tissue-culture flasks at the concentration of 0.3 to 0.4 × 106 cells/cm2 using 
Murine Mesencult as medium (Stem Cell Technologies, Cat# 05513). Cells were kept in a 
humidified 5% CO2 incubator at 37°C, and the medium was refreshed every 3 to 4 days, 
for about 4 to 5 weeks; only adherent cells were collected following 10-minute incubation 
at 37°C with Trypsin-EDTA 1X.  
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After the first cut and for the subsequent 4 or 5 passages, the cells were plated in 25-
cm2 flasks at 1.2 to 2.0 × 104 cells/cm2. For the following passages, cells were routinely 
seeded at 4 to 10 × 103 cells/cm2 reaching confluence after 4 to 5 days. Mature MSCs were 
defined by their ability to differentiate into bone, cartilage and fat and by the expression of 
CD9+, Sca-1+, CD44+ and CD73+ and the lack of hematopoietic markers CD45-, CD34- 
and CD11b-, as previously reported (Zappia et al., 2005).  
Human bone marrow stem cells were obtained from marrow aspirates of bone marrow 
donors (Divisions of Hematology, San Martino Hospital, Genoa, Italy). From 
approximately 1000 ml of marrow aspirate, ready for transplantation, 10 ml aliquots were 
taken and centrifuged on a Ficoll separating solution (Seromed, Berlin, Germany) for 20 
minutes at 800 x g. The  cell fraction was recovered, counted, suspended in complete 
MesenCultTM Medium (StemCell Technologies, Cat# 05411) and plated at 5 × 106 cells  in 
75 cm2 flask. The medium was changed after 3 days and then three times a week. When 
cells reached confluence (after 14DIV), they were detached by means of Trypsine-EDTA 
1X, counted, and reseeded in 75 cm2 flasks at a density of 1 x 105 MSCs per flask. 
3.5 Isolation of MSC-derived exosomes and treatment of astrocytes  
Exosomes were isolated from mouse or human MSCs. At confluence, MSC medium plus 
supplement was substituted with 10 ml MesenCultTM serum-free medium and then primed 
with 10nM IFN-γ (Recombinant Mouse IFN-gamma Protein, R&D systems, Cat#485-MI; 
Recombinant Human IFN-γ, R&D, 285-IF). Cells were incubated for 24 hours at 37°C and 
5% CO2 in O2. Next day, 1mM Adenosine 5′-triphosphate disodium salt hydrate (ATP, 
Sigma-Aldrich, Cat# A6419) was added to the medium for 20 minutes in order to promote 
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the release of exosomes by increasing the exposition on cytoplasmic membrane surface of 
phosphatidylserine, due to the activation of ATP  P2X7 receptor (Wilson et al., 2004).  
Medium was collected in 15ml falcon tubes and centrifuged 20 minutes at 2000 x g to 
remove debris and added with 5 ml of Total Exosome Isolation Kit (Invitrogen, Cat# 
4478359) per 10 ml MSC-medium and stored overnight at 4°C. The day after, this mix was 
centrifuged 12,000 x g 1 hour. The supernatant was discarded and the exosome-pellet 
suspended in DMEM. MSCs were detached with Trypsin-EDTA 1X and counted by 
Neubayer Chamber to determine the exosome amount to be added in astrocyte medium. In 
each experiment, the ratio 1:6 between astrocytes and MSC derived-exosomes was 
maintained. 
Mouse SOD1G93A astrocytes and iAstrocytes were treated with MSC-derived exosomes for 
24 hours in DMEM without FBS or knockout serum, respectively. After 24 hour treatment, 
mouse astrocytes were collected as cell pellet for Western blotting, or fixed with 
paraformaldehyde (PFA) for quantitative immunofluorescence experiments. Instead, after 
exosome treatment, human astrocytes required a wash-out period of 24 hours. Then 
iAstrocytes were detached and the cell pellet store at -80° for Western blot experiments. To 
study MN viability, medium containing exosomes was removed after 24 hours and MNs 
were seeded immediately on treated astrocytes, both in mouse and human experiments.  
3.6 Confocal microscopy experiments 
Astrocytes, seeded on 12mm diameter glass coverslips, were fixed with 4% PFA (Sigma-
Aldirich, Cat# 47608) for 20 minutes at room temperature, protected from light. After 
fixing, PFA was removed and astrocytes were washed 3x with PBS 1X. Then, cells were 
permeabilized with methanol for 5 minutes at -20°C and washed 3x with PBS 1X. A 
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solution of 0.5% bovine serum albumin (BSA) in PBS was used as blocking solution for 15 
minutes at room temperature.  
All primary antibodies were diluted in 3% PBS-BSA blocking solution. Incubation was 
performed overnight at 4°C with the primary antibodies at the proper working dilution 
(Table 2). 
The day after, cells were washed 3x in 0.5% PBS-BSA before the incubation of 1 hour at 
room temperature with the secondary antibody, diluted 1:3000 in PBS containing 3% BSA 
(Table 2).  
Then, cells were washed 3 times in PBS and the coverslip was assembled on a microscopy 
glass slide through FluoroshieldTM with DAPI (Sigma-Aldrich, Cat# F6057). Fluorescence 
image (512 x 512 x 8 bit) acquisition was performed by a three-channel Leica TCS SP5 
laser-scanning confocal microscope equipped with 458, 476, 488, 514, 543 and 633 nm 
excitation lines through a plan-apochromatic oil immersion objective 63x/1.4. Light 
collection was optimized according to the combination of the chosen fluorochromes, and 
sequential channel acquisition was performed to avoid cross-talk. The Leica “LAS AF” 
software package was used for image acquisition. The quantitative analyses of co-
localization and the relative protein expression level were performed by calculating co-






Table 2. List of primary and secondary antibodies with the respective working dilution, the 




3.7 iAstrocyte immunofluorescence experiments 
Cells were fixed with 4% PFA for 15 minutes and washed 3× with PBS before the 
blocking and permeabilizing solution, consisting of PBS with 10% horse Serum and 0.1% 
Triton X-100, was applied for 1 hour. All primary antibodies were diluted in blocking 
solution. Incubation was performed overnight at 4 °C with the following primary 
antibodies: rabbit polyclonal anti-GFAP (1:1000), chicken polyclonal anti-vimentin 
(1:1000) and rabbit polyclonal anti-CD44 (1:500). The day after, cells were washed 3× in 
PBS before the secondary antibody (anti-rabbit Alexa Fluor 488, anti-chicken Alexa Fluor 
488, anti-rabbit Alexa Fluor 568) and DAPI, diluted in blocking solution (1:2000), were 
applied for 1 hour at room temperature. Then, cells were washed 3× in PBS. Astrocytes 
were analyzed by Opera Phenix High-Content Screening System (PerkinElmer). 
3.8 Western blot experiments 
The samples for Western blot analysis were collected by detaching cells with trypsin-
EDTA and re-suspended them in PBS. Cells were centrifuged at 17,000 x g for 1 minute 
and PBS was removed. Cell pellets were stored at -80°C. Pellets were lysed by IP lysis 
buffer [150mM NaCl, 50mM HEPES, 1mM EDTA, 1mM DDT, 0,5% (v/v) Triton X-100, 
protease inhibitor cocktail (PIC), pH 8.0] + phosphatase inhibitors. Lysates were incubated 
for 15 minutes in ice, then they were centrifuged 17,000 x g for 5 minutes at 4°C. The 
lysate supernatant which contains soluble proteins was stored. Protein concentration was 
determined by BCA protein assay.  
Appropriate amount (15 μg) of total proteins was separated by SDS-polyacrylamide gel 
electrophoresis using 4–20% precast gels (Bio-Rad, Cat# 4568094) and transferred to 
nitrocellulose membranes. Non-specific membrane binding sites were saturated in 5% 
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skimmed-milk solution and membranes were incubated overnight at 4 °C with the primary 
antibodies (Table 3).  
After incubation with appropriate peroxidase-coupled secondary antibodies, protein bands 
were detected by a Western blotting detection system (SuperSignalTM West Femto 
Maximum Sensitivity Substrate, Thermo Fisher Scientific, Cat# 34095). Bands were 
detected and analysed for density using an enhanced chemiluminescence system (Alliance 
6.7 WL 20 M, UVITEC, Cambridge, UK) and UV1D software (UVITEC). Bands of 
interest were normalized for GAPDH or β-actin level in the same membrane. The 
concentration of proteins felt in the linear portion of the curve. 
Table 3. List of primary antibodies used to perform Western blot analysis, reporting the 




3.9 Enzyme-linked immunosorbent assay 
Astrocytes, cultured in 35mm Petri dish, were treated with MSC-derived exosome for 24 
hours in DMEM serum free. Then, DMEM containing exosomes was replaced with 
complete fresh DMEM and astrocyte-conditioned medium was collected 48 hours after 
exosome withdraw.  
Cell-conditioned medium was filtered with 0.22µm sterile filter. Then, TNF-α, IL-1β, IL-6 
and CCL2 concentrations were measured with a specific enzyme-linked immunosorbent 
assay (ELISA) kit (R&D Systems, Cat# DY401, DY410, DY406 and DY479, respectively) 
according to the manufacturer’s protocol. ELISA 96-wellplate was pre-treated for 24 hours 
at room temperature with the capture antibody for TNF-α (1:50), IL-1β (1:50), IL-6 (1:50) 
or CCL2 (1:500), then the excess of antibody was washed using the Wash buffer (R&D 
systems, Cat# WA126) and the plate was blocked by 1 hour incubation with Reagent 
Diluent (R&D systems, Cat# DY995).  
At this point it was possible to add the standard and samples. Standard solution was 
prepared by diluting recombinant TNF-α, IL-1β, IL-6 or CCL2 in Reagent Diluent to have 
a concentration of  1000 pg/ml, 2000 pg/ml, 1000 pg/ml or 250 pg/ml as first point of the 
standard curve, respectively. A seven-point standard curve was generate using 2-fold serial 
dilutions in Reagent Diluent. 100 µl of standard at the diverse concentrations was added to 
each well and for each concentration of standard point was done a triplicate.  
To collect the appropriate amount of cytokines for the analysis, 150-200 µl of medium per 
well was added. Each sample was loaded in duplicate. Three wells were used as blank, and 
were loaded with 100 µl filter water. Wells were incubated for 2 hours at room temperature 
to allow the binding of the specific cytokine with the antibody.  
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Then, the medium was aspirated and wells were washed 3x with Wash buffer and 
incubated for 2 hours with 100 µl of the detection antibody for TNF-α, IL-1β, IL-6 and 
CCL2 per well, each diluted 1:60 in Reagent Diluent. Wells were washed 3x with Wash 
buffer and 100 µl Streptavidin-HRP (1:40 in Reagent Diluent) were added to each well for 
20 minutes, protected from light.  
Streptavidin-HRP was washed 3x with Wash buffer and re-placed with 100 µl of Substrate 
Solution [1:1 mixture of Color Reagent A (H2O2) and Color Reagent B 
(Tetramethylbenzidine); R&D systems, Cat# DY999)]. The plate was incubated 20 
minutes at room temperature, protected from light. Finally, 50 µl of Stop Solution (2N 
H2SO4, R&D systems, Cat# DY994) were used to block the reaction and the plate was 
ready for the acquisition.  
Absorbance was measured at 450 nm with a microplate reader (SpectraMax 340PC 
Microplate Reader, Molecular devices, San Jose, California, USA). The standard curve 
was constructed by plotting the mean absorbance for each standard on the y-axis against 
the concentration on the x-axis and by drawing the best fit curve trough the points on the 
graph. The concentration of the samples can be obtained from the absorbance by regression 
analysis on the basis of the standard curve.  
3.10 Motor neuron preparation from SOD1G93A embryos and co-cultures with 
SOD1G93A astrocytes 
MNs were prepared from spinal cord of SOD1G93A E13.5 mouse embryos (Vandenbergheet 
al., 1998; Wiese et al., 2009). Spinal cord was isolated from embryos by microscopy 
dissection, then meninges and the dorsal root ganglia were removed. The tissue was 
digested with 0.5% trypsin (Sigma-Aldrich, Cat# T4799) in Hank’s Balance Salt Solution 
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(HBSS) for 20 minutes at 37°C. Then, trypsin solution was replaced with a mix of 0.4% 
BSA (Sigma-Aldrich, Cat# A3311) in Leibovitz-15 medium (Sigma-Aldrich, Cat# L5520)  
and 0.02 mg/ml Deoxyribonuclease I (DNAse; Sigma-Aldrich, Cat#DN25) and gently 
triturated with P1000 pipette.  
The tissue homogenate was stratified on 6.2% OptiPrep (Sigma-Aldrich, Cat# D1556) 
cushion and centrifuged 500 x g for 15 minutes at room temperature. After centrifuging, 
the motor neuron-enriched cell population was localized at the interface between the 
OptiPrep solution and the medium. The MN band was collected and re-suspended in 3 ml 
of MN medium: Neurobasal medium (Gibco, Cat# 21103-049), 2% B27 supplement 
(Gibco, Cat# 17504044), 2% horse serum (Gibco, Cat# 16050130), 0.5mM stable L-
Glutamine (Gibco, Cat#35050038), 25µM Mercaptoethanol (Sigma-Aldrich, Cat# M6250), 
10 ng/ml ciliary neurotrophic factor (CNTF; Sigma-Aldrich, Cat# C3835), 100 pg/ml glial-
derived neurotrophic factor (GDNF; Sigma-Aldrich, Cat# G1401), 5µg/ml 
Penicillin/Streptomycin.  
Motor neurons were centrifuged at 75 x g for 20 minutes to remove Optiprep impurity. The 
pellet containing MNs was diluted in 1 ml of MN medium plus 50µl of Chick Embryo 
Extract (US Biological, Cat# C3999).  
 MNs were seeded at a density of 5 x 104 MNs in a 35mm Petri dish on confluent adult 
astrocytes prepared from 120 days-old SOD1G93A mice, previously treated or not with 
exosomes. After 3 days the medium was removed and replaced with fresh MN medium 
and then it was changed three times a week. On day 4 after seeding, MNs in an area of 1 
cm2 were counted to asses viability. The number of MNs was recorded three times a week 
for 14 days. The number of MNs at day 4 were considered as 100% of survival. The 
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percentage of survival at the other time-points was calculated as % of the number of MNs 
at day 4, in the same Petri dish. 
 
3.11 Immunofluorescence experiments on astrocyte-MN co-cultures 
The co-culture system was prepared as described above. At day 7 after seeding, when MNs 
were completely mature and the number of cells was still enough high, astrocytes and MNs 
were fixed with 4% PFA for 20 minutes at room temperature, protected from light. The 
fixing solution was removed and cells were washed 3x with PBS 1X. Cells were then 
permeabilised with methanol for 5 minutes at -20°C and washed 3x with PBS 1X. A 
solution of 0.5% BSA in PBS was used as blocking solution for 15 minutes at room 
temperature.  
All primary antibodies were diluted in 3% PBS-BSA blocking solution. Incubation was 
performed overnight at 4°C with the following primary antibodies: rabbit polyclonal anti-
Homebox9 antibody (Hb9, 1:800; Abcam, Cat# ab92606), rabbit polyclonal anti-Islet-1 
antibody (1:100, abcam, Cat# ab109517) or chicken polyclonal anti-β-Tubulin III (1:1000; 
Chemicon International, Cat# AB9354).  
The day after, cells were washed 3x in 0.5% PBS and incubated for 1 hour at room 
temperature with the secondary antibodies. The following secondary antibodies were used: 
96 
 
donkey anti-rabbit Alexa Fluor A488-conjugated (Thermo Fisher Scientific, Cat# R37118) 
and goat anti-chicken Alexa Fluor A467-conjugated (Thermo Fisher Scientific, Cat# 
A21449). Antibodies were diluted 1:3000 in PBS containing 3% BSA. Finally, the cells 
were washed again 3x with PBS 1X and covered with a glass coverslip, fastened with the 
prolong reagent FluoroshieldTM containing DAPI. Fluorescence image acquisition was 
performed by an Olympus BX41 microscope through a 40x objective. 
3.12 Motor Neuron Differentiation from mouse embryonic stem cells and co-culture 
of Motor Neurons and Astrocytes 
Mouse embryonic stem cells expressing GFP under the MN-specific promoter HB9 were 
cultured on primary mouse embryonic fibroblasts (Merck, Burlington, MA, USA). For 
differentiation into MNs, cells were harvested with trypsin and suspended in DFK10 
culture medium consisting of knock-out DMEM/F12 (Gibco, Waltham, MA, USA), 10% 
knockout serum replacement (Gibco, Waltham, MA, USA), 1% N2 (Gibco, Waltham, MA, 
USA), 1 mM L-glutamine (Gibco, Waltham, MA, USA), 0.5% glucose (Sigma, St. Louis, 
MO, USA) and 0.0016% 2-mercaptoethanol (Sigma, St. Louis, MO, USA). 
Cells were seeded on non-adherent Petri dishes to allow the formation of embryoid bodies. 
After 1 day of recovery, 2 μM retinoic acid (Sigma, St. Louis, MO, USA) and 1 μM 
smoothened agonist (SAG; Millipore, St. Louis, MO, USA) were added freshly every day 
in new medium from day 2 to day 7 post-seeding to induce mouse embryo stem cell 
(mESC) differentiation into MNs. After 7 days of differentiation, embryoid bodies were 
dissociated using 200UI/ml papain (Sigma, St. Louis, MO, USA) and sorted using FACS. 
Human astrocytes were plated in 96-well plates coated with human fibronectin (2.5 μg/mL) 
at a density of 10,000 per well. Two days later, FACS sorted GFP-positive MNs were 
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suspended in MN media consisting of DMEM/F12, 5% horse serum, 2% N2, 2% B27 plus 
GDNF (10 ng/mL), BDNF (10 ng/mL), and CNTF (10 ng/mL) and added to astrocytes at a 
density of 10,000 per well.  
Each plate was scanned every day, until day 3 after MN seeding, with the fully automated 
IN CELL 6000 confocal plate reader to capture GFP-positive cells. The IN CELL 
Developer and Analyzer softwares were used to create whole-well pictures and count. 
3.13 Transfection of mouse astrocytes with single synthetic miRNA (mimic) 
SOD1G93A astrocytes were plated in 24-wellplates on 12mm coverslips for confocal 
microscopy or in 35mm Petri dishes for qPCR. Cells were transfected with the following 
miRNA mimics: miR-466q, mirR-467f, miR-466m-5p, miR-466i-3p, miR-466i-5p, miR-
5126, miR-467g, miR-3082-5p, and miR-669c-3p (Qiagen, Hilden, Germany). To 
demonstrate the specificity of the mimic effect on its mRNA target, cells were always 
transfected also with a negative control (scramble). Astrocytes were transfected with 
miRNA mimics at a final concentration of 5 nM using HiPerFect Transfection Reagent 
(Qiagen, Cat# 301704) according to the manufacturer's instructions. HiPerFect 
Transfection Reagent enables highly efficient miRNA transfection, allowing translation 
repression of target mRNA using low miRNA concentration. After 48 hours incubation at 
37°C in humidified 5% CO2, astrocytes were fixed with 4% PFA for confocal microscopy 
or were detached with Accutase® (Euroclone, Cat# ECB3056D) and the cell pellet 





3.14 qPCR experiments 
SOD1G93A astrocytes, after transfection with single synthetic miRNA mimics, were 
collected for qPCR analysis as described above. RNA was isolated by the phenol-
chloroform extraction procedure, using QIAzol Lysis Reagent. The purity of the RNA was 
evaluated by spectrophotometric analysis at the absorbance 230, 260 and 280 nm, to 
exclude the presence of peptides, phenols, aromatic compounds, or carbohydrates and 
proteins. The cDNA was synthesized according to the instructions provided by the kit used 
(Transcriptor First Strand cDNA synthesis kit, Roche Diagnostics, Germany).  
Quantification of the gene expression was evaluated in duplicate, in a final volume of 20 μl 
containing 50 ng cDNA, 1 μl of each pair of forward and reverse primers (20 μM) 
(synthetized by Tib Molbiol, Genova, Italy) and 10 μl of FastStart Essential DNA Green 
Master (Roche, Cat# 06402712001), using the LightCycler 480 (Roche) amplifier. The 
amplification of GAPDH gene was adopted as housekeeping gene to normalize data.  
Gene expression was expressed as relative mRNA amount (fold induction) compared with 
the control sample. 
3.15 Statistical analysis 
Data are expressed as the mean ± s.e.m., and p value < 0.05 was considered significant. 
Statistical comparison of two means were performed by unpaired two-tailed Student's t-test 
while multiple comparisons were performed using the analysis of variance (one-way 
ANOVA) followed by the Bonferroni's post hoc test. Analyses were performed by means 














4.1 Mouse astrocyte characterization and treatment with exosomes derived from 
mouse mesenchymal stem cells 
4.1.1 Characterization of MSC-derived exosomes 
Exosomes were isolated from the medium of MSCs stimulated or not with IFN-γ. The 
purity of the exosome preparation was analysed by measuring the expression of Alix and 
CD9, high-enriched proteins of exosomes, using Western blot analysis. Alix represents one 
of the accessory protein which is associate with the endosomal sorting complex for 
transport (ESCRT). This latter is involved in membrane budding and scission of vesicles 
from multi-vesicular bodies, playing a potential role in exosome formation. CD9 belongs 
to tetraspanin protein family, that are composed of four transmembrane domains and 
resulted enriched >100-fold in exosomes (Raposo and Stoorvogel, 2013).  
Both markers were significantly elevated in exosome samples, validating our isolation 
method to obtain a population of microvesicles enriched in exosomes (Figure 1A). 
Moreover, in order to verify the morphology of isolated microvesicles, we performed 
electron microscopy experiments. The most part of microvesicles ranged between 40 and 













Figure 1. Characterization of exosomes isolated from MSC medium through Invitrogen 
Exosome Isolation Kit. 
A)  Representative bands for ALIX and CD9, exosome selective markers. B) Electron microscopy 
image showing that the most part of the isolated microvesicles size ranged between 40 and 100 nm. 
 
 
miRNA expression was analysed in order to select possible mediators of exosome 
functions. Microarray analysis on MSCs and IFN-γ-primed MSCs was carried out by LC-
Sciences company (Houston, TX, USA). The miRNA panel highlighted nine miRNAs 
(miR-466q, miR-467f, miR-466m-5p, miR-466i-3p, miR-466i-5p, miR-467g, miR-5126, 
miR-3082-5p, and miR-669c-3p) that were significant up-regulated in MSCs after IFN-γ 
stimulation compared to non-primed MSCs (data not shown). Then, the expression of these 
nine up-regulated miRNAs was quantified in MSC- and IFN-γ-primed-MSC- derived 
exosomes.  
qPCR experiments on exosomes revealed that the expression of miR-466q, miR-467f, 
miR-466m-5p, and miR-466i-3p was significantly increased also in exosomes from IFN-γ-
primed MSCs compared to untreated MSCs. On the contrary, the expression of miR-466i-
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5p, miR-467g, miR-5126, miR-3082-5p, and miR-669c-3p was down-regulated in 




Figure 2. RT-PCR quantification of selected miRNAs present in exosomes derived from 
MSCs pre-treated or not with IFN-γ 
Quantitative analyses of miRNAs contained in exosomes derived from mouse untreated- and IFN-
γ-primed- MSCs. Data represent the mean ± SEM of three independent experiments run in 
triplicate. The miRNA expression of exosomes isolated from unstimulated-MSCs is reported as 1.  
*P < 0.05 at least vs. IFN-γ-primed- MSC-derived exosomes (two-tailed Student’s t-test). 
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4.1.2 Exosome treatment reduces astrogliosis in SOD1G93A astrocytes 
GFAP, Vimentin and S100β are markers identifying reactive astrocytes. GFAP and 
Vimentin are structural component of astrocyte cytoskeleton. In particular, GFAP 
represents the essential subunit which constitutes type III intermediate filaments in 
astrocytes (Tardy et al., 1990). 
Also Vimentin belongs to a protein family of intermediate filaments and plays a crucial 
role in supporting and anchoring the organelles in the cytosol. It is involved in cell shape 
maintaining, integrity of cytosol preservation and cytoskeletal interaction stabilization, 
both in physiological condition and in response to stress stimuli (Goldman et al., 1996). It 
has been reported that GFAP and vimentin are over-expressed in ALS in relation to a 
reactive and strongly proliferative state of astrocytes in the disease (Benninger et al., 2016; 
Schiffer et al., 1996).  
S100β is a calcium binding protein expressed selectively in glial cells. It is involved in 
several homeostatic functions, such as microtubule assembly, axonal proliferation, 
astrogliosis, calcium concentration, inflammation. There is a lot of evidence of its 
dysregulation in ALS. Indeed, in patients, S100β is increased in brain cortex astrocytes, 
and in astrocytes and motor neurons in the spinal cord and its level, which resulted higher 
in the CSF of ALS patients, is directly correlated with worsing of prognosis of the disease 
(Serrano et al., 2017).  
We quantified the expression level of GFAP, Vimentin and S100β by western blot (Figure 
3). The three markers of astrogliosis were significantly up-regulated in SOD1G93A 
astrocytes compared to WT astrocytes [1148% increase (P < 0.05, F(2,7)=13.362), 180% 
increase (P < 0.05, F(2,12)=10.998), 185% increase (P < 0.05, F(2,15)=6.751), respectively]. 
The treatment of SOD1G93A astrocytes with exosomes for 24 hours was able to reverse the 
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up-regulation of GFAP [66% decrease (P < 0.05, F(2,7)=13.362)], vimentin [72% decrease 
(P < 0.05, F(2,12)=10.998)], and S100β [77% decrease (P < 0.05, F(2,15)=6.751)] compared to 






Figure 3. Western blot quantification of GFAP, vimentin and S100β expression in cell lysates 
from primary cultures of spinal cord astrocytes from WT and SOD1G93A adult mice.  
(A) Representative immunoreactive bands for GFAP, vimentin, S100β, and GAPDH; (B, C, D) 
Quantification of protein expression as per scanned band density in WT astrocytes, untreated 
SOD1G93A astrocytes and SOD1G93A astrocytes treated for 24h with exosomes. Protein expression 
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level was calculated as relative density, normalized to the housekeeping protein GAPDH. Data 
presented are means ± SEM of 4 independent experiments. *P < 0.05 vs. WT astrocytes; #P < 0.05 
vs. untreated SOD1G93A astrocytes (One-way ANOVA followed by Bonferroni post hoc-test). 
 
The same expression trend of GFAP, Vimentin and S100β was observed by confocal 
microscopy analyses, confirming a higher expression of the three reactive astrocytic 
markers in SOD1G93A astrocytes compared to WT astrocytes [GFAP: 51% increase (P < 
0.001, F(2,30)=90.452); Vimentin: 21% increase (P < 0.01, F(2,22)=50.181); S100β: 25% 
increase (P < 0.001, F(2,12)=39.622), respectively], and the positive effects of exosome 
treatment on GFAP [45% decrease (P < 0.001,F(2,30)=90.452)], vimentin [77% decrease (P 
< 0.001, F(2,22)=50.181) and S100β [132% decrease (P < 0.001, F(2,12)=39.622)] over-







Figure 4. Immunocytochemical quantification of GFAP, vimentin and S100β expression in 
primary cultures of spinal cord astrocytes from WT and SOD1G93A adult mice.  
(A, C, E) Representative confocal microscopy immunocytochemical images for GAPDH (red) and 
GFAP (green) (upper panel), GAPDH (red) and vimentin (green) (middle panel) and for GAPDH 
(red) and S100β (green) (lower panel) in WT astrocytes, untreated SOD1G93A astrocytes and 
SOD1G93A astrocytes treated for 24h with exosomes. Nuclei were stained with 4',6-diamidin-2-
fenilindolo (DAPI, blue). The merge panels represent the co-expression of GFAP and GAPDH, of 
vimentin and GAPDH, or of S100β and GAPDH, respectively. Scale bar: 100 µm. (B, D, F) 
Quantification of protein expression, as per relative fluorescence intensity, was performed 
calculating the co-localization coefficients (Manders et al., 1992) using Image-J software analyses. 
Data are expressed as relative fluorescence intensity of GFAP, vimentin or S100β normalized 
respect to the fluorescence intensity of the housekeeping protein GAPDH. The relative intensity of 
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control WT astrocytes is reported as 1. Data presented are means ± SEM of n=3 experiments run in 
triplicate (three different coverslips for each experimental condition); statistical analysis was 
performed by one-way ANOVA followed by Bonferroni post hoc-test. *P < 0.001 vs. WT 
astrocytes; #P < 0.001 vs. untreated SOD1G93A astrocytes. 
 
 
4.1.3 The over-expression and the abnormal release of pro-inflammatory cytokines in 
SOD1G93A astrocytes are partially rescued upon exposure to MSC-derived exosomes 
Astrocytes secrete various pro-inflammatory cytokines and chemokines. It has been 
observed a dysregulation of cytokine production and secretion in several 
neurodegenerative diseases and also in ALS (Farina et al., 2007; Holden 2007). To verify 
possible effects of the exosome treatment on the pro-inflammatory phenotype of SOD1G93A 
astrocytes, we analysed the expression of the cytokines TNF-α, IL-1β, IL-6, and of the 
chemokine CCL2 by confocal microscopy.  
The expression level of TNF-α, IL-1β, IL-6, and CCL2 was significant increased in 
SOD1G93A astrocytes compared to WT astrocytes [TNF-α: 32% increase (P < 0.001, 
F(2,27)=65.648); IL-1β: 63% increase (P < 0.001, F(2,24)=434.190); IL-6: 46% increase (P < 
0.001, F(2,21)=69.674); CCL2: 37% increase (P < 0.001, F(2,18)=90.554)].  
The treatment with MSC-derived exosomes was able to reverse the up-regulation of TNF-α 
[79% decrease (P < 0.001, F(2,27)=65.648)], IL-1β [64% decrease (P < 0.001, 
F(2,24)=434.190)], IL-6 [66% decrease (P < 0.001, F(2,21)=69.674)], and CCL2 [115% 



















Figure 5. Immunocytochemical quantification of IL-1β, IL-6, TNFα and CCL2 expression in 
primary cultures of spinal cord astrocytes from WT and SOD1G93A adult mice.  
(A, C, E, G) Representative confocal microscopy immunocytochemical images for GAPDH (red) 
and TNF-α (green), GAPDH (red) and IL-1β (green), GAPDH (red) and IL-6 (green), or GAPDH 
(red) and CCL2 (green) in WT astrocytes, untreated SOD1G93A astrocytes and exosome-treated 
SOD1G93A astrocytes. Nuclei were stained with DAPI (blue). The merge panels represent the co-
expression of TNF-α, IL-1β, IL-6, or CCL2 with GAPDH. Scale bar: 100 µm. (B, D, F, H) 
Quantification of protein expression, as per relative fluorescence intensity, was performed 
calculating the co-localization coefficients (Manders et al., 1992) using Image-J software analyses. 
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Data are expressed as relative fluorescence intensity of TNF-α, IL-1β, IL-6, or CCL2, normalized 
to the fluorescence intensity of the housekeeping protein GAPDH. The relative intensity of control 
WT astrocytes is reported as 1. Data presented are means ± SEM of 3 experiments run in triplicate 
(three different coverslips for each experimental condition). *P < 0.001 vs. WT astrocytes; # P 




Then, we quantified the release of TNF-α, IL-1β, IL-6, and CCL2 in the culture medium 
collected from WT-, SOD1G93A- and exosome-treated SOD1G93A astrocytes. The release of 
TNF-α, IL-1β, IL-6, CCL-2 was massively augmented in SOD1G93A astrocytes compared 
to WT astrocytes [TNF-α: 571% increase (P < 0.001, F(2,6)=170.073); IL-1β: 351% 
increase (P < 0.001, F(2,6)=542.972); IL-6: 758% increase (P < 0.001, F(2,6)=481.467); 
CCL2: 96% increase (P < 0.001, F(2,6)=44.549)]. 
TNF-α, IL-1β, IL-6 and CCL2 release was significantly reduced by 40% (P < 0.001, 
F(2,6)=170.073), 12% (P < 0.05, F(2,6)=542.972), 20% (P < 0.05, F(2,6)=481.467), and 56% 
(P < 0,05, F(2,6)=44.549), respectively, in SOD1G93A astrocyte-conditioned medium 48 






Figure 6. Immuno-enzimatic quantification of TNF-α, IL-1β, IL-6 and CCL2 concentration in 
the supernatant of primary cultures of spinal cord astrocytes from WT and SOD1G93A adult 
mice.  
Bar plots report the concentration of the pro-inflammatory cytokines TNF-α (A), IL-1β (B) IL-6 
(C) and CCL2 (D) in the supernatant of WT astrocytes, untreated SOD1G93A astrocytes, and 
exosome-treated SOD1G93A astrocyte cultures. Protein concentration was determined as per specific 
ELISA commercial kits. Data presented are means ± SEM of 3 independent experiments run in 
triplicate (three analyses for each experimental condition). *P < 0.001 vs. WT astrocytes; #P< 0.05 
vs. untreated SOD1G93A astrocytes (One-way ANOVA followed by Bonferroni post-hoc test). 
 
 
4.1.4 Exosome treatment normalizes NLRP3 inflammasome over-expression in SOD1G93A 
astrocytes 
NLRP3 is a protein complex strictly related to the inflammatory environment. Its assembly 
determines the cleavage through caspase-1 of IL-1β and IL-18 and their conversion in the 
active form, exacerbating neuroinflammation and promoting cell apoptosis and necroptosis 
(Mangan et al., 2018).  
NLRP3 expression was analysed by Western blot. SOD1G93A astrocytes showed a higher 
expression of NLRP3 than WT astrocytes [237% increase (P < 0.05, F(2,10)=9.562)]. 
SOD1G93A astrocytes treated with MSC-derived exosomes retained a lower expression of 
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NLRP3 compared to untreated SOD1G93A astrocytes [72% decrease (P < 0.05, 
F(2,10)=9.562)] (Figure 7A and 7B). 
The same pattern was confirmed by confocal microscopy experiments. In accordance with 
Western blot data, NLRP3 was up-regulated by 35% (P < 0.001, F(2,24)=80.841) in 
SOD1G93A astrocytes compared to WT astrocytes. Upon exposure to MSC-derived 
exosomes a significant reduction of NLRP3 expression in SOD1G93A astrocytes compared 
to untreated SOD1G93A astrocytes was detected [77% decrease (P < 0.001, F(2,24)=80.841)] 









Figure 7. Western blot and immunocytochemical quantification of NLRP3-inflammasome 
complex expression in primary cultures of spinal cord astrocytes from WT and SOD1G93A 
adult mice.  
(A) Representative immunoreactive bands for NLRP3 inflammasome complex in WT astrocytes, 
untreated SOD1G93A astrocytes and SOD1G93A astrocytes treated with IFNγ-primed MSC-derived 
exosomes for 24h. (B) Western blot quantification of protein expression as per scanned band 
density. Protein expression was calculated as relative band density normalized to the housekeeping 
protein GAPDH. Data presented are means ± SEM of 4 independent experiments. *P <0.05 vs. WT 
astrocytes; #P < 0.05 vs. untreated SOD1G93A astrocytes (One-way ANOVA followed by Bonferroni 
post-hoc test). (C) Representative confocal microscopy immunocytochemical images for GAPDH 
(red), NLRP3 (green) and DAPI (blue), in WT astrocytes, untreated SOD1G93A astrocytes and 
SOD1G93A astrocytes treated with IFNγ-primed MSC-derived exosomes for 24h. The merge panels 
represent the co-expression of NLRP3 with GAPDH. Scale bar: 100 µm. (D) Quantification of 
protein expression, as per relative fluorescence intensity, was performed calculating the co-
localization coefficients (Manders et al., 1992) using Image-J software analyses. Data are 
expressed as relative fluorescence intensity of NLRP3 normalized to the fluorescence intensity of 
the housekeeping protein GAPDH. The relative intensity of control WT astrocytes is reported as 1. 
Data are presented as the means ± SEM of 3 experiments run in triplicate (three different coverslips 
for each experimental condition). *P < 0.001 vs. WT astrocytes; #P < 0.001 vs. untreated SOD1G93A 
astrocytes (One- way ANOVA followed by Bonferroni post-hoc test). 
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4.1.5 IL-10 expression is increased by MSC-derived exosomes in SOD1G93A astrocytes 
Astrocytes secrete also anti-inflammatory cytokines, that can ameliorate the extracellular 
milieu and contribute to determine the phenotype of activated astrocytes (Burmeister and 
Marriott, 2018). It has been shown above that astrocyte produce and secrete a wide panel 
of pro-inflammatory cytokines; we measured here the expression of the anti-inflammatory 
cytokine IL-10 as a paradigm of the anti-inflammatory activity of SOD1G93A astrocytes.  
Confocal microscopy showed that the total cellular expression of IL-10 was significant 
decreased, by 27% (P < 0.001, F(2,24)=250.037), in SOD1G93A astrocytes compared to WT 
astrocytes. After the treatment with exosomes IL-10 down-regulation was almost 
completely reversed to control levels compared to untreated SOD1G93A astrocytes (P < 






Figure 8. Immunocytochemical quantification of IL-10 expression in primary cultures of 
spinal cord astrocytes from WT and SOD1G93A adult mice.  
(A) Representative confocal microscopy images for GAPDH (red) and IL-10 (green) in WT 
astrocytes, untreated SOD1G93A astrocytes and SOD1G93A astrocytes treated for 24h with IFNγ-
primed MSC-derived exosomes. Nuclei were stained with DAPI (blue). The merge panels represent 
the co-expression of IL-10 with GAPDH. Scale bar: 100 µm. (B) Quantification of protein 
expression, as per relative fluorescence intensity, was performed calculating the co-localization 
coefficients (Manders et al., 1992) using Image-J software analyses. Data are expressed as relative 
fluorescence intensity of IL-10 normalized to the fluorescence intensity of the housekeeping 
protein GAPDH. The relative intensity of control WT astrocytes is reported as 1. Data presented 
are means ± SEM of 3 experiments run in triplicate (three different coverslips for each 
experimental condition). *P < 0.001 vs. WT astrocytes; #P < 0.001 vs. untreated SOD1G93A 
astrocytes (One- way ANOVA followed by Bonferroni post-hoc test). 
 
 
4.1.6 Exosome treatment boosts the anti-oxidant response that is reduced in SOD1G93A 
astrocytes 
Nrf2 represents a transcriptional factor promoting the transcription of genes that are under 
the control of ARE, inducing the synthesis of anti-oxidant proteins; therefore, an increased 
nuclear localization of Nrf2 is potential linked with a stronger activation of pathways 
protecting the cell to oxidative stress (Petri et al., 2012). 
The resistance to oxidative stress was measured by quantifying the total cellular expression 
and the nuclear fraction of Nrf2 in WT-, SOD1G93A- and exosome-treated SOD1G93A 
astrocytes by confocal microscopy experiments. Nrf2 expression strongly diminished in 
SOD1G93A astrocytes, both in the cytosol [32% decrease (P < 0.001, F(2,18)=42.142)]  and 
nuclei [61% decrease (P < 0.001, F(2,18)=288.227)], compared to WT astrocytes.  
After 24 hours exposure to MSC-derived exosomes, the total cellular expression of Nrf2 
was increased by 68% (P < 0.001, F(2,18)=42.142) compared to untreated SOD1G93A 
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astrocytes. In addition, the active nuclear fraction of Nrf2 was increased by 77% (P < 








Figure 9. Immunocytochemical quantification of Nrf-2 expression in primary cultures of 
spinal cord astrocytes from WT and SOD1G93A adult mice.  
(A) Representative confocal microscopy immunocytochemical images for GAPDH (red) and Nrf-2 
(green) in WT astrocytes, untreated SOD1G93A astrocytes and exosome-treated SOD1G93A astrocytes. 
Nuclei were stained with DAPI (blue). The merge panels represent the co-expression of Nrf2 and 
GAPDH. Scale bar: 100 µm. (B, C) Quantification of protein expression, as per relative 
fluorescence intensity, was performed calculating the co-localization coefficients (Manders et al., 
1992) using Image-J software analyses. Data are expressed as relative fluorescence intensity of 
Nrf2 normalized to the fluorescence intensity of the housekeeping protein GAPDH or to the 
fluorescence intensity of the nuclear staining DAPI. The relative intensity of control WT astrocytes 
is reported as 1. Data presented are means ± SEM of 3 experiments run in triplicate (three different 
coverslips for each experimental condition); *P < 0.001 vs. WT astrocytes; #P < 0.001 vs. untreated 
SOD1G93A astrocytes (One- way ANOVA followed by Bonferroni post-hoc test). 
 
 
4.1.7 Characterization of motor neurons isolated from SOD1G93A mouse embryos 
Motor neurons were prepared from SOD1G93A mouse embryos and seeded on mature and 
confluent SOD1G93A astrocytes, prepared from 120 days-old SOD1G93A mice. A panel of 
markers selective for motor neurons, were chosen to determine the purity of the 
preparation. In particular, β-Tubulin III was used as generic neuronal marker, to indentify 
soma, axon and dendrites, while Hb9 and Islet-1 because they selectively label motor 
neurons.  
As shown in figure 10, the most part of neurons were positive for Hb9 and Islet-1, as well 
as for β-Tubulin III, confirming that our preparation is enriched in motor neurons. In 






Figure 10. Immunocytochemical characterization of motor neurons isolated from the spinal 
cord of SOD1G93A embryos (E13.5).  
Representative images of spinal cord SOD1G93A MNs co-cultured in the presence of SOD1G93A 
astrocytes and stained for (A) β-tubulin III (green) and DAPI (blue), (B) β-tubulin III (green) and 
HB9 (red), and (C) β-tubulin III (green) and Islet1 (red). Scale bar: 20 µm. 
 
 
4.1.8 SOD1G93A astrocyte phenotype amelioration has a positive impact on motor neuron 
viability 
Experiments on co-cultures of motor neurons isolated from SOD1G93A mouse embryos and 
adult SOD1G93A astrocytes, treated or not with MSC-derived exosomes, were performed in 
order to evaluate if the positive modulation exerted by MSC-derived exosomes on the 
astrocyte phenotype can impact on  MN survival.  
The viability of MNs were assessed starting 4 days after seeding and for further 10 days. 
When analyzing the viability of SOD1G93A MNs co-cultured with SOD1G93A astrocytes, we 
observed a constant and fast decrease of MN number during the experimental time [day 4: 
100% viability; day 6: 50% viability; day 8: 33% viability; day 10: 16% viability; day 12: 
11% viability; day 14: 5%viability].  
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The previous exosome treatment of astrocytes had a positive impact on their ability to 
prevent neuronal degeneration. Again, a constant reduction of MN number was detected, 
but the amount of MNs was higher at each time point when they were grown on exosome-
treated astrocytes [day 4: 100% viability; day 6: 72% viability (P< 0.001, t= -3.710); day 8: 
50% viability (P<0.01, t=-2.854); day 10: 37% viability (P < 0.001, t= -4.944); day 12: 
19% viability (P < 0.001, t= -3.157); day 14: 12% viability (P < 0.01, t= -2.983)]. 
Significance was calculated vs. survival of MNs co-cultured with untreated SOD1G93A 












Figure 11. Viability of motor neurons co-cultured in the presence of untreated and exosome-
treated spinal cord astrocytes from adult SOD1G93A mice 
(A) Representative phase-contrast microscopy images (10x) at day 8 after seeding of MNs on 
SOD1G93A astrocytes (left panel) or on SOD1G93A astrocytes treated with exosomes for 24h (right 
panel). (B) Quantitative analysis of MN viability.  The analysis was performed by the direct count 
of viable MNs in a previously defined area for the analyses (1 square centimeter divided in 100 
quadrants). MN viability was expressed as % survival of MNs co-cultured with exosome-treated 
SOD1G93A astrocytes vs. survival of MNs co-cultured with untreated SOD1G93A astrocytes. Data 
represent the means ± SEM of 5 independent experiments. *P<0.01, **P<0.001 vs. MN/untreated 





4.1.9 Transfection with single synthetic miRNA mimic reduces astrogliosis and 
inflammation of SOD1G93A astrocytes 
As previously described, when MSCs were stimulated with IFN-γ their miRNA expression 
pattern changed compared to unstimulated MSCs, suggesting a possible role in mediating 
the immunomodulatory functions of MSCs and MSC-derived exosomes. We hypothesized 
that miRNAs contained in exosomes could be the mediators of the beneficial effects of 
exosome treatment. To test our hypothesis we transfected SOD1G93A astrocytes with 
synthetic miRNAs, which have been found up-regulated in IFN-γ- primed-MSCs and 
present in exosomes. 
After 48 hour transfection we quantified the expression of GFAP, TNF-α and IL-1β by 
confocal microscopy. All miRNA mimics determined a significant reduction of GFAP, 
TNF-α and IL-1β, except miR-5126 and miR-467g. The percentage of variation of GFAP 
(P < 0.001, F(11,66)=17.012), TNF-α (P < 0.001, F(11,78)=58.167) and IL-1β (P < 0.001, 
F(11,84)=42.485) expression vs. SOD1G93A was summarize in table 4 and in figure 12. 

























































































































































Modifications of GFAP, TNF-α or IL-1β expression are indicated as percentage variation vs. non 
transfected SOD1G93A astrocytes (100% expression). Data are the mean ± s.e.m. of 3 indipendent 
experiments run in triplicate (three different coverslips for each experimental condition). There was 
no significant difference between SOD1G93A astrocytes and SOD1G93A astrocytes transfected with 








Figure 12. Immunocytochemical quantification of GFAP, IL-1β and TNF-α expression in 
spinal cord primary cultures of WT and SOD1G93A adult mouse astrocytes exposed to miRNA 
mimics. 
Astrocytes from SOD1G93A mice were cultured as described in the Methods section, and transfected 
with the single synthetic miRNAs that are mimics of the miRNAs upregulated in IFNγ-primed- 
MSCs and present in exosomes. After 48h exposure to the miRNA mimics, expression of GFAP 
(A), TNF-α (B) and IL-1β (C) was assessed by immunocytochemistry and laser confocal 
microscopy. The transfection solution (HighPerfect buffer) and a scrambled miRNA were used as 
controls. Quantification of protein expression, as per relative fluorescence intensity, was performed 
calculating the co-localization coefficients (Manders et al., 1992) using Image-J software analyses. 
Data are expressed as relative fluorescence intensity of GFAP, TNF-α or IL-1β normalized to the 
fluorescence intensity of the housekeeping protein GAPDH (confocal microscopy images not 
shown). The relative intensity of control WT astrocytes is reported as 1. Data presented are means 
± SEM of 3 experiments run in triplicate (three different coverslips for each experimental 
condition). *P < 0.001 vs. WT astrocytes; #P < 0.001 vs. SOD1G93Aastrocytes + HighPerfect buffer; 
§P < 0.001 vs. SOD1G93Aastrocytes + scrambled miRNA (two-way ANOVA followed by 




4.1.10 Identification of the pathways targeted by miRNAs 
The most effective miRNAs, tested above, were selected for further studies in order to 
elucidate the pathways affected by the exosome treatment based on their predicted targets. 
Noteworthy, miR-466q, miR-466m-5p, miR-466i-3p and miR-467f, that were identified as 
potential messenger molecules, in virtue of their significant effect in ameliorating the 
phenotype of SOD1G93A astrocytes, were also the four miRNAs up-regulated both in IFN-
γ-primed-MSCs and in exosomes derived from IFN-γ-primed-MSCs. 
First of all, computational analysis was performed and relevant target pathways, regulating 
inflammation, cytokine synthesis and oxidative stress, were identified by miRWalk or 
miRBase database. 
In this respect, miR-466m-5p presents a wide range of actions. Indeed, it affects several 
inflammatory pathways, such as MAPK, NFҡB and TLR signalling pathways.  
In particular, miR-466m-5p can reduce the translation of Mitogen-Activated 
Protein Kinase KinaseKinase 8 (MAP3K8), which is involved in the phosphorylation and 
activation of p38 and NFκB, promoting the transcription of cytokine genes (Figure 13A 
and 13B).  
Mitogen-activated protein kinase-11 (MAPK11) is a second target of miR-466m-5p. In 
stress condition, MAPK11 is in the phosphorylated form and it phosphorylates the 
Activating Transcription Factor (ATF2), which promotes the transcription of the pro-
inflammatory cytokine TNF-α (Mahlknecht et al., 2004) (Figure 13 C).  
Moreover, miR-466m-5p is potentially able to reduce the translation of TNF Receptor 
Associated Factor 6 (TRAF6), TGF-β Activated Kinase 1 and Mitogen-Activated Protein 
Kinase KinaseKinase 7 (MAP3K7) Binding Protein 2 (TAB2) and p65. These three 
proteins determine the activation of NFҡB signalling pathway. TRAF6 and TAB2 
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assembly with MAP3K7 and TAB1 in response to LPS or pro-inflammatory cytokines and 
this protein complex phosphorylates downstream kinases, such as IKKB and MAPK, 
leading to the activation of the transcription factors NFҡB and AP-1, respectively (Walsh 
et al., 2015). In addition, the modulation of p65 expression directly affects NFҡB complex 
assembly; indeed p65 is one of the subunits that form the active complex with pro-
inflammatory function (Lawrence, 2009) (Figure 13D). 
Moreover, miR-466m-5p is able to increase the resistance to oxidative stress of cells, 
decreasing the translation of the transcription factor BTB and CNC homology 1  (BACH1), 
which is a functional inhibitor of Nrf2, by competing for the same binding site of ARE. A 
reduction of BACH1 facilitates the binding of Nrf2 to the transcription factor ARE and 
promotes the activation of anti-oxidant mechanisms (Zhang et al., 2018) (Figure 13E). 
Some targets of miR-466m-5p are shared with the other selected miRNAs. For instance, 
miR-467f and miR-466i-3p inhibit the transcription of MAP3K8 (Figure 13A), miR-466i-
3p reduces the expression of MAPK11, HDAC3 and ATF2 (Figure 13C). Moreover, miR-
466q and miR-466i-3p can act on MAPKAPK2, which phosporylates IκB allowing NFκB 
translocation into the nucleus and represents a downstream kinase of p38 promoting 















Figure 13.  Target pathways of miRNAs shuttled by MSC-derived exosomes 
We selected four miRNAs (miR-466q, miR-467f, miR-466m-5p, miR-466i-3p) on the basis of their 
ability to reduce the activation state of SOD1G93A astrocytes by decreasing GFAP, IL-1β and TNF-α 
overexpression (see Fig. 10). The selected miRNAs mainly affect pathways related to 
inflammation, in particular NFҡB and MAPK pathways. Interestingly, one of these miRNAs, miR-
466m-5p, modulates also pathways that lead to the reduction of the oxidative stress. miRNA targets 
were identified through miRWalk and miRBase databases. (A) Graphical representation of p38 
signaling pathway and miRNAs targeting two of the kinases involved in the activation of p38. (B) 
Graphical representation of p65 canonical signaling pathway and miRNAs targeting two of the 
kinases involved in the phosphorylation and activation of p65. (C) Graphical representation of 
Toll-like receptor (TLR) signaling pathway for Activating Transcription Factor 2 (ATF2) 
activation and TNF-α synthesis. The indicated miRNAs could affect ATF2 activation through the 
downregulation of their relevant targets that are components of the pathway, as described in 
miRWalk and miRBase database. (D) Graphical representation of TLR-4 signaling pathway 
activating p65 translocation to the nucleus and miRNA targets inhibiting some crucial steps of the 
cascade. (E) Graphical representation of Nrf2 pathway and predicted miRNAs modulating 








4.1.11 Validation of the pathways targeted by miRNAs 
The panel of pathways identified by in-silico studies has been validated by qPCR analysis.  
MAPK-11 showed the most promising results. Indeed it was significantly increased in 
SOD1G93A astrocytes compared to WT astrocytes [193% increase (P < 0.05, t=-3.529)] and 
transfection of SOD1G93A astrocytes with miR-467f and miR-466q determined a strong 
reduction of MAPK-11 over-expression [87% decrease (P < 0.05, t=2.360); 76% decrease 
(P < 0.05, t=2.312), respectively]. Also miR-466i-3p and miR-466m-5p reduced MAPK11 
mRNA, altrough non significantly (20% decrease; n.s., t=0.740; 58% decrease; n.s., 
t=1.739 respectively) (Figure 14A). 
The other selected targets, MAP3K8, MAPKAPK2 and TRAF6, were not affected by 
miRNA transfection. 
MAP3K8 was significantly augmented in SOD1G93A astrocytes compared to control 
astrocytes (105% increase; P< 0.05, t=-3.432). However, any of the tested miRNAs was 
able to modulate the expression of this kinase (Figure 14B).  
Similarly, MAPKAPK2 showed a trend to increase in SOD1G93A astrocytes compared to 
WT even if not significant (t=-1.589). However, its mRNA expression was not modified in 
SOD1G93A astrocytes by exposure to miRNA transfection (Figure 14C). 
TRAF6 is a target selected only for miR-466m-5p, but the results discouraged its 
involvement in astrocyte phenotype modulation, since TRAF6 mRNA expression was not 
different among control-, SOD1G93A- and transfected-SOD1G93A astrocytes (Figure 14D). 
Finally, the expression of BACH1 was measured in WT and SOD1G93A astrocytes. 
However, the cycles needed to amplify the gene were too elevated, indicating a too low 







Figure 14. qPCR analysis of MAPK11, MAP3K8, MAPKAPK2 and TRAF6 expression in 
spinal cord primary cultures of WT and SOD1G93A adult mouse astrocytes exposed to miRNA 
mimics. 
Quantification of (A) MAPK11, (B) MPA3K8, (C) MAPKAPK2 and (D) TRAF6 expression by 
qPCR. The mRNA expression was normalized to the expression of the housekeeping gene 
GAPDH. The relative expression of control WT astrocytes is reported as 1. Data presented are 
means ± SEM of 4 experiments run in duplicate. *P < 0.05 vs. WT astrocytes; #P < 0.05 vs. 




4.2 Human astrocyte characterization and treatment with human MSC-derived 
exosomes 
4.2.1 Human astrocyte characterization 
Human astrocytes were differentiated from fibroblasts derived from two ALS patients 
carrying the SOD14AV mutation (patients 100 and 102) and one non-ALS patient 
(individual 155). After four weeks of differentiation protocol to obtain inducible 
neuroprogenitor cells (iNPCs), astrocytes were prepared by switching iNPCs medium with 
astrocyte medium.  
To confirm the efficacy of the differentiation protocol, the expression of GFAP, vimentin 
and CD44, selective markers for astrocytes, was analysed by immunofluorescence. 
iAstrocytes result highly positive to these markers (Figure 15). These results confirm that 






Figure 15. Immunocytochemical characterization of human astrocytes from control and ALS 
patients. 
Representative images of human astrocytes (iAstrocytes) differentiated from fibroblasts derived 
from control and ALS patients. iAstrocytes were stained for (A) GFAP (red) and DAPI (blue), (B) 
Vimentin (green) and DAPI (blue), and (C) CD44 (green) and DAPI (blue). Scale bar: 100 µm. 
 
 
4.2.2 Treatment with exosomes isolated from human MSCs exerts a mild effects on 
iAstrocytes phenotype 
As described above, the experiments were performed on iAstrocytes derived from one non-
ALS patient (control astrocytes, n. 155) and on two different lines of SOD1A4V iAstrocytes 
derived from distinct patients (n. 100 and 102). The expression of p-p65, NLRP3, Nrf2 and 
NQO1 was analysed by Western blot experiments.  
The phosphorylated form of p65 was significantly higher in iAstrocytes from patient 102 
compared to control iAstrocytes (P < 0.05, t = -4.668). No significant difference was 
detected in patient 100 iAstrocytes vs. control iAstrocytes (t= -0.573). Exosome treatment 
reduced p-p65 expression by 7% (n.s., t=0.169) and by 29% (n.s., t=1.790) in iAstrocytes 
derived from patient 100 and patient 102, respectively (Figure 16).  
Also NLRP3 expression was not significantly modified between ALS and control 
iAstrocytes. Upon exposure to exosomes, the trend to a decrease of NLRP3 expression was 
observed in both patients’ iAstrocytes compared to their respective untreated control 
(patient 100-iAstrocytes= 25% decrease, n.s., t=0.685; patient 102-iAstrocytes= 12% 








Figure 16. Western blot quantification of phospho-p65 and NLRP3-inflammosome complex 
expression in cell lysates from cultures of human astrocytes from control and SOD1A4V 
patients. 
(A) Representative immunoreactive bands for phospho-p65, NLRP3-inflammosome complex and 
β-actin in control (individual 155) iAstrocytes, patient-100 and patient-102 untreated SOD14AV 
iAstrocytes and patient-100 and patient-102 SOD14AV iAstrocytes treated with IFNγ-primed MSC-
derived exosomes for 24h. (B) Quantification of protein expression as per scanned band density in 
control  iAstrocytes, untreated SOD1A4V  iAstrocytes and SOD1A4V iAstrocytes treated for 24h with 
exosomes. Protein expression was calculated as relative band density normalized to the 
housekeeping protein β-actin. Data presented are means ± SEM of 3 independent experiments. *P 
<0.05 vs. control iAstrocytes (two-tailed Student’s t-test). 
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In accordance with experiments performed using mouse astrocytes, cell resistance to 
oxidative stress was measured. Nrf2 was strongly decreased in iAstrocytes from patients 
100 and 102 compared to control iAstrocytes (65% decrease, n.s., t= 2.607, and 88% 
decrease, n.s., t= 2.642, respectively). Exosome treatment significantly reversed the down-
regulation of Nrf2 in patient 102 iAstrocytes compared to untreated iAstrocytes (126% 
increase, P < 0.05, t= -7.005). In iAstrocytes derived from patient 100, exosome treatment 
determined an augmentation of Nrf2 expression by 67% compared to untreated 
iAstrocytes(100) (n.s., t= -0.552). 
Finally, NQO1 expression was significant lower in ALS iAstrocytes compared to control 
iAstrocytes (patient 100-iAstrocytes= 68% decrease, P < 0.05, t = -3.904; patient 102-
iAstrocytes= 88% decrease, P < 0.001, t= 20.254). The treatment with exosomes 
determined a trend to amelioration of this parameter since iAstrocytes derived from patient 
100 and patient 102 showed an increase of NQO1 expression by 77% (n.s., t = -0.864) and 






Figure 17. Western blot quantification of Nrf2 and NQO1 expression in cell lysates from 
cultures of human astrocytes from control and SOD1A4V patients. 
(A) Representative immunoreactive bands for Nrf2, NQO1 and β-actin in control (individual 155) 
iAstrocytes, patient-100 and patient-102 untreated SOD1A4V iAstrocytes and patient-100 and 
patient-102 SOD1A4V iAstrocytes treated with IFNγ-primed MSC-derived exosomes for 24h. (B, C) 
Quantification of protein expression as per scanned band density in control  iAstrocytes, untreated 
SOD1A4V iAstrocytes and SOD1A4V iAstrocytes treated for 24h with exosomes. Protein expression 
was calculated as relative band density normalized to the housekeeping protein β-actin. Data 
presented are means ± SEM of 3 independent experiments. *P < 0.05 vs. untreated 102 iAstrocytes, 








4.2.3 iAstrocytes treated with human MSC-derived exosomes are more supportive for MNs 
compared to untreated iAstrocytes 
MNs, derived from mouse embryonic stem cells and expressing GFP under the MN-
specific promoter Hb9, were co-cultured with iAstrocytes from patient 100 and patient 
102, treated or not with exosomes derived from human MSCs. 
iAstrocytes were treated with exosomes for 24 hours, then MNs were seeded. MNs were 
counted for 3 days and MN viability was measured as percentage of survival between day 
3 and day 1. 
When cultured on untreated iAstrocytes, the percentage of MN survival at day 3 was 33% 
for iAstrocytes from patient 100 and 38% for iAstrocytes from patient 102. The treatment 
with exosomes was able to partially rescue MN degeneration in the co-culture system. The 
percentage of MN survival at day 3 was 56% (P < 0.05, t= -2.524) and 47% (n.s., t= -
1.303) in treated -patient 100-iAstrocytes and in –patient 102-iAstrocytes, respectively 
(Figure 18).  
As a whole, the experiments with human astrocytes suggest that the treatment with 
exosomes ameliorates their phenotype and demonstrate that this amelioration would have a 
positive impact on MN survival. However, more experiments are needed to verify the 












Figure 18. Viability of motor neurons co-cultured in the presence of untreated or exosome-
treated iAstrocytes from patients, carrying the A4V ALS-linked SOD1 mutation. 
A) Representative phase-contrast microscopy images of MN morphology at day 3 after seeding on 
patient-100 iAstrocytes treated or not with exosomes. Images obtained with the InCell® were used 
for semi-automated high throughput analysis with Columbus microscopy software. B) Quantitative 
analysis of MN viability. The number of motor neurons were quantified automatically, and only 
motor neurons bearing axons were counted. Histograms represent MN survival expressed as 
percentage of the ratio between the number of MNs at day 3 and that at day 1. Day 1 is considered 
as 100% survival. Data represent the means ± SEM of 3 independent experiments, run in triplicate. 

















MSCs are largely studied as innovative therapy for ALS and other neurodegenerative 
diseases. However, the mechanisms of action of MSCs have been only partially elucidated. 
Initially, it was proposed a direct therapeutic effect of MSCs after infusion, driven by 
migration to the sites of damage, engraft, differentiation and interaction with other cells. 
Nowadays, the beneficial effects of MSCs are mostly attributed to paracrine mechanisms 
rather than differentiation of MSCs in other cellular types (Mendt et al., 2019). 
In one of our previous studies, we reported that a single intravenous administration of 
MSCs in SOD1G93A mice determined an extension of lifespan, an amelioration of motor 
skills and a reduction of astrogliosis and inflammation in spinal cord (Uccelli et al., 2012). 
These beneficial effects were not exerted by MSC differentiation; indeed the most part of 
injected cells were sequestered in lungs and hardly reached the spinal cord, as described 
later also in several other studies using MSCs as a treatment (Mendt et al., 2019). Thus, in 
our study we proposed that paracrine mechanisms, implying cell-to-cell communication by 
diffusing messengers, could be at the basis of the observed effects. 
The present study highlights the role of exosomes derived from MSCs as possible 
mediators of  the functions of MSCs themselves. To elucidate the regulatory mechanisms 
involved in the modulation of ALS characteristics by exosomes, we focused on astrocytes 
derived from SOD1G93A mice and from ALS patients, because of their relevant function in 
disease progression. Indeed, it is well recognised that ALS is a non-cell autonomous 
disease (Lee et al., 2016) and glial cells fulfil a crucial function in MN death, by losing the 
ability of support of MNs, exerted in physiological conditions through the release of 
neurotrophic factors and to the maintenance of synapses homeostasis. Instead, they become 
harmful by releasing neurotoxic factors, such as pro-inflammatory cytokines, chemokines, 
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complement factors and products derived from oxidative stress (Lee et al., 2016, 
Yamanaka et al., 2017). 
In our mouse model experiments, we utilized astrocytes prepared from 120 days-old 
SOD1G93A mice, at the late stage of the disease, and age-matched WT mice. In spite of the 
difficulties to obtain and expand adult astrocytes respect to the new born ones, we decided 
to use these cells because they represent, in our belief, a more appropriate disease model. 
Certainly, they matured in-vivo during the evolution of the disease, spanning from the pre-
symptomatic, low-progressing, to the symptomatic, fast-progressing, stages and are, 
therefore, activated because exposed to a “true” pathological environment. Adult mouse-
derived astrocytes parallel, in a way, the human astrocytes derived from patient’s 
reprogrammed fibroblasts. Accordingly, SOD1G93A astrocytes and human iNPC-derived 
SOD1-astrocytes showed a stronger reactivity and an inflammatory phenotype compared to 
control astrocytes. The treatment with exosomes derived from MSCs was able to reduce 
the  toxic activation of SOD1G93A astrocytes and, even if less emphasised, of iAstrocytes.  
Several findings support the involvement of paracrine mechanisms as the main mode of 
action of MSCs. Sun and Colleagues demonstrated that MSCs and MSC conditioned 
medium exerted a comparable ameliorative effect in different in vitro model of ALS. The 
administration of MSCs or MSC conditioned medium to primary motor neurons, NSC-34 
cells and astrocytes was neuroprotective against staurosporine toxicity. In particular, in 
SOD1G93A neonatal astrocytes, MSC conditioned medium was able to positively modulated 
MAPK/Erk1/2 and PI3-K/Akt signalling pathways, that are involved in differentiation, 
proliferation, growth and survival of neuron and astrocytes, to stimulate the synthesis of 
many neurotrophic and neuroprotective factors and to reduce the inflammatory response 
upon exposure to LPS through the down-regulation of TNF-α, IL-6 and iNOS gene 
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expression (Sun et al., 2013). A further study revealed several soluble factors (PGE2, TGF-
β, IL-10) and extracellular vesicles released from MSCs, that were able to abolish 
inflammatory responses and sustain regenerative processes (Zhou et al., 2019). 
MSC-derived exosomes were reported to promote the switch of macrophages to M2 anti-
inflammatory phenotype in bronchopulmonary dysplasia, to down-regulate the level of 
inflammatory cytokines (Willis et al., 2018) and to increase the expression of anti-
inflammatory factors, such as PGE2 (Hyvärinen et al., 2018). Moreover, they reduced the 
activation of T cells, B cells and dendritic cells, but promoted the proliferation of Treg 
(Del Fattore et al., 2015, Budoni et al., 2013, Reis et al., 2018).  
Studies on a spinal cord injury rodent model sustain the effectiveness of MSC-derived EVs 
in protect neurons from degeneration, mainly through the suppression of the NFҡB 
signalling pathway activation in astrocytes and perycites (Wang et al. 2018; Lu et al., 
2019).  
In our project we wanted to elucidate in depth whether exosomes were able to ameliorate 
the noxious phenotype of astrocytes prepared from SOD1G93A mice and which are the 
components of the exosome cargo involved in this positive modulation. Among the 
molecules contained into exosomes there are miRNAs, non-coding RNAs which modulate 
the expression of up to 30% of all mammalian protein-encoding genes. Notably, miRNAs 
are selectively sorted in EVs, suggesting their pivotal role in cell-to-cell communication 
(Qiu et al., 2018). Therefore, we analysed the miRNA cargo of exosomes and identified 




Exosome treatment determined a decreased expression and release of the pro-inflammatory 
cytokines TNF-α, IL-1β, IL-6 and of the chemokine CCL2 in SOD1G93A astrocytes. The 
reduction of cytokine secretion is probably linked to the observed amelioration of MN 
survival. Kia and Colleagues identified TNF-α as one main toxic factor released from 
astrocytes, causing MN degeneration through the activation of NFҡB signalling pathway 
but also through the alteration of AMPA receptors (Kia et al., 2018). The correlation 
between TNF-α and excitotoxicity has been reported by several research groups. It has 
been observed that TNF-α can exacerbate AMPA receptor-mediated excitotoxicity of 
lumbar spinal cord MNs, possibly by increasing AMPA permeability to Ca2+ (Hermann et 
al., 2001, Yin et al., 2012). In adding, TNF-α was reported to down-regulate astrocytic 
EAAT2 expression through the NFҡB binding to the EAAT2 promoter (Sitcheran et al., 
2005). These findings suggest that a reduction of TNF-α expression could be strongly 
ameliorative of the ALS astrocytic phenotype, not only for the influence on the 
inflammatory pattern but also in reducing excitotoxicity, one of the major features of ALS 
pathogenesis. 
Pro-inflammatory stimuli driven by activation of TNF-α receptors (TNFR1 and TNFR2) 
determine the activation of NFҡB, which induces NLRP3 transcription, as well as that of 
other key pro-inflammatory genes, including that encoding for pro-IL-1β. The activation of 
NLRP3 leads to the cleavage of pro-IL-1β and pro-IL-18 to the respective active form and, 
consequently, to their secretion. Moreover, NLRP3 seems involved in necroptosis, a type 
of inflammatory cell death. Indeed, its assembly can be induced by RIP3 and pseudokinase 
mixed-lineage kinase domain-like protein (MLKL), the major components of necroptosis 
pathway, through the activation of caspase 8. These findings suggest a role of NLRP3 in 
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exacerbating the pro-inflammatory stimuli in cells, which can potentially promote 
necroptotic cell death.  
Because of the relevant role of NLRP3, it turns out to be a possible target in several 
diseases characterized by an inflammatory component, such as multiple sclerosis, 
Alzheimer disease, traumatic brain injury, Parkinson’s disease (Mangan et al., 2018, Chen 
et al., 2018). Also in ALS, NLRP3 was reported to be increased (Johann et al., 2015, 
Gugliandolo et al., 2017). In accordance, we detected an increase of NLRP3 in SOD1G93A 
astrocytes. Exosome treatment normalized this activation, contributing to the reduction of 
IL-1β. We hypothesize that a reduction in NLRP3 could also reduce necroptosis-mediated 
cell death in astrocytes, that reflects in an amelioration of MN viability, due to a lower 
release of inflammatory toxic factors. To confirm this hypothesis we plan to analyse the 
expression of RIP3 and MLKL and their phosphorylation state in SOD1G93A MNs co-
cultured with SOD1G93A astrocytes treated or not with exosomes. 
The ameliorative effects of exosomes affected also the reactive phenotype of SOD1G93A 
astrocytes. GFAP, vimentin and S100β expression were significantly down-regulated in 
SOD1G93A exposed to exosomes. In normal condition astrogliosis has a neuroprotective and 
regenerative scope, however, reactive astrogliosis is often exacerbated in 
neurodegenerative diseases, including ALS, and astrocytes are subjected to degeneration 
and gain of toxic function (Verkhratsky and Zorec, 2018). A reduction of astrogliosis 
markers, together with the increased survival of MNs when grew on exosome-treated 
astrocytes, strongly suggest that exosome treatment promotes a switch of astrocytes to a 
less neurotoxic phenotype.  
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The decrease of S100β could affect also cell injury and the expression of pro-inflammatory 
genes. S100β was reported to behave as a component of the DAMPs when, released in 
high concentrations, participates in the cascade of events causing cell injury, and to bind 
the Receptor for Advanced Glycation End products (RAGE), leading to microglia 
migration. Serrano and Colleagues demonstrated that silencing of S100β in SOD1G93A 
astrocytes determined a down-regulation of GFAP, TNF-α, CXCL10 and CCL6 
expression. Therefore, the significant reduction of S100β expression, observed upon 
exposure to exosomes, may determine a synergic action with MSC- derived exosomes in 
decreasing inflammation in ALS. 
In last decades, it has been documented that MSCs have the ability to reduce the toxic 
effect of oxidative stress, in addition to their immunomodulatory function. MSCs and 
MSC-derived exosomes were reported to decrease oxidative stress by reducing ROS 
production and over-expressing anti-oxidant enzymes, and also inhibiting NLRP3 
activation following H2O2 treatment (Alhazzani et al., 2018; Xia et al., 2019). Further, in 
our previous study we detected that MSC injection in SOD1G93A mice determined a 
reduction of oxidative stress condition at the level of spinal cord of these mice through the 
induction of the glutathione S-transferase (Uccelli et al., 2012). 
The modulation of oxidative stress response has been largely studied as a possible 
therapeutic target in ALS, in part due to the mutation of genes that regulate detoxification 
of ROS. Nrf2 is a transcription factor that activates ARE, promoting transcription of 
numerous cytoprotective proteins, such as glutathione S-transferase, NQO1, Heme 
oxygenase-1, and glutamate-cysteine ligase. The expression of Nrf2 is decreased in ALS 
patients and rodent model of the disease (Petri et al., 2012).  
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We found that Nrf2 is down-regulated in SOD1G93A astrocytes compared to WT astrocytes. 
The Nrf2 impairment was significantly rescued by exosome treatment. By analysing 
miRNA pathways, we revealed that the up-regulated miRNA miR-466m-5p can exert an 
anti-oxidant effect abolishing the transcription of BACH1, which inhibits ARE by 
competing with Nrf2 for the same binding site. In addition, Xia and Colleagues detected 
the presence in exosomes of antioxidant proteins such as heat shock protein of 75 kDa 
(HSP75), phospholipid hydroperoxide glutathione peroxidase, and peroxiredoxin-1, 
suggesting a further synergic mechanism of action of the exosome treatment.  
Recent studies showed that the induction of Nrf2-ARE pathway by pharmacological 
interventions determines an increase of MN survival both in-vitro and in-vivo models of 
ALS, possibly by increasing the secretion of glutathione (Mead et al., 2013; Kanno et al., 
2012). Also, an interplay between Nrf2 and NFҡB has been described, which contributes 
to worsening the inflammatory state. The down-regulation or ablation of Nrf2 determines 
an increased activation of NFҡB and, consequently, of cytokine production following brain 
injury, inducing astrogliosis, demyelination and neuronal death (Pan et al., 2012; Neymotin 
et al., 2011). These findings highlight the contribute of rescuing Nrf2 expression in 
supporting MN viability in our co-culture system. 
To verify whether all the advantageous modifications of the astrocyte phenotype, that led 
also to a reduction of pro-inflammatory cytokine secretion, observed after exposure to 
exosomes, were able to positively impact on MN well-being, we measured the survival of 
MNs when co-cultured with SOD1G93A astrocytes previously exposed to exosomes or to 
standard culture medium. Results highlighted that the survival was absolutely augmented 
when MNs were exposed to astrocytes pre-treated with exosomes. Notably, our 
experimental method allows to unequivocally attribute the increase of MN survival to the 
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amelioration of astrocyte phenotype. In fact, astrocytes were treated with MSC-derived 
exosomes, while MNs were added after exosome wash-out. This implies that the 
diminished expression of pro-inflammatory cytokines and the improved response to 
oxidative stress in SOD1G93A astrocytes can potentially slowdown MN degeneration. 
As already described above, the reduction of the release of pro-inflammatory cytokines, 
especially TNF-α, exerts a positive impact on MN survival mitigating phenomena linked to 
chronic and acute inflammation, such as the trigger of apoptosis and necroptosis pathways 
through TNFR activation, NLRP3 assembly, Caspase 3 activity and complement cascade 
activation (Zhang et al., 2017). In addition, the increased resistance to oxidative stress, 
through the normalization of Nrf2 expression, can possibly reduce mitochondria damage 
and malfunction, such as alteration of the mitochondrial electron transport chain and 
unpaired oxidative phosphorylation, with consequent lower level of ATP synthesis that has 
been observed in different ALS models (Ravera et al., 2018, Pharaoh et al., 2019), and 
restore cellular homeostasis and ROS levels. 
Indeed, in response to stress, Nrf2 was reported to modulate the expression of detoxifying 
enzymes and to regulate the transcription of genes involved in mitochondria biogenesis and 
proliferation (Hayashi et al., 2017). We can hypothesize that the environment surrounding 
MNs becomes less toxic upon exposure of astrocytes to MSC-derived exosomes because of 
the lower production and release of ROS. Interestingly, it has been reported that the 
overexpression of Nrf2 in astrocytes completely protects MNs from mutant SOD1 toxicity 
in co-cultures and delays disease onset in the SOD1G93A mouse model (Vargas et al., 
2008). At the basis of the improvement of MN survival there was a decrease of the NO-
dependent toxicity, mediated by Nrf2 activation, which enhance glutathione biosynthesis, 
inhibiting, in turn,  p75NTR-dependent motor neuron apoptosis (Vargas et al., 2006). 
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The less toxic astrocyte phenotype can affect also other cellular type involved in ALS. For 
instance, the decreased release of CCL2 may reduce the recruitment of macrophages and 
M1 microglia in CNS and the activation of phosphatidylinositol-3 kinase/Akt and MAPK, 
contributing to alleviate pro-inflammatory response and gliosis (Kawaguchi-Niida et al., 
2013). Further, the reduction of TNF-α and IL-1β expression, together with the increased 
expression of IL-10 in exosome-treated SOD1G93A astrocytes can lead to an overall 
improvement of CNS environment and determine a shift of M1 microglia to the rest state.  
Thus, astrocytes might succeed in supporting MN viability directly, as in our experiments, 
by reducing the toxicity of the extracellular milieu, and indirectly, by ameliorated the 
noxious phenotype of microglia and of other cell types. Indeed, in future studies we plan to 
study in depth the influence of astrocytes on microglia of SOD1G93A mice. Whether the 
exosome-treated astrocyte conditioned medium is able to modulate the SOD1G93A 
microglia activation state and the evaluation of the soluble factors released by SOD1G93A 
astrocytes and regulated by exposure to MSC-derived exosomes will pave the way to these 
studies. 
Astrocytes play a pivotal roles in maintaining BBB integrity through the establishment of 
tight junctions between endothelial cells. In ALS, it was reported a reduced expression of 
proteins involved in tight junction formation and the degeneration of astrocyte end-feet, 
leading to BBB disruption and red blood and immune cell extravasation (Sweeney et al., 
2019). Garbuzova-Davis and Colleagues demonstrated that the transplantation of bone 
marrow MSCs in symptomatic SOD1G93A mice ameliorates the BBB structure and 
functions. These findings suggest that a rescue of astrocyte activation can contribute to 
BBB restoration, not only by directly stabilizing tight junctions but also reducing pro-
inflammatory stimuli on pericytes and endothelial cells. Indeed, the excessive pericyte 
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migration, reported in ALS, was decreased following the reduction of NFκB activation (Lu 
et al., 2019; Garbuzova-Davis et al., 2018). 
This evidence hypothesizes positive cross-talk between astrocytes and other cells of CNS 
and immune system, paving the way to further studies to better understand the essential 
role of astrocytes in ALS and how their modulation can affect the whole CNS 
environment. 
In the attempt to identify the molecular determinants of the exosome effects, we identified 
nine up-regulated miRNAs in mouse MSCs after stimulation with IFN-γ. These miRNAs 
were also present in exosomes but only four were over-expressed, when compared to 
exosomes isolated from unstimulated MSCs. These four miRNAs can potentially inhibit 
the translation of several kinase proteins and transcriptional factors involved in NFҡB and 
MAPK pathways, reducing inflammatory response activation. There is evidence in rodent 
models of spinal cord injury that administration of MSCs or MSC-derived exosomes 
ameliorates A1 astrocyte phenotype by reducing the expression of phospho-IҡBα and, 
therefore, phospho-p65 translocation into the nucleus (Wang et al., 2018, Lu et al., 2019), 
supporting the relevance of our identified  miRNAs in the modulation of NFҡB pathway.  
Another identified pathway is p38-ERK, that induces cell apoptosis and resulted altered in 
ALS (Bendotti et al., 2005). miR-466q, miR-467f and miR-466i-3p can affect the 
translation of several kinases involved in p38 phosphorylation, determining a lower 
activation of this pro-apoptotic pathway. Modulation of the p38 pathway was observed 
also in other models. For instance, increased phosphorylation of p38 and ERK was 
reported in chondrocytes exposed to IL-1β, that was reversed upon exposure to exosomes 
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derived from MSCs. The normalization of p38-ERK activation leads also to a reduction of 
apoptosis (Qi et al., 2018).  
Identified targets of miR-466q, miR467f, miR-466m-5p and miR-466i-3p were validated 
by qPCR. The only significant modification of mRNA expression, upon transfection with 
single synthetic miRNA mimics, was detected for MAPK11, while the other targets were 
not significantly affected.  
Notably, the strong reduction of MAPK11 is in accordance with the results obtained with 
exosome treatment. Indeed, MAPK11 phosphorylates ATF2 promoting the synthesis of 
TNF-α, which was the cytokine mostly affected by exosome treatment in our experiments. 
This finding strongly supports the modulation of MAPK11 expression by exosome 
treatment, granting that a direct inhibition of its synthesis can lead to a partial restoration of 
astrocyte-MN cross-talk , since TNF-α is one of the main neurotoxic factors released from 
astrocytes. 
The phenotype characterization of SOD1A4V iAstrocytes derived from iNPCs did not show 
strong inflammatory activation compared to control iAstrocytes. However, exosome 
treatment determined a trend of reduction of p-p65 and NLRP3, specially, in patient 102 
iAstrocytes. These results suggest the presence of a modulatory effect on inflammation, 
even if less substantial, also in human-derived astrocytes.  
More consistent positive effects were detected in the anti-oxidative pathways, even if not 
significant, that deserve further analysis. Most important, in the human model represented 
by MN-iAstrocytes co-cultures, as seen in companion rodent  experiments, we obtained an 
amelioration of MN viability, supporting the essential role of exosomes in counteract 
astrocyte toxicity. Thanks to a preliminary analysis of miRNAs contained in exosomes 
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from human MSCs, we identified miR-29b-3p as a possible mediator of the anti-oxidant 
effects and MN survival improvement (data not shown).  
miR-29b-3p has been found down-regulated in several neurological disorders, including 
ALS, and the restoration of its levels promotes neuronal survival by down-regulating the 
expression of the pro-apoptotic proteins of the BH3-only family (Paladino et al., 2018; 
Klatt et al., 2019). Moreover, miR-29b-3p acts also on Nrf2 pathway by inhibiting the 
translation of BACH2, a negative competitor of Nrf2 for the ARE binding site, supporting 
its involvement in Nrf2 expression and regulation. Interestingly, it has been reported that 
Nrf2 is able to positively regulate miR-29b-3p expression, which can potentially determine 
an increase in neuronal survival (Paladino et al., 2018). Further studies are request to 
clarify which pathways are modified by exosome-shuttled miRNAs. 
Thanks to the identification of the pathways affected by the miRNA cargo of exosomes, 
both in human and rodent exosomes from primed MSCs, it is possible to hypothesize the 
prospective of a treatment with selected miRNAs, through non-viral methods such as lipid-
based or polymeric nanoparticle-based delivery systems or viral vectors such as adenovirus 
vectors and adeno-associated virus (AAV) vectors (Slotaand Booth, 2019). miRNA-based 
therapeutics have been proposed and largely studied to treat disorders such as cancer, heart 
diseases and diabetes (Rupaimoole et al., 2017). Currently, miRNA treatment are 
becoming a promising alternative to classical therapeutic approaches also in 
neurodegenerative diseases and neurological disorders 
A treatment with artificial miR‑124a oligonucleotides, that can normalize the increase in 
EAAT2 expression associated with decreased miR‑124a expression, that is observed in 
mutant SOD1 murine spinal cords, has been already tested in ALS (Morel et al., 2013). 
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Two other studies reported that the administration of artificial miRNA against mutated 
SOD1 determined an extension of lifespan of SOD1-linked ALS animal models (Borel et 
al., 2018; Stoica et al., 2016), supporting not only the role of SOD1 in the disease 
pathogenesis but also that the administration of artificial miRNA through AAV9 viral 
vector technology to treat ALS is safe and effective, paving the way to the discovery of 
other possible targets for a multimodal therapeutic approach.  
5.1 Conclusion 
In the present work we established that exosomes derived from MSCs are one of the 
mediators of the therapeutic effect of MSCs, proving a comparable modulatory action on 
inflammation and oxidative stress. Their action is due also to the transport of miRNAs, that 
we demonstrated are helpful for the amelioration of astrocyte phenotype and MN survival. 
These results encourage the develop of MSC-derived exosome-based therapy or miRNA-
based therapy, with a wide range of action on different features of ALS.  
The administration of MSC-derived exosomes containing modulatory miRNAs instead of 
MSCs themselves presents some relevant advantages; first of all, the bypass of ethical 
issues and safety concerns related to fate and long persistence of replicating cells in the 
host, but also the removal of the high-cost burden of cell expansion for transplantation in 
patients. However, primary questions concerning the hypothesis of a possible exosome-
based therapy are still unsolved: how exosomes can be produce on upscale following good 
manufacture practice conditions? How exosome-based products can be precisely defined 
and characterized for purity and exosome number? What are the pharmacodynamic and 
pharmacokinetic properties of exosomes?  
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The same questions are applicable also for miRNA-based therapy, although there are 
already studies on their safety after administration in in-vivo models.  
In conclusion, to succeed in the design of an effectiveness and safe exosome based-therapy 
or miRNA-based therapy, it is firstly necessary to define the behaviour of these innovative 
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